Structure and Function of Isocitrate Dehydrogenase From Escherichia coli ML308 by McKee, Jillian Stewart
 
 
 
 
 
 
 
https://theses.gla.ac.uk/ 
 
 
 
 
Theses Digitisation: 
https://www.gla.ac.uk/myglasgow/research/enlighten/theses/digitisation/ 
This is a digitised version of the original print thesis. 
 
 
 
 
 
 
 
 
Copyright and moral rights for this work are retained by the author 
 
A copy can be downloaded for personal non-commercial research or study, 
without prior permission or charge 
 
This work cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the author 
 
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the author 
 
When referring to this work, full bibliographic details including the author, 
title, awarding institution and date of the thesis must be given 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten: Theses 
https://theses.gla.ac.uk/ 
research-enlighten@glasgow.ac.uk 
STRUCTURE AND FUNCTION OF ISOCITRATE DEHYDROGENASE 
FROM ESCHERICHIA COLI ML308
by
Jillian Stewart McKee
A Thesis submitted for the degree of Ph.D in the 
Faculty of Science, University of Glasgow
May 1989
ProQuest Number: 10970908
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 10970908
Published by ProQuest LLC(2018). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLC.
ProQuest LLC.
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106- 1346
For Mum and Dad
Part of this work reported in this thesis has been 
submitted for publication as follows:
1. McKee, J.S. & Nimmo, H.G. (1989) Biochem. J. in press.
’Evidence for an arginine residue at the coenzyme binding 
site of Escherichia coli isocitrate dehydrogenase*.
2. McKee, J.S., f-jlodan, R. & Nimmo, H.G. (1989) Biochimie,
submitted.
’Studies of the phosphorylation of Escherichia coli 
isocitrate dehydrogenase. A recognition of the enzyme by 
ICDH kinase/phosphatase and effects of phosphorylation on 
its structure and properties'.
(i)
Page
CONTENTS OF THESIS 
Contents
List of Figures ^
List of Tables (xvi)
Abbreviations (xvii)
Acknowledgements (xix)
Summary x^ x ^
(ii)
LIST OF CONTENTS Page
CHAPTER ONE - INTRODUCTION
1.1 Isocitrate dehydrogenase from Escherichia coli
ML 308 1
1.1.1 Introduction 1
1.1.2 E.coli metabolism during growth on a single carbon
source 1
(a) Growth on glucose 2
(b) Growth on acetate 3
1.1.3 Reversible inactivation of isocitrate dehydrogenase 4
1.2 Phosphorylation of E.coli isocitrate dehydrogenase 7
1.2.1 Covalent modification 7
1.2.2 Protein phosphorylation ^
1.2.3 Phosphorylation of E.coli isocitrate dehydrogenase 12
1.2.4 In vivo phosphorylation of isocitrate dehydrogenase 1 3
1.2.5 A bifunctional kinase/phosphatase 1 3
1.3 Comparison of the active and inactive forms of
isocitrate dehydrogenase 18
1.4 Aims of Thesis 20
CHAPTER TWO - MATERIALS AND METHODS
(iii)
Page
2.1 Materials 29
2.1.1 Biochemicals 29
2.1.2 Enzymes 29
2.1.3 Radiochemicals 3®
2.1.4 Chemicals for polyacrylamide gel electrophoresis 30
2.1.5 Chromatographic media and reagents 30
2.1.6 Miscellaneous materials 30
2.2 General biochemical methods 31
2.2.1 pH and conductivity measurements 31
2.2.2 Glassware and plastics 31
2.2.3 Micropipettes 31
2.2.4 Distilled water 31
2.2.5 Dialysis 31
2.2.6 Protein estimations 32
2.2.7 Concentration of protein samples 32
2.2.8 Preparation of chromatographic media 32
2.2.9 Lyophilisation 33
2.2.10 Sterilisation 33
2.3 Microbiological techniques 33
2.3.1 Bacterial strains 33
2.3.2 Storage of bacteria 34
2.3.3 Media 34
(a) Nutrient broth 34
(b) Nutrient agar 34
(c) BCIG agar 35
(d) L-broth 35
(iv)
Page
2.3.3 (continued
(e) Defined media for specifically pre-inducing
inocula 35
(f) Defined media for large scale growth 35
(g) Specific supplements to defined media 36
2.3.4 Growth of bacteria 36
(a) Preparation of specifically pre-induced
inocula 36
(b) Large scale batch culture 36
(c) Measurement of growth 37
(d) Harvesting of cells 37
(e) Growth of E.coli EB 106 37
(f) Growth of E.coli TGl/pCK505 37
2.3.5 Disruption of bacteria 38
2.4 Enzyme assays 38
2.4.1 Instrumentation 38
2.4.2 Assays 38
(a) Isocitrate dehydrogenase 38
(b) Isocitrate dehydrogenase kinase 38
(c) Isocitrate dehydrogenase phosphatase 39
2.5 Methods of protein purification 40
2.5.1 Purification buffers 40
(a) ICDH 40
(b) ICDH kinase/phosphatase 40
(v)
Page
2.5.2 Purification of isocitrate dehydrogenase from
E.coli ML 308 40
(a) Preparation of crude extract 41
(b) Protamine sulphate treatment 41
(c) Ammonium sulphate fractionation 41
(d) Ion exchange: DEAE cellulose chromatography 41
(e) Procion red Sepharose chromatography 42
2.5.3 Purification of ICDH kinase/phosphatase from
E.coli KAT-l/pEM9 42
(a) Preparation of crude extract 42
(b) Protamine sulphate fractionation 42
(c) Ammonium sulphate fractionation 42
(d) Ion exchange chromatography at pH7.3 43
(e) Chromatography on blue dextran sepharose 43
(f) Ion exchange chromatography at pH7.3 on Mono Q 43
(g) Ion exchange chromatography at pH9.0 on Mono Q 44
(h) Gel filtration on an FPLC Superose 12 column 44
2.5.4 Purification of ICDH from E.coli TGl/pCK505 44
(a) Preparation of crude extract 44
(b) Protamine sulphate treatment 44
(c) Ammonium sulphate fractionation 44
(d) Ion exchange chromatography at pH6.5 on Mono Q 45
2.6 Polyacrylamide gel electrophoresis techniques 45
2.6.1 Non-denaturing polyacrylamide gel electrophoresis 45
2.6.2 Staining for ICDH activity in non-denaturing gels 46
2.6.3 SDS polyacrylamide gel electrophoresis (discontinuous
system) 46
(vi)
Page
2.6.4 Staining gels for protein 47
(a) Coomassie blue 47
(b) Silver stain 47
2.6.5 Drying and autoradiography of polyacrylamide gels 48
2.7 Modification of ICDH with phenylglyoxal 48
2.7.1 Incubations with phenylglyoxal 48
14
2.7.2 Incorporation of [7- C]-phenylglyoxal 48
2.7.3 Large scale labelling of ICDH for HPLC 49
(a) Labelling 49
(b) Digestion with pepsin 49
(c) HPLC reverse phase chromatography 49
2.7.4 Reaction with NaBH. 49
4
2.7.5 Inactivation of dephosphorylated ICDH-P
with phenylglyoxal 50
2.7.6 Digestion of [32P]-ICDH and [7-14C]-phenylglyoxal
- ICDH with thermolysin 50
2.8 Digestion of ICDH and ICDH-P with chymotrypsin 50
2.9 Synthetic peptide studies 51
2.9.1 Preparation of peptides 51
2.9.2 Analysis of peptide HN2 51
(a) Amino acid analysis 51
(b) Liquid phase sequencing 51
2.9.3 Phosphorylation of synthetic peptides 52
2.9.4 Detection of phosphorylated peptides 52
(a) Thin layer electrophoresis 52
(b) High voltage paper electrophoresis 52
(c) Anion exchange resin analysis 53
(vii)
Paj&e
2.10 Phosphorylation of chymotryptic digests of ICDH 53
2.11 Immunoblotting techniques 54
2.11.1 Stock solutions 54
2.11.2 Conditions 54
2.12 Circular dichroism 55
CHAPTER THREE - CHEMICAL MODIFICATION OF ISOCITRATE 
DEHYDROGENASE WITH PHENYLGLYOXAL
3.1 Introduction 59
3.2 Purification of ICDH 60
3.3 Inactivation of ICDH with phenylglyoxal 60
3.3.1 Effect of phenylglyoxal concentration 60
3.3.2 Protection against inactivation 61
3.3.3 Inactivation of ICDH from E.coli TGl/pCK505 with
phenylglyoxal 62
3.3.4 Labelling of ICDH with [7-^C]-phenylglyoxal 63
3.3.5 Labelling of phosphorylated ICDH with
14
[7- C]-phenylglyoxal 64
3.4 Effect of phenylglyoxal on chymotryptic digestion
of ICDH and ICDH-P 65
3.5 Discussion 66
(viii)
Page
CHAPTER FOUR - ATTEMPTS TO ISOLATE A PEPTIDE LABELLED
SITE OF ICDH
4.1 Introduction
4.2.1 Large scale labelling of ICDH with [7-^C]-
96phenylglyoxal
4.2.2 Labelling ^
974.2.3 HPLC analysis of peptides
4.3 Stability of the phenylglyoxal - arginine adduct 98
4.3.1 Dialysis 98
4.3.2 Washing with trichloroacetic acid 98
4.3.3 Stabilisation with NaBH. 99
4
32
4.4 Comparison of thermolytic digests of P-ICDH and
[7-14C]-phenylglyoxal-ICDH 99
4.5 Discussion 100
CHAPTER FIVE - SUBSTRATE RECOGNITION OF ICDH KINASE
115
5.1 Introduction
5.2 Preparation of synthetic peptides 117
(ix)
Page
5.3 Phosphorylation of synthetic peptides 1 1 7
5.3.1 Electrophoretic analysis of phosphorylation n g
5.3.2 Anion exchange resin analysis 1 1 9
5.4 Phosphorylation of chymotryptic digests of ICDH 120
5.5 Discussion 120
CHAPTER SIX - CONFORMATIONAL ANALYSIS OF ISOCITRATE 
DEHYDROGENASE WITH CIRCULAR DICHROISM
6.1 Introduction 138
6.2 Analysis of ICDH and ICDH-P conformations 139
6.3 Discussion 141
CHAPTER SEVEN - GENERAL DISCUSSION
7.1 Role of phosphorylation of ICDH 159
7.2 The active site of isocitrate dehydrogenase 160
7.3 ICDH kinase/phosphatase 161
7.4 Future work 163
REFERENCES 165
(x)
LIST OF FIGURES Page
CHAPTER OWE
1.1 Isocitrate dehydrogenase 22
1.2 The TCA cycle and glyoxylate bypass in E.coli 23
1.3 (a) Isocitrate lyase 24
(b) Malate synthase
(c) Phosphoenolpyruvate carboxylase
1.4 Control of the phosphorylation state of isocitrate
n c
dehydrogenase
1.5 Hypothetical scheme for the inactivation of isocitrate
dehydrogenase by phosphorylation ^
CHAPTER TWO
2.1 Basic scheme of solid phase peptide synthesis 56
2.2 Electrophoretic analysis of peptides 57
CHAPTER THREE
3.1 Purification of isocitrate dehydrogenase from E.coli
ML308 71
3.2 Inactivation of isocitrate dehydrogenase with 20mM
phenylglyoxal 7^
3.3 Inactivation of isocitrate dehydrogenase with the
dicarbonyl reagents 2 ,3-butanedione and
l,Z-cyclohexanedione 73
3.4 Effect of phenylglyoxal concentration on the inactivation
of isocitrate dehydrogenase 74
3.5
3.6
3.7
3.8
3.9
3.10
3.11
3.12
3.13
3.14
3.15
3.16
Inactivation of isocitrate dehydrogenase with 20mM 
phenylglyoxal - protection with NADP*
Inactivation of isocitrate dehydrogenase with 20mM 
phenylglyoxal - protection with isocitrate
• 4* *
Determination of Kg for NADP m  the presence 
of 20mM phenylglyoxal
Determination of the K value for isocitrate in
s
the presence of 20mM phenylglyoxal
Abortive substrate protection experiments
Inactivation of isocitrate dehydrogenase from
E.coli TGl/pCK505 with phenylglyoxal
14
Incorporation of [7- C]-phenylglyoxal into 
isocitrate dehydrogenase - %  inactivation vs 
incorporation
14
Incorporation of [7- C3-phenylglyoxal into
isocitrate dehydrogenase - effect of 200uM NADP+
14
Incorporation of [7- C 3-phenylglyoxal into 
isocitrate dehydrogenase - effect of lOOuM isocitrate 
and phosphorylation
Correlation between incorporation of label into 
isocitrate dehydrogenase and loss of enzyme activity 
Effect of phosphorylated isocitrate dehydrogenase 
reactivation mix components on phenylglyoxal 
inactivation of isocitrate dehydrogenase 
Reactivation of phosphorylated isocitrate 
dehydrogenase followed by phenylglyoxal inactivation
(xi)
Page
75
76
77
78
79
80
81
82
83
84
85
86
3.17
3.18
CHAPTER
4.1
4.2
4.3
4.4
4.5
4.6
4.7
4.8
Digestion of isocitrate dehydrogenase with 
chymotrypsin - effect of phenylglyoxal 
Digestion of phosphorylated isocitrate dehydrogenase 
with chymotrypsin - effect of phenylglyoxal
FOUR
Determination of the K value for citrate in
s
the presence of lOmM phenylglyoxal
HPLC separation of isocitrate dehydrogenase
peptic digests - (A)
HPLC separation of isocitrate dehydrogenase 
peptic digests -(B )
HPLC separation of isocitrate dehydrogenase
peptic digests - (C)
14
Loss of [7- C ]-phenylglyoxal from filter 
paper discs
32
Digestion of [ P3-phospho-isocitrate
14dehydrogenase and [7- C3-phenylglyoxal-isocitrate
dehydrogenase with thermolysin - silver stain 
32
Digestion of [ P3-phospho-isocitrate dehydrogenase 
14and [7- C3-phenylglyoxal-isocitrate dehydrogenase 
with thermolysin - autoradiograph
Scheme proposed for the reaction of arginine residues 
with dicarbonyl reagents
(xii)
Page
87
88
103
104
105
106
107
108
109
110
(xiii)
CHAPTER
5.1
5.2
5.3
5.4
5.5
5.6
5.7
5.8
5.9
5.10
5.11
5.12
FIVE
Sequence of peptide HN2
HPLC analysis of peptide HN2
Inactivation of isocitrate dehydrogenase with
ICDH kinase
Phosphorylation of kemptide by the catalytic
subunit of cAMP-dependent protein kinase.
Electrophoretic analysis - ninhydrin stain
Phosphorylation of kemptide by the catalytic
subunit of cAMP-dependent protein kinase.
Electrophoretic analysis - autoradiogram
Phosphorylation of HN2 with ICDH kinase.
Electrophoretic analysis - ninhydrin stain
Phosphorylation of HN2 with ICDH kinase.
Electrophoretic analysis - autoradiogram 
32
Incorporation of P into synthetic peptides
- anion exchange resin analysis
32
Incorporation of P into synthetic peptides
- anion exchange resin analysis
SDS analysis of peptide HN2 and chymotryptic 
digests of ICDH
Autoradiograph of isocitrate dehydrogenase 
chymotryptic digests kinase assays 
Structure of phosphorylase a
Page
124
125
126
127
128
129
130
131
132
133
134
135
(xiv)
Pa&e
CHAPTER SIX
6.1 Circular dichroism spectrum of isocitrate 
dehydrogenase
6.2 Circular dichroism spectrum of isocitrate
dehydrogenase in the presence of 150uM NADP*
6.3 Circular dichroism difference spectrum of the
isocitrate dehydrogenase +• 150uM NADP+ spectrum 
subtracted from the spectrum for isocitrate 
dehydrogenase
6.4 Circular dichroism spectrum of isocitrate
dehydrogenase in the presence of 50uM NADPH
6.5 Circular dichroism difference spectrum of the
isocitrate dehydrogenase + 50uM NADPH spectrum 
subtracted from the spectrum for isocitrate 
dehydrogenase
6.6 Circular dichroism spectrum of phosphorylated
isocitrate dehydrogenase
6.7 Circular dichroism spectrum of phosphorylated
isocitrate dehydrogenase in the presence of 150uM 
NADPH
6.8 Circular dichroism spectrum of the phosphorylated
isocitrate dehydrogenase + 150uM NADP* spectrum 
subtracted from the spectrum for phosphorylated 
isocitrate dehydrogenase
6.9 Circular dichroism spectrum of phosphorylated
isocitrate dehydrogenase in the presence of 
50uM NADPH
144
145
146
147
148
149
150
151
152
(xv)
6.10
6.11
6.12
6.13
6 . 1 4
6.15
Circular dichroism difference spectrum of the 
phosphorylated isocitrate dehydrogenase +• 50uM 
NADPH spectrum subtracted from the spectrum for 
phosphorylated isocitrate dehydrogenase 
Circular dichroism difference spectrum of the 
phosphorylated isocitrate dehydrogenase spectrum 
subtracted from the spectrum for isocitrate 
dehydrogenase
Circular dichroism difference spectrum of the 
phosphorylated isocitrate dehydrogenase +■ 150uM 
NADP+ spectrum subtracted from the spectrum for 
isocitrate dehydrogenase + 150uM NADP+
Circular dichroism difference spectrum of the 
phosphorylated isocitrate dehydrogenase + 50uM 
NADPH spectrum subtracted from the spectrum for 
isocitrate dehydrogenase +• 50uM NADP+
Circular dichroism spectrum of 150uM NADP+ 
Circular dichroism spectrum of 50uM NADPH
Page
153
154
155
156
157
158
(xvi)
LIST OF TABLES Page
CHAPTER ONE
1.1 Competition between isocitrate dehydrogenase and
isocitrate lyase 27
1.2 Phosphorylation sequences of selected eukaryotic
protein kinases 28
CHAPTER TWO
2.1 Preparation of SDS polyacrylamide gels 58
CHAPTER THREE
3.1 Purification of isocitrate dehydrogenase from
E.coli ML308 grown on 20mM glvcerol 89
3.2 Comparison of K and K values of isocitrate 
s m
dehydrogenase for NADP* and isocitrate 90
3.3
14
Incorporation of [7- C]-phenylglyoxal into 
isocitrate dehydrogenase and phosphorylated 
isocitrate dehydrogenase - effect of NADP+ and
isocitrate 91
3.4 Selective modification of arginyl residues 92
3.5 Comparison of the inactivation of three enzyme
activities with different dicarbonyl reagents 93
3.6 Comparison of the inactivation of a selection of
enzyme activities with phenylglyoxal 94
(xvii)
CHAPTER FOUR 
14
4.1 C-radioactivity associated with Peak 1 from
Figure 4.2 for three isocitrate dehydrogenase
phenylglyoxal incubations
14 . . 144.2 C-radioactivity associated with the [7- C3-
phenylglyoxal-isocitrate dehydrogenase peptic 
digests during the purification procedures 
employed
4.3 Effect of dialysis on the reactivation of
isocitrate dehydrogenase inactivated with 
phenylglyoxal
4.4 Effect of NaBH^ on the stability of the isocitrate
dehydrogenase-phenylglyoxal adduct
CHAPTER FIVE
5.1 Amino acid analysis of peptide HN2
5.2 Gas phase sequencing of peptide HN2
Page
111
112
113
114
136
137
(xvii
ABBREVIATIONS
All abbreviations used in this thesis are those recommended 
by the Biochemical Society, London, except for those listed below.
Bicine N,N-bis(2-hydroxyethyl) glycine
BSA Bovine serum albumin
cAMP cyclic AMP
CD Circular dichroism
DEAE Diethylaminoethyl
DTT Dithiothreitol
FPLC Fast Protein Liquid Chromatography
HPLC High Pressure Liquid Chromatography
ICDH Isocitrate dehydrogenase
ICL Isocitrate lyase
MOPS Morpholino propane sulphonic acid
NADP Nicotinamide - adenine dinucleotide phosphate
ORD Optical rotary dispersion
PAGE Polyacrylamide gel electrophoresis
PEP phosphoenolpyruvate
PG phenylglyoxal
PMSF Phenylmethylsulphonyl fluoride
SDS Sodium dodecyl sulphate
TCA Trichloroacetic acid
TEMED NjNjN'N'-tetramethylethylenediamine
TFA Trifluoroacetic acid
Tris Tris (hydroxy methyl) aminomethane
(xix)
Acknowledgements
I would like to thank my supervisor Dr. H.G. Nimmo for his 
constant help and encouragement throughout the supervision of this 
work. I should also like to thank the late Professor Smellie and 
Professor M.D. Houslay for making available the facilities of the 
Biochemistry Department; the Science and Engineering Research 
Council for a Research Studentship, 1985-88 and Professor R.H. Pain, 
Department of Biochemistry and Genetics, University of Newcastle, 
for his valuable discussion of the C.D. data.
My thanks are also due to the members of D-Floor: Mr. John
Greene who keeps D-Floor operating; Mrs, Margaret Fairbairn for 
keeping us supplied with clean glassware; Miss Fiona Douglas for 
growing the E.coli cells; also Gavin, Anne, Stewart, Jill, Peter, 
Helena, Pamela, Alan and Graeme.
I am grateful to Mrs. M. McKenzie and Mrs. S. Brown for 
typing this thesis.
Finally, I wish to thank my husband, Hugh, for his 
encouragement during my three years of study.
(xx)
Summary
The level of activity of the NADP-dependent isocitrate
dehydrogenase (ICDH) of E,coli ML308 is controlled by a reversible
phosphorylation mechanism during growth on acetate as sole carbon
source. Under such conditions the enzymes of the glyoxylate
bypass, isocitrate lyase (ICL) and malate synthase are induced.
This results in competition between ICDH and ICL for the available
isocitrate. To allow efficient use of isocitrate via the
glyoxylate bypass ICDH is phosphorylated on a single serine residue
per subunit which completely inactivates it. Phosphorylation of
ICDH is believed to occur at the NADP binding site, and so the
enzyme is inactive because it cannot bind its cofactor.
In this study chemical modification of ICDH has been used
to study the active site of the enzyme. In particular we wished to
identify any positively charged amino acid residues located at the
NADP* binding site of ICDH.
Since arginine residues are often found at nucleotide
binding sites we chose the arginine specific reagent phenylglyoxal.
Phenylglyoxal was found to inactivate ICDH in a pseudo-first-order
process. The inactivation was rapid and reproducible.
Phenylglyoxal was found not to be an affinity label for ICDH.
Protection against inactivation could be achieved either by NADP
binding to the enzyme or by phosphorylation. These results
suggested the existence of an arginine residue at the cofactor
binding site of ICDH. Analysis of the reaction using 
14
(7- C)-phenylglyoxal indicated that complete inactivation of the 
enzyme corresponded to incorporation of 1 mole of phenylglyoxal per 
mole of ICDH subunits.
14
Initial analysis of the arginine-[7- C]-phenylglyoxal 
adduct suggested the inactivation product was stable. However any
(xxi)
attempts to isolate a labelled peptide from peptic digests of ICDH 
revealed that the product was not stable under the conditions 
necessary to isolate a labelled peptide. However some indirect 
evidence was obtained that the same peptide in ICDH could be 
labelled by either phenylglyoxal or phosphorylation.
The analysis of substrate specificity of ICDH 
kinase/phosphatase using a 14-residue synthetic peptide 
corresponding to the known ICDH phosphorylation sequence indicated 
that the kinase activity did not recognise this primary sequence as 
a substrate. Furthermore attempts to phosphorylate chymotryptic 
digests of ICDH also failed. These results indicated that ICDH 
kinase appeared only to recognise intact ICDH as a phosphorylatable 
substrate. Possible reasons for this recognition mechanism will be 
discussed.
Finally, analysis of the conformation of ICDH on substrate 
binding or phosphorylation using circular dichroism in the near U.V. 
region was carried out. This indicated a change at 292nm for the 
active enzyme thought to occur as a result of NADP binding to the 
enzyme. However no such change was detected for phosphorylated 
ICDH indicating an inability of the phospho-form to bind NADP. 
Comparison of the CD spectra for active and phosphorylated ICDH 
showed no detectable change in conformation occurred on 
phosphorylation. These results suggested that phosphorylated ICDH 
is inactive because it is unable to bind its cofactor.
CHAPTER ONE
Introduction
1.1 Isocitrate dehydrogenase from Escherichia coli ML308
1.1.1 Introduction
The oxidative decarboxylation of isocitrate to give
2-oxoglutarate and carbon dioxide is catalysed by the enzyme isocitrate
dehydrogenase (Fig.1.1). The enzyme is found in most microorganisms,
animals and plants (Plaut, 1963). The work reported in this thesis is
concerned with the NADP-dependent isocitrate dehydrogenase from
Escherichia coli. E.coli like most bacteria, contains only an
NADP-dependent isocitrate dehydrogenase (Raglan et al. , 1966).
Eukaryotics, on the other hand, contain both an NAD and an NADP-dependent
enzyme, distinct also from each other by their cellular localisation,
mitochondrial and cytoplasmic respectively (Ernster & Navazio, 1956).
NADP-dependent isocitrate dehydrogenase (threo-D^-isocitrate
NADP+ oxidoreductase (decarboxylating) EC 1.1.1.42), hereafter ICDH,
2 +
requires Mn for the oxidative decarboxylation of isocitrate (Adler et
al., 1939). Further studies demonstrated that it was the
2 +
decarboxylation reaction as opposed to the oxidation that required Mn
2 + 2+ - 
(Ochoa, 1948) and that Mg could be substituted for the Mn
although it was less effective (Moyle, 1956). The natural coenzyme for
. + +* 
this ICDH is NADP . NAD is not active. ICDH is a TCA cycle enzyme;
its function is to produce 2-oxoglutarate for further oxidation in the
Krebs cycle and for biosynthesis.
1.1.2 Escherichia coli metabolism durinR growth on a single carbon 
source
In bacteria, as in animal tissues, catabolism is responsible for 
the breakdown of foodstuffs into a narrow range of small molecules which 
serve as the building blocks for the macromolecular constituents of the 
cell. The initial pathways of catabolism for most foodstuffs converge 
at the level of acetyl CoA. In most bacteria the Krebs cycle (Krebs and 
Johnston, 1937) serves as the final common pathway for the oxidation of 
these acetyl groups to CO^ and H^O with the concomitant
2.
production of reduced pyridine nucleotides and flavins. These reduced 
coenzymes transfer their high potential-electrons to 0^ via the 
electron transport chain generating ATP as a result of oxidative 
phosphorylation.
The TCA cycle also plays a role in biosynthesis by providing the 
necessary intermediates. Cells continually draw off oxaloacetate, 
2-oxoglutarate and succinyl CoA from the TCA cycle for biosynthetic 
reactions (Fig.1.2). When the cycle functions in its biosynthetic 
capacity, the removal of cyclic intermediates would prevent the 
regeneration of oxaloacetate and the cycle would cease to function.
Thus there must exist pathways ancillary to the TCA cycle which function 
to replenish the pools of cyclic intermediates and lead to the 
regeneration of oxaloacetate. Kornberg (1966) reviewed the evidence 
that different ancillary or anaplerotic pathways are required depending 
on the nature of the carbon source on which the organism is growing.
(a) Growth on glucose
Analysis of the carbon flux of E.coli during growth on glucose 
suggests that flux through the Krebs cycle is relatively small and is 
almost exclusively for biosynthesis. Nevertheless an anaplerotic 
reaction is still required. Kornberg and his coworkers studied mutant 
strains of E.coli that were unable to grow on glucose unless the medium 
was supplemented with certain dicarboxylic acids. They found that these 
mutants lacked the enzyme phosphoenolpyruvate carboxylase (EC 4.1.1.31) 
(Canovas & Kornberg, 1965 and 1966; Ashworth & Kornberg, 1966). The 
reaction carried out by this enzyme (Fig.1.3c) thus replenished the 
supply of oxaloacetate in the Krebs cycle. Phosphoenolpyruvate 
carboxylase was found to be activated by acetyl CoA. The 
rationalisation of this effect is that if the pool of oxaloacetate is 
reduced the acetyl CoA levels build up in the cell which results in an 
activation of PEP carboxylase (Canovas & Kornberg, 1966). During growth
on glucose, or an equivalent carbon source, there is no evidence that 
ICDH plays a significant role in regulating the flux through the Krebs 
cycle. It is not under any allosteric control, however the enzyme is 
subjected to concerted inhibition by glyoxylate and oxaloacetate. This 
inhibition is partly caused by a condensation of glyoxylate and 
oxaloacetate to yield the unstable compound oxalomalate, which is an 
extremely potent competitive inhibitor of ICDH, and partly caused by the 
slow binding of glyoxylate and oxaloacetate to the isocitrate binding 
site of the enzyme. Neither mechanism, however, seems to be 
physiologically significant (Nimmo, 1986). Holms and Bennett (1971), 
however, found that growth of E.coli on glucose resulted in approximately 
17% of the glucose carbon accumulating as acetate. When the glucose was
exhausted the cells adapted to utilise the acetate. During oxidation of
the acetate there was a drop in the activity of ICDH to approximately 25% 
of its original level. To understand the reasons for this decrease, we 
need to consider the metabolic pathways involved in growth on acetate.
(b) Growth on acetate
Growth of E.coli on acetate as sole carbon source requires the 
induction of the enzymes of the glyoxylate bypass, isocitrate lyase (EC 
4.1.3.1) and malate synthase (EC 4.1.3.2) (Kornberg, 1966). Isocitrate 
lyase catalyses the formation of glyoxylate and succinate from the 
cleavage of isocitrate (Fig.1.3a). Malate synthase catalyses the 
condensation of acetyl CoA with glyoxylate to give malate (Fig.1.3b).
The sequential operation of these enzymes was first demonstrated using 
extracts of Pseudomonas fluorescens (Kornberg & Madsen, 1957).
Subsequent studies with E.coli showed that both enzymes of the glyoxylate 
bypass are synthesised adaptively when the organism is switched to 
acetate metabolism (Reeves & Ajl, 1960).
4.
The induction of the enzymes of the glyoxylate bypass creates a
branchpoint at isocitrate (Fig,1.2), This results in competition
between ICDH and isocitrate lyase for the available common substrate
isocitrate. If the isocitrate is used by ICDH then the net effect is
loss of acetate carbon as CO^. However, isocitrate lyase (ICL)
bypasses the CO^ releasing enzymatic reactions of the TCA cycle
resulting in efficient use of acetate carbon for both cycle maintenance
and supply of biosynthetic precursors. Table 1.1 shows data related to
the competition arising between ICDH and ICL for isocitrate in E.coli.
The K value of ICDH for isocitrate is much lower than ICL, and as a 
m
result the available isocitrate would be utilised by ICDH. Thus the 
acetate carbon would be lost as CO^* there would be no available 
precursors for biosynthetic purposes, and cell growth would stop.
Therefore in order to allow flux of carbon through the glyoxylate bypass 
to occur, there must be some means either of inhibiting ICDH or 
activating the ICL in. vivo.
1.1.3 Reversible inactivation of isocitrate dehydrogenase
The observations made by Bennett and Holms during the comparison 
of the levels of three TCA cycle enzymes, ICDH, malate dehydrogenase and 
2-oxoglutarate dehydrogenase, in E.coli ML308 grown on different carbon 
sources indicated that ICDH can be reversibly inactivated in. vivo (Holms 
& Bennett, 1971; Bennett & Holms, 1975). These workers measured the 
specific activities of malate dehydrogenase, 2-oxoglutarate dehydrogenase 
and isocitrate dehydrogenase in cultures of E.coli ML308 over a four hour 
period after the cessation of growth on either limiting glycerol or 
limiting glucose. After cessation of growth on glycerol the three 
enzyme activities remained constant during the four hour period.
However, in the four hour period after cessation of growth on glucose the 
activity of the ICDH fell and after two hours in stationary phase, 80% of 
the original activity had been lost. During the following two hours
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ICDH activity rose again and four hours after growth ceased ICDH activity 
was restored to 75% of its maximum value. Malate dehydrogenase and
2-oxoglutarate dehydrogenase activities were unaffected during this four 
hour period (Holms & Bennett, 1971). This apparent
inactivation/activation of ICDH after growth on glucose was attributed to 
the fact that E.coli excretes acetate during growth on glucose but not on 
glycerol (Britten, 1954; Holms & Bennett, 1971).
After growth on glucose the enzymes of the glyoxylate bypass 
were induced and the excreted acetate oxidised. During the period of 
adaption to and use of acetate, the activity of ICDH declined, and it 
recovered only after the exhaustion of acetate in the medium. The 
addition of chloramphenicol at the end of growth on limiting glucose 
prevented the increase in isocitrate lyase activity and the loss of ICDH 
activity (Holms & Bennett, 1971). Loss of ICDH activity after cessation 
of growth on limited glucose could be prevented by addition of further 
glucose, pyruvate or any TCA cycle intermediate. However, when growth 
ceased a second time loss of ICDH activity was observed (Holms & Bennett, 
1971).
Since the variation in ICDH activity occurred on adaptation to 
acetate as sole carbon and energy source, Bennett and Holms (1975) 
examined the state of the enzyme in cells fully adapted to acetate.
They found the apparent activity of ICDH during exponential growth on 
acetate was one third of the level found for growth on glucose. When 
pyruvate was added to acetate grown cultures there was an immediate and 
rapid 3- to 4-fold increase in ICDH activity accompanied by an increase 
in growth rate. Chloramphenicol added simultaneously with pyruvate 
barely affected the changes in activity indicating that protein synthesis 
was not involved (Bennett and Holms, 1975). Further experiments carried 
out by the same workers, including dialysis and mixing of the extracts 
showed that changes in the intracellular level of a reversible activator
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were not involved in the observed changes in the level of ICDH activity 
(Bennett and Holms* 1975). E.coli ICDH is strongly inhibited by a 
mixture of glyoxylate and oxaloacetate (Shiio and Ozaki, 1968; Harr and 
Weber* 1968; Bennett and Holms* 1975). Shiio and Ozaki postulated that 
this inhibition in principle could be responsible for the low enzyme 
activities observed in cells with an operating glyoxylate bypass.
However* Bennett and Holms (1975) showed that extracts exhibiting either 
maximum or minimum ICDH activity were inhibited to the same degree by the 
two metabolites. They also detected no difference in the K values of 
the ICDH for NADP or isocitrate or in its pH or temperature dependence.
The evidence of Bennett and Holms (1975) indicated that the 
observed changes in the activity of ICDH observed during shifts to and 
from media containing acetate as sole source of carbon and energy were 
independent of protein degradation and de novo synthesis and were 
unaffected by freely dissociable low molecular weight molecules which 
might affect enzyme activity.
Bennett and Holms (1975) concluded from their results that 
either reversible covalent modification of ICDH or some form of 
reversible association of ICDH with some other macromolecule was 
responsible for the modulation of ICDH activity of cells growing on 
acetate. They also proposed that the role of inactivation of ICDH was 
to allow isocitrate lyase to compete successfully for isocitrate under 
conditions in which the operation of the glyoxylate bypass was essential 
for growth (Bennett and Holms* 1975).
Phosphorylation of ICDH was first implicated by the work of
32
Garnak and Reeves (1979a). They added P^ to E.coli K12 grown to
stationary phase on limiting glycerol in a low-phosphate medium.
Addition of acetate to the culture caused both a partial reduction in
32
ICDH activity and incorporation of P-phosphate into the enzyme. At 
this stage* however, the relationship between the phosphorylation and the
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activity of ICDH was not established. The system was, however, better 
characterised by the work of Nimmo and his coworkers (Borthwick et al.« 
1984a) and Koshland and coworkers (LaPorte and Koshland, 1983) (see 
Sections 1.2.3-1.2.5).
1.2 Phosphorylation of E.coli isocitrate dehydrogenase
1.2.1 Covalent modification
Recognition of the reversible covalent modification of proteins
as a major regulatory process was a result of work on mammalian glycogen
metabolism. Glycogen phosphorylase was shown to exist in two
interconvertible forms, a relatively inactive form, phosphorylase b and
an active form phosphorylase a. In resting muscle phosphorylase is in
the b form. The regulation of phosphorylase b by AMP was the first
example of the control of enzyme activity by an allosteric effector (Cori
et al.. 1938). Phosphorylase b is inactive in the absence of AMP, but
is just as active as phosphorylase a in its presence. The regulation of
phosphorylase b by AMP is however critically dependent on the substrate
inorganic phosphate (P^). As the concentration of P^ increases, the
concentration of AMP required for half maximal activation decreases and
conversely, the K for P. decreases as AMP increases (HelmreicVt and 
m i
Cori, 1964). On the other hand, activation by AMP is antagonised by 
both ATP and glucose-6-phosphate. Phosphorylase b is converted to 
phosphorylase a by an Mg-ATP requiring enzyme phosphorylase kinase.
This phosphorylation alleviates the allosteric control of phosphorylase a 
by AMP.
Fischer and Krebs (1955) demonstrated the ATP dependent 
conversion of phosphorylase b to a in cell free extracts of rabbit 
muscle. At the same time Sutherland and Wosilait (1955) showed that 
phosphate is liberated from purified rabbit liver phosphorylase a as it 
is inactivated enzymatically. Together these early observations 
indicated that the ATP-dependent phosphorylation of phosphorylase b
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converts the enzyme to the active form phosphorylase a and the subsequent 
release of this phosphate results in the regeneration of phosphorylase 
b. Since these initial observations of protein phosphorylation in 
glycogen metabolism a complex regulatory network has been uncovered. In 
1983 more than six protein kinases, four phosphoprotein phosphatases and 
several thermostable regulatory proteins had been discovered (Cohen,
1983; review Cohen, 1988).
Little or no progress however was made in understanding the
mechanism of activation of glycogenolysis in skeletal muscle until the
1950s. Earl Sutherland showed an enhancement of glycogenolysis and
phosphorylase activity by incubating liver slices with adrenalin.
However, the response to adrenalin was lost when the liver slices were
homogenised. With the discovery of the chemical nature of the change in
phosphorylase activity, phosphorylation, it became clear that ATP and 
2+
Mg would be necessary for inactivation. When added to the 
homogenised tissue they restored the sensitivity to adrenalin. These 
findings allowed the hormone response to be separated into two stages.
The first was action of adrenalin on the membrane to produce a small heat 
stable factor and the second was replacement by this factor of the 
hormone signal to increase the proportion of phosphorylase a. The 
factor was identified as adenosine 3*5' cyclic monophosphate (cAMP) 
(Robison et al., 1971).
The discovery that cAMP promoted the conversion of phosphorylase 
b to a indicated that this molecule must activate phosphorylase kinase or 
inhibit protein phosphatase-1. The discovery by Krebs and his coworkers 
(Walsh et al., 1968) of the enzyme cyclic AMP dependent protein kinase 
resolved the problem of how cAMP affected certain enzyme activities.
This enzyme phosphorylates phosphorylase kinase and activates it. This 
active form of phosphorylase kinase phosphorylates its substrate 
phosphorylase to give the a form.
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It was soon realised, however, that cAMP-dependent protein 
kinase did not just phosphorylate phosphorylase kinase but a whole range 
of substrates (reviewed Cohen, 1983). Similarly cAMP itself is produced 
in a variety of tissues in response to the interaction of many different 
hormones with their receptors. The hypothesis, therefore, arose that 
the specificity of hormones which act through cAMP is determined by 
whether their receptors are present on the plasma membrane of a target 
cell and which physiological substrates for cAMP-dependent protein kinase 
are present within these cells (Kuo and Greengard, 1969; Krebs, 1972).
In 1983 about 40 enzymes were known to be controlled by 
phosphorylation (Cohen, 1983). It is now recognised as the major 
mechanism by which intracellular events are controlled by extracellular 
stimuli and also in control of intracellular processes from within the 
cell itself in eukaryotes.
Covalent modification, however, is not restricted to protein 
phosphorylation/dephosphorylation reactions. Modifications have been 
described including acetylation-deacetylation (Gottscholl et al., 1982), 
uridylylation-deuridylylation (Adler et al., 1973), adenylylotion —  
deadenylyl&tion (Holyer et al., 1967), methylation-demethylation (Springer 
and Koshland, 1977) and also limited proteolysis e.g. chymotrypsinogen 
activation (Stroud et al., 1977). For the scope of this thesis we will 
only discuss phosphorylation- dephosphorylation reactions. This 
modification is very widespread in biological systems.
1.2.2 Protein phosphorylation
Protein kinases which catalyse protein phosphorylation reactions 
can be distinguished by their specificity with respect to the particular 
amino acid residue which serves as a phosphate acceptor.
The major group of protein kinases phosphorylate serine or 
threonine residues, for example in glycogen metabolism (Cohen, 1983).
Protein kinases catalysing the transfer of phosphoryl groups to histidine
or lysine residues have been reported by Smith et al. (1974). The most
recently described group of kinases phosphorylate tyrosine residues.
Examples include receptors for epidermal growth factor and insulin, and
the src gene product. A common feature connecting many but not all of
the eukaryotic protein kinases is their activation within the cell by a
second messenger which is released in response to an extracellular
stimulus such as hormone-receptor binding. Such second messengers
2+
mclude cAMP, cGMP, diacylglycerol and Ca . The most studied example 
of a protein kinase is probably cAMP-dependent protein kinase. The 
formation of cAMP within the cell occurs in a variety of tissues in 
response to hormone-receptor interaction. This complex stimulates 
adenylate cyclase to produce cAMP within the cell. cAMP-dependent 
protein kinase appears to be the only protein in mammalian cells that 
binds cAMP with high affinity (apart from cAMP phosphodiesterase). The 
enzyme exists in isoenzymatic forms designated as type I and type II 
(Reimann et al., 1971), consisting of two catalytic subunits and two 
regulatory subunits, which bind cAMP. In the absence of cAMP the 
regulatory (R) and catalytic (C) subunits have a high affinity for each 
other, but on binding of the nucleotide this affinity is decreased by a 
factor of 10 . The holoenzyme ^ 2 ^2  ^ *S *nac^ ve because a part 
of the regulatory subunit directly impedes the active site of the 
catalytic subunit. It has been proposed that cAMP binds to the R 
subunit of I*2C2 ^orm^nB an intermediate ternary complex 
cAMP^R^C^. A conformational change then occurs in the R subunit 
and they dissociate from the C subunits (R^(cAMP)^ + 2C) (Hoppe,
1985).
Similarly, the only protein kinases whose substrate 
specificities are reasonably well understood are the cAMP and 
cGMP-dependent kinases and the casein kinases. It was originally
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proposed for cAMP-dependent protein kinases that the tertiary structure 
of the protein substrate was important in substrate recognition (Langan, 
1973). However Daile and Carnegie (1974) demonstrated that bovine 
cardiac and brain enzymes could phosphorylate a 17 amino acid residue 
peptide. Bylund and Krebs (1975) showed that the denaturation of 
lysozyme enhanced its susceptibility to phosphorylation and proposed that 
the kinase recognised some feature of the primary structure around the 
target residue. Further work proved this idea to be correct. On the 
basis of the amino acid sequence analysis and studies with synthetic 
peptides, reviewed by Krebs and Beavo (1979), three main patterns have 
emerged as target sites for cAMP-dependent protein kinases:
Lys-Arg-X-X-Ser(P)
Arg-Arg-X-Ser(P )
Arg-Arg-Ser(P )
Table 1.2 shows a range of recognition sequences for a variety of protein 
kinases, and examples of physiological substrates.
Protein phosphorylation has thus been recognised to be an 
important mechanism for controlling cellular processes in eukaryotic 
cells, and information concerning new phosphorylated proteins, substrate 
specificity, mechanism of action and metabolic significance is increasing 
every year. In contrast to eukaryotes, the occurrence of protein 
phosphorylation in prokaryotes was for a long time a matter of 
controversy. It is only over the last decade that the existence of 
protein kinases and phosphatases has been well established (reviewed by 
Cozzone, 1984).
Vang and Koshland (1978) labelled Salmonella typhimurium cells
32
with P. and isolated at least four ribonuclease resistant and
l
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pronase sensitive P - c o n t a m m g  species using SDS polyacrylamide gel
electrophoresis. Incubation of a cell free extract with 
32
[gamma- Pl-ATP indicated that the same proteins could be labelled in.
12.
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vitro and in vivo. The phosphorylation reaction required Mg
Hydrolysis of the labelled proteins in 6N HCl at 110°C for 4 hours
liberated labelled material which was found to co-migrate with
phosphoserine and phosphothreonine standards. The finding of the two
labelled phosphoamino acids in the labelled proteins was a strong
argument that there was covalent modification (Wang and Koshland,
1978). If the phosphorylation reactions observed in prokaryotes are
analogous to eukaryotic phosphorylation reactions it would be expected
that prokaryotic phosphorylation would also serve to regulate some aspect
of cellular function.
Such a function has been determined for the phosphorylation
reaction of Escherichia coli isocitrate dehydrogenase. Only in this
case of prokaryotic phosphorylation has the physiological role and the
molecular details of the phosphorylation system been well studied on a
level comparable to eukaryotic systems (reviewed by Nimmo, 1984).
1.2.3 Phosphorylation of E.coli isocitrate dehydrogenase
The ICDH of E.coli is a dimer of identical subunits of M 
  r
45000 (Borthwick et al., 1984a). I have already discussed its location
at the branchpoint between the TCA cycle and glyoxylate bypass and its
inactivation/activation during growth on acetate as sole carbon source.
Results from Reeves* group first showed that during adaptation
to acetate the ICDH of E.coli becomes phosphorylated (Garnak and Reeves,
1979a,b). When acetate was added to a culture of E.coli K12 grown to
32
stationary phase and then incubated with P^, this caused partial
32
inactivation of ICDH. A phosphorylated form of ICDH containing P as 
phosphoserine was isolated from the culture and shown to be 
immunologically identical to active ICDH from glucose grown cells. 
Borthwick et al. (1984a) isolated the active form of ICDH from glycerol 
grown cells and the inactive form from acetate.grown cells. They showed 
that the two forms could be resolved by non-denaturing gel
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electrophoresis and differed in charge but not molecular weight, amino 
acid composition or 2-dimensional peptide maps. The alkali-labile 
phosphate content of the two forms was determined. This showed that 
active ICDH contained no detectable phosphate whereas the inactive form 
contained somewhat less than one mole phosphate/45000g. Thus the data 
suggested a difference between the two forms of one phosphate group per 
subunit (Borthwick et al., 1984a).
The result that this reversible phosphorylation reaction only 
occurs during growth on acetate as sole carbon source, indicates a 
roetabolically significant role for the inactivation reaction. 
Phosphorylation of ICDH during acetate growth, and hence inactivation of 
the ICDH, releases the competition between ICDH and ICL for the available 
isocitrate, thus allowing efficient use of acetate carbon via the 
glyoxylate bypass.
1.2.4 In vivo phosphorylation of ICDH
An important part of studying a phosphorylation system is to
establish its occurrence in. vivo. By using cells labelled with 
32
[ P]-P., Borthwick et al. (1984b), showed that activation and
inactivation of ICDH correlated with its dephosphorylation and 
rephosphorylation respectively. Their results indicated that the 
reversible changes in the activity of cells grown on acetate were solely 
due to phosphorylation/dephosphorylation. Isolation of the in vivo 
phosphorylated form followed by chymotryptic digestion indicated that the 
same phosphopeptide was present as compared to the in vitro 
phosphorylated ICDH (Borthwick et al., 1984b). Thus the serine residue 
labelled in vivo is the same as that phosphorylated by purified kinase in 
vitro.
1.2.5 A bifunctional ICDH kinase/phosphatase
Purification of ICDH kinase and ICDH phosphatase activities was 
first achieved by LaPorte and Koshland (1982). ICDH kinase was purified
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using three steps: ammonium sulphate fractionation; DEAE-Sephacel
chromatography and affinity chromatography using ICDH immobilised on 
Sepharose 4B. When they started to purify the phosphatase activity it 
was apparent that the same purification steps were needed, and that the 
ratio of the kinase and phosphatase activities remained constant 
throughout the purification procedure. They tried to separate the two 
activities using ion-exchange, Sephadex G150 and again on the ICDH 
affinity column but found that the two activities were always eluted 
superimposably. The purified enzyme, with both activities, gave only 
one band on SDS gels. This suggested either that the two activities 
were located on the same polypeptide chain or on two different subunits 
with the same electrophoretic mobility, and chromatographic behaviour.
The former was later shown to be the case by cloning and deletion 
mutagenesis experiments (LaPorte and Chung, 1985), and maps the gene to 
the glyoxylate bypass operon.
An unusual feature of the ICDH phosphatase activity is its
absolute requirement for ATP or ADP (LaPorte and Koshland, 1982). The
32
radioactivity released from [ P]-phospho-ICDH appears as inorganic 
phosphate rather than ATP, indicating that dephosphorylation had not 
simply resulted from the back reaction of the kinase (LaPorte and 
Koshland, 1982). During experiments intended to identify the role of 
the nucleotide in the phosphatase reaction, Stueland et al. (1987) 
discovered that ICDH kinase/phosphatase catalysed an ATPase reaction. 
Further characterisation of the ATPase activity indicated that the 
activity was associated with the bifunctional enzyme not a contaminating 
ATPase. Experiments carried out with mutant derivatives of ICDH 
kinase/phosphatase which were nearly devoid of ICDH phosphatase activity 
retain both ICDH kinase and ATPase activity, indicating that ATP 
hydrolysis does not result from the cyclic phosphorylation of ICDH. 
However, the ICDH kinase and ATPase activities of these mutant proteins
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differ significantly from the wild type ICDH kinase/phosphatase expressed 
from the parent allele. This suggested that ICDH kinase and ICDH 
phosphatase do not reside on structurally independent domains. ATP 
hydrolysis was only partially inhibited by phospho- and dephospho-ICDH 
with saturating levels of phospho-ICDH decreasing the rate of ATP 
hydrolysis by a factor of approximately 5. During further analysis of 
the kinetic behaviour of the wild-type and mutant proteins, Stueland et 
al. (1987) found that the ICDH kinase, ATPase and residual ICDH 
phosphatase activities of the mutant proteins all exhibit reduction in 
their affinity for phospho-ICDH. They propose that the simultaneous 
loss of affinity for phospho-ICDH by all three activities might suggest 
that the ICDH kinase, ICDH phosphatase and ATPase reactions are catalysed 
by the same active site (Stueland et al., 1987). They propose that the 
kinase and phosphatase reactions occur at the same active site and that 
the phosphatase reaction results from the kinase back reaction tightly 
coupled to ATP hydrolysis and this model in part provides an explanation 
for the observation that the ICDH phosphatase reaction is absolutely 
dependent on either ATP or ADP (Stueland et al., 1987). The results of 
Varela and Nimmo (1988), using photoaffinity labelling confirm one 
prediction of this model, that the ICDH kinase/phosphatase contains only 
one ATP binding site.
Nimmo et al. (1984) went on to better characterise the two 
reactions, and their effect on ICDH activity using ICDH 
kinase/phosphatase purified over a thousand fold from E.coli ML308. 
Results showed that the kinase catalyses the transfer of the 
gamma-phosphate group of ATP to a serine residue of active ICDH with a 
stoichiometry of 1 per subunit. Phosphorylation essentially totally 
inactivated ICDH. ICDH phosphatase was capable of catalysing full 
reactivation of phosphorylated ICDH provided that the kinase was not 
active simultaneously. Nimmo et al. (1984) reported an absolute
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requirement of a divalent metal ion for phosphatase activity and also
confirmed the requirement for ADP or ATP. Analysis of the phosphatase
reaction showed that the product was P. and hence reactivation was not
produced by reversal of the kinase (see above). Experiments carried out
by Nimmo et al. (1984) showed that the kinase and phosphatase activities
could be active simultaneously in vitro. In the presence of ATP alone,
32
assaying for ICDH phosphatase activity, P was released from the 
32
substrate P-phospho-ICDH. However, in these conditions the activity
of the ICDH remained at a very low level. This indicated that both ICDH
kinase and ICDH phosphatase were active under these conditions: the
32
P. removed by the phosphatase was replaced by unlabelled phosphate
from the ATP present in the incubation. The results of Borthwick et al.
(1984b) showed that both activities can be active simultaneously in
32
vivo: addition of P^ to cells growing on acetate in which the ICDH
32was about 75% phosphorylated resulted in more rapid P-labelling of 
the ICDH than could be accounted for by de novo protein synthesis.
Nimmo et al. (1984) proposed that the phosphorylation state of ICDH in 
intact cells, grown on acetate, represents a steady state balance between 
the activities of ICDH kinase and ICDH phosphatase.
Figure 1.4 shows the control of the two activities by a range of 
metabolites. Metabolites which inhibit the kinase stimulate the 
phosphatase therefore resulting in increased sensitivity of the system 
(Nimmo and Niirano, 1984). These workers proposed that the 
phosphorylation of ICDH by the kinase renders it rate limiting in the TCA 
cycle, resulting in an increase in the level of isocitrate in the cell. 
This rise in isocitrate levels allows isocitrate lyase to operate at an 
increased level, and allows efficient use of acetate carbon via the 
glyoxylate bypass (Nimmo and Nimmo, 1984).
Isocitrate lyase has been purified from E.coli ML308 and its 
kinetic properties studied (Mackintosh and Nimmo, 1988). Product and
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dead-end inhibition studies showed that the enzyme obeyed a random-order
equilibrium mechanism. It is inhibited by several biosynthetic
precursors, notably: phosphoenolpyruvate, 2-oxoglutarate and
3-phosphoglycerate. Kinetic analysis, however, showed that in all cases
these metabolites merely act as substrate analogues and that allosteric
effects are not involved. Table 1.2. shows a comparison of K values
m
for ICDH and ICL, taking into consideration the known inhibitors of ICL
(Nimmo et al., 1987). The inactivation of ICDH by phosphorylation would
thus enable the isocitrate levels within the cells to increase to allow
flux through isocitrate lyase. El-Mansi et al. (1985) measured the
levels of isocitrate within the cell for acetate and glycerol growth and
their results agree with the theory of a rise in intracellular isocitrate
levels as a result of ICDH phosphorylation.
Nimmo and his coworkers therefore studied regulation of the
enzyme activities of the components of the system to reach a conclusion
about the metabolic significance of ICDH phosphorylation. At the same
time LaPorte et al. (1984) reported the results of a theoretical analysis
of the fluxes through the two limbs emerging from a branchpoint as a
function of the kinetic parameters of the two competing enzymes. They
showed that the partitioning of flux was extremely sensitive to changes
in the activity of one enzyme if its K for the common substrate was
m
much lower than that of the competing enzyme. They suggested that the
conditions apply to ICDH (low K for isocitrate) and isocitrate lyase
m
(high K for isocitrate) and that the * branchpoint effect' may 
m
contribute to the control of flux between the TCA cycle and the
glyoxylate bypass in intact cells. Walsh and Koshland (1984) developed
techniques that allowed them to determine the net rates of carbon flux
through the central metabolic pathways during growth on acetate. They
then studied the transition caused by the addition of glucose to acetate 
grown cells (Walsh and Koshland, 1985). This perturbation caused
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dramatic decreases in the flux through isocitrate lyase and the 
intracellular content of isocitrate. These changes apparently resulted 
from a 4-fold increase in ICDH activity, caused by dephosphorylation, and 
a 5-fold decrease in the flux through citrate synthase.
Two groups, working independently, and using different 
approaches, thus came to the same conclusions concerning the metabolic 
significance of ICDH phosphorylation, namely that it serves as a 
regulation mechanism to optimise the division of flux between the TCA 
cycle and the glyoxylate bypass.
1.3 Comparison of the active and inactive forms of ICDH
The phosphorylated and non-phosphorylated forms of ICDH can be 
separated by non-denaturing gel electrophoresis. They differ in charge 
but not in size (Borthwick et al., 1984a). The purification procedure 
for the two forms of ICDH employed by Borthwick and his coworkers involve 
a chromatographic step using Procion-red sepharose. It is thought that 
triazine dyes bind to the nucleotide-binding sites of many enzymes.
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They obtained specific elution of active ICDH from the matrix by NADP , 
which was consistent with such an effect. However, Borthwick et al. 
(1984a) found that the inactive, phosphorylated, form of ICDH was unable 
to bind to the triazine dye. Garland and Nimmo (1984) later proposed 
that enzyme phosphorylation occurred at the NADP binding site and as a 
result was unable to bind its cofactor NADP*.
Garland and Nimmo (1984) looked at the differences between 
phosphorylated and non-phosphorylated ICDH using limited proteolysis and 
fluorimetry. Digestion with chymotrypsin and other proteases revealed 
that the inactive form was resistant to proteolysis but the active form 
was not. NADP* could protect the active form but not the inactive 
form. In the case of eukaryotic enzymes regulated by 
phosphorylation/dephosphorylation there is evidence from proteolysis 
experiments that the phosphorylation site is not part of the active site,
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and proteolytic removal of the phosphorylated residue can occur which 
mimics the effects of dephosphorylation (e.g. Huang and Cabib, 1974). 
Phosphorylated ICDH did not conform to this pattern. Garland and Nimmo 
(1984) were unable to reactivate ICDH by proteolysis.
Garland and Nimmo (1984) showed that addition of NADPH to active
ICDH resulted in an enhancement of the fluorescence of the coenzyme with
no wavelength shift in its emission and excitation spectra. The
addition of NADPH to inactive ICDH had no effect on either fluorescence
yield or the emission and excitation spectra of the coenzyme. The
conclusion was reached that NADPH bound tightly to active ICDH but
to
appeared unable to bind^inactive ICDH (Garland and Nimmo, 1984).
The hypothesis proposed by Nimmo (1984) to explain the 
differences between the active and inactive forms of ICDH proposes that 
binding of NADP* to the active form of ICDH promotes a conformational 
change, as shown by proteolysis protection, and that phosphorylation 
occurs close to or at the NADP binding site producing a similar 
conformational change. The introduction of a negatively charged 
phosphate group near the coenzyme binding site could prevent binding of 
NADP by charge repulsion (Fig.1.5). This also explains why 
phosphorylated ICDH cannot be reactivated by proteolysis. Removal of 
the phosphorylated serine would disrupt the active site of the enzyme.
Thorsness and Koshland (1987) used site-directed mutagenesis to 
change the phosphorylatable serine residue to a negatively charged amino 
acid, aspartate. They found that this inactivated the enzyme.
However, they did not isolate the mutant ICDH and check its 
conformation. It is therefore possible that the mutant protein is 
inactive due to an inability to fold correctly. Thus their data do not 
prove conclusively that inactivation was as a result of the introduction 
of the negative charge.
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The amino acid sequence round the phosphorylation site has been
determined for ICDH from E.coli ML308 (Borthwick et al., 1984c) and
E.coli K12 (Malloy et el., 1984). The phosphoserine is located in a
unique 22-residue chymotryptic peptide, the first 14 residues of which
have been sequenced. This was the first phosphorylation sequence
reported for a bacterial protein kinase. The sequence is unlike that of
sequences at eukaryotic phosphorylation sites.
If the theory of how phosphorylation affects ICDH activity
proposed by Nimmo (1984), see Figure 1.5, is correct then E.coli
provides a phosphorylation system whose mechanism is quite different from
those involved in most other phosphorylation systems known, and provides
a good basic model for further structural analysis of the protein.
1.4 Aims of thesis
This introduction has described how in E.coli ICDH activity is
controlled by a reversible phosphorylation mechanism catalysed by the
bifunctional enzyme ICDH kinase/phosphatase. The components of the
system have already been well studied and a hypothesis proposed as to how
phosphorylation affects ICDH activity (Fig.1.5). It remains to look at
the structural and functional aspects of how phosphorylation affects ICDH
activity. When I started my research in October 1985 my objectives were
divided into three main areas
i) Active site studies
With the use of chemical modification of amino acid residues I
hoped to be able to identify residues located at the active site of
ICDH. In particular I wanted to identify any positively charged 
• • •
residues involved m  NADP binding and to investigate whether these 
interacted with the phosphate group in phospho-ICDH.
ii) Substrate recoRnition studies
What feature of ICDH does ICDH kinase recognise as a substrate 
and phosphorylate? In particular I intended to use synthetic peptides 
as trial substrates.
iii) Conformation studies
How is the conformation of ICDH affected by substrate binding 
and phosphorylation? I hoped to be able to detect and compare changes 
in the conformation of ICDH induced by binding of substrates or by 
phosphorylation.
Figure 1.1 Isocitrate dehydrogenase catalyses the oxidative 
decarboxylation of isocitrate to give 2-oxoglutarate
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Figure 1.2 The TCA cycle and glyoxylate bypass in E.coli
1. Isocitrate lyase
2. Malate synthase A
3. Phosphoenolpyruvate carboxylase
4. Isocitrate dehydrogenase
represents routes to biosynthesis
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Figure 1,3
A
B
ISOCITRATE LYASE catalyses the reversible aldol 
cleavage of isocitrate to form succinate and glyoxylate
MALATE SYNTHASE catalyses the condensation of 
glyoxylate with acetyl CoA to form malate
C PHOSPHOENOLPYRUVATE CARBOXYLASE catalyses the
carboxylation of phosphoenolpyruvate to form 
oxaloacetate
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Figure 1.4 Control of the phosphorylation state of isocitrate
dehydrogenase
+ and - represent stimulatory and inhibitory effects 
respectively. Both ICDH kinase and ICDH phosphatase are 
associated with a single bifunctional protein. Figure from 
Nimmo (1984).
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Figure 1.5 Hypothetical scheme for the inactivation of isocitrate 
dehydrogenase by phosphorylation
The hatched area represents the coenzyme binding site and the 
CH^OH group is the side chain of the phosphorylated serine 
residue. The positive sign at the surface of the enzyme represents 
a positively charged group (or groups) that interact with the 
negatively charged phosphate groups of NADP+ . Taken from Nimmo 
(1984).
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Active ICDH
Binding ot NADP
NADP
Table 1.1 Competition between isocitrate dehydrogenase and 
isocitrate lyase
Taken from Nimmo et al.., 1987,
* at 40pM NADP* (Nimmo, 1986). The concentrations of
isocitrate in E.coli ML308 growing on glycerol and acetate 
are 20pM and 0.57mM, respectively (El-Mansi et al.., 1985).
ICDH - isocitrate dehydrogenase 
ICL - isocitrate lyase
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Table 1.1
ICDH ICL
Specific activity in acetate 
grown cells
0.9u/mg 0.8u/mg
Km for Ds-isocitrate 
ignoring inhibitors
5jiM* 63jiM
Significant inhibitors none 3-phosphoglycerate
(Ki=0.8mM:
intracellular conc. = 
2.5mM)
Sulphate
<Ki=20mM:
intracellular conc. 
unknown)
Estimated Km for Ds -
isocitrate in intact cells 5jjM 260jiM
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CHAPTER TWO
Materials and Methods
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2.1 Materials
2.1.1 Biochemicals
Ammonium sulphate (enzyme grade), glycine, hydrogen peroxide 
methionine, D,L-norleucine and urea were from BDH Chemicals, Poole,
Dorset, U.K.
Ampicillin, Benzamidine, N,N-bis (2-hydroxyethyl) glycine 
(Bicine), Bromophenol blue, 2,3-butanedione, DL-isocitrate (trisodium 
salt), morpholino propane sulphonic acid (MOPS), naladixic acid, 
ninhydrin, 2-oxoglutarate, phenylglyoxal, phenylmethylsulphonyl fluoride 
(PMSF), Protamine sulphate (salmon, grade II), silver nitrate, sodium 
borohydride and tris-(hydroxymethyl) aminomethane (Tris) were from Sigma 
(London) Chemical Company, Poole, Dorset, U.K. Adenosine 5' diphosphate 
(ADP), adenosine 5* triphosphate (ATP), nicotinamide adenine dinucleotide 
phosphate (NADP+), phenazine methosulphate, phosphoenol pyruvate (PEP) 
and tetranitro blue tetrazolium were from Boehringer Corporation (London) 
Ltd., Lewes, Sussex, U.K.
Dithiothreitol was from Koch Light Laboratories, Colnbrook, 
Berks, U.K.
1,1-cyclohexanedione was from Aldrich Chemical Company, Ltd., 
Gillingham, Dorset, U.K.
2.1.2 Enzymes
Protein kinase catalytic subunit (Bovine heart) was from Sigma 
(London) Chemical Company, Poole, Dorset, U.K. Alpha-chymotrypsin, 
pepsin and Bacillus thermoproteolvticus thermolysin were from Worthington 
Biochemical Corporation, Freehold, New Xersey, U.S.A.
Staphylococcus aureus V8 protease was obtained from Miles, 
Slough, U.K.
Purified preparations of ICDH kinase/phosphatase (Nimmo et al., 
1984) were gifts from Dr. H.G. Nimmo.
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2.1.3 Radiochemicals
All radiochemicals were from Amersham International, Bucks, U.K. 
and were as listed below:
32
Adenosine 5'-[gamma- P]-triphosphate (3000Ci/mmol) 
[7-^Cj-phenylglyoxal . (25mCi/mmol).
2.1.4 Chemicals for polyacrylamide gel electrophoresis 
Acrylamide monomer, ammonium persulphate, 2-mercaptoethanol,
N,N* methylenebisacrylamide, sodium dodecylsulphate (SDS), and N,N,N*N* 
tetramethyl ethylenediamine (TEMED) were ’analar* grade materials from 
BDH Chemicals, Poole, Dorset, U.K.
2.1.5 Chromatographic media and reagents
Silica gel thin layer chromatography plates were from
Machercy-Nagel and Company, West Germany. Sephadex G50, Sephadex G25 
and Mono Q ion exchange pre-packed column were from Pharmacia, Milton 
Keynes, Bucks, U.K.
Chromatography paper (3MM) and diethylaminoethyl (DEAE) 
cellulose (microgranular form, DE52) were from Whatman Biochemicals, 
Maidstone, Kent, U.K. Anion exchange resin AG1-X8 (100-200 mesh) was 
from Bio-Rad Laboratories, Richmond, California, U.S.A.
Procion red sepharose was prepared by Dr. H.G. Nimmo.
2.1.6 Miscellaneous Materials
Vitamin B^ was from Fluka AG, Bucks S.G. Switzerland. Bovine 
serum albumin, coomassie brilliant blue G250/kemptide, low M^ standard 
proteins for SDS PAGE, lubrol PX and Tween 20 were from Sigma (London) 
Chemical Company, Poole, Dorset, U.K.
Chymostatin was from Boehringer Corporation (London) Ltd., 
Lewes, Sussex, U.K.
Nutrient broth (CM1) and Nutrient agar No.l (CM3) were from 
Oxoid Ltd., Sasingstoke, Hants, U.K.
Bactotryptone and yeast extract were from Difco Laboratories, 
Detroit, Michigan, U.S.A.
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Normal goat serum and peroxidase conjugate goat anti rabbit IgG 
were from the Scottish Antibody Production Unit Ltd., Carluke, Lanarks, 
U.K.
All other chemicals were from BDH Chemicals Ltd., Poole, Dorset,
U.K. and were of the highest grade obtainable.
2.2 General biochemical methods
2.2.1 pH and conductivity measurements
All pH measurements were made with a Radiometer pH probe 
calibrated at room temperature using standards of pH7 and pH4 prepared 
from tablets obtained from the manufacturer.
Conductivity measurements were made on a Radiometer conductivity 
meter, type CDM2e (Radiometer, Copenhagen, Denmark).
2.2.2 Glassware and plastics
Glassware was washed with Haemo-sol solutions (Alfred Cox 
(Surgical) Ltd., U.K.), rinsed with tap water and then distilled water 
and dried in an oven. Plastic tips for micropipettes were used from a 
newly opened bag.
2.2.3 Micropipettes
For dispensing volumes of 5jil-lml adjustable *Finnpipettes* 
(Finnpipette Ky, Pulti 9, SF-00810, Helsinki 81, Finland) were used. 
Volumes of 0.5|il-5pl were dispensed using micro-syringes (Scientific 
Glass Engineering Pty Ltd., North Melbourne, Australia 3051).
2.2.4 Distilled water
Glass distilled water stored in polythene containers was used in 
all experiments.
2.2.5 Dialysis
Dialysis membranes (Scientific Instruments Centre Ltd., London), 
were boiled for 5 min in 1% (w/v) EDTA pH7.0, stored in 20% ethanol and 
rinsed in distilled water prior to use.
2.2.6 Protein estimations
Protein concentrations were determined by the method of Bradford 
(1976). This method is based on the binding of Coomassie Brilliant Blue 
to the protein. The reagent was prepared by dissolving lOOmg Coomassie 
Brilliant Blue G250 in 50ml of 95% (v/v) ethanol and 100ml of 85% (w/v) 
orthophosphoric acid. The reagent was made up to 1 litre with distilled 
water and filtered. For each set of assays, a standard curve in the 
range 0-25jig protein was obtained using a lmg/ml BSA solution which was 
made up assuming a lmg/ml BSA solution has an absorbance of 0.62 at 
280nm. To each sample 2.5mls of Bradford Reagent was added, the samples 
vortexed and allowed to stand for 2 minutes. The absorbances were 
recorded at 595nm. The amount of protein present in the unknown sampies 
was estimated from the standard curve.
Protein concentrations of the fractions elicited from columns 
were monitored at 280nm.
2.2.7 Concentration of protein samples
Samples of greater than 10ml were concentrated by vacuum 
dialysis. Smaller volumes were concentrated using Centricon 30 
micro-concentrators (Amicon Ltd., Stonehouse, U.K.).
2.2.8 Preparation of chromatographic media
Sephadex G-25 and G-50 were swollen and poured according to the 
manufacturers instructions.
DEAE-cellulose (Whatman DE-52) was obtained pre-swollen. It 
was resuspended in starting buffer, and the pH adjusted to the correct 
value before equilibration in starting buffer. Procion-red Sepharose 
was suspended in starting buffer. After use it was washed with either 
6M Guanidinium Chloride or 8M urea. Anion exchange resin AG1-X8 
(Bio-Rad, Richmond, USA) was suspended in starting buffer and discarded 
after use.
All columns were poured at room temperature, stored in 0.02% 
(w/v) sodium azide and equilibrated with starting buffer before use.
2.2.9 Lvoph i1i s at i on
Samples were frozen in a suitable vessel by dipping into a 
methanol/dry ice mixture. Tops were sealed with Nescofilm punctured 
with a needle. Samples were placed in a dessicator connected to a 
Flexi-dry (FTS Systems Inc., Stone Ridge, N.Y., USA) and vacuum 
maintained by a high vacuum pump (Javac Pty., Ltd., U.K.)
2.2.10 Sterilisation
Solutions for the preparation of growth media were autoclaved in 
a Manlove-Alliot Autoclave supplied with steam from a Speedlec-electrode 
boiler. Media were autoclaved at 15 p.s.i. for 25 min except carbon
sources which were autoclaved at 5 p.s.i. for 50 min.
Because of their probable heat lability the following compounds
were sterilised by filtration through 0.22pm pore-sized Millex G.V.
filters (Millipore Ltd,, U.K.) into sterile bottles: ampicillin,
methionine, vitamin and naladixic acid.
2.3 Microbiological techniques
2.3.1 Bacterial strains
Escherichia coli ML308 (ATCC 15224) was originally obtained from 
the American Type Culture Collection (Rockville, Maryland, USA). It has 
been maintained in Glasgow for twenty years. It has the genetic
. - f f f ,
configuration l z y a for the lac operon. Because defective 
repressor is produced, synthesis of the products of the operon 
(beta-galactosidase, beta-galactosidase permease and thiogalactoside 
transferase) is constitutive. The identity of the organism can 
therefore be checked by assaying for beta-galactosidase which is present 
during growth on all media. In all other respects the strain is 
regarded as wild type.
Escherichia coli strains LE392 (a K12 derivative) and KAT-1 (an 
ace B+ ace A mutant) derived from LE392 by transposon TnlO insertion 
(Maloy and Nunn, 1982) were from the late Dr. W.D. Nunn (University of 
California, Irvine, USA). The plasmid bearing strain KAT-l/pEM9 was
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constructed by Dr. E.M.T. El-Mansi (El-Mansi et al., 1987). Growth of 
this strain is described in Methods 2.3.4.
Escherichia coli EB106 was obtained from the E.coli genetic 
stock centre (Yale Univ., New Haven, USA). It has the genetic 
configuration icd , dad RI , trp A62, trp E61, tna S, lambda 
(Apostolakus et al., 1982). Growth of this strain is described in 
Methods 2.3.4 (e).
Escherichia coli TGl/pCK505 a K12 derivative ( lac pro. Sup E, 
thi, hsd D5/f \  tra D36, pro A+B+ , lac 1^, lac z, M15) contains 
a plasmid carrying the ICDH gene. It was constructed by Dr. K.
Duncan. The original strain E.coli TGI was from Anglian Biotechnology 
Ltd., Hawkins Road, Colchester, Essex and the plasmid pCK505 from D.E. 
Koshlands laboratory, University of California, Berkeley, California. 
Growth of this strain is described in Methods 2.3.4 (f).
2.3.2 StoraRe of bacteria
o
Organisms were maintained in nutrient broth, stored at 4 C. 
Subcultures were made at 6 to 12 monthly intervals. Samples were 
checked for homogeneity microscopically and in the case of E.coli ML308, 
by plating out on nutrient agar containing lOpg/ml 
5-bromo-4-chloro-indoxy -beta-galactoside (BCIG agar). A cell 
constitutive for beta-galactosidase produces a blue colony on BCIG agar 
so a homogenous culture of lac-constitutive cells produces only blue 
clones.
2.3.3 Media
(a) Nutrient broth was prepared from Oxoid dehydrated granules
dispensed in 10ml aliquots into Universals and sterilised by autoclaving 
at 15 p.s.i.
(b) Nutrient aRar. 15g agar was dissolved in 1 litre nutrient
broth, sterilised at 15 p.s.i., poured into petri dishes in a filtered 
air cabinet and allowed to solidify. Plates were stored at 4°C.
(c) BCIG agar. BCIG (2mg/ml in dimethylformamide) was added to 
nutrient agar to a final concentration of lOpg/ml, Plates were stored 
at 4°C.
(d) L-broth. lOg bactotryptone, 5g yeast extract and lOg NaCl were 
dissolved in 1 litre of distilled water pH to 7.5. Solution was 
dispensed in the volumes necessary and sterilised by autoclaving at 15 
p.s.i.
(e) Defined media for specifically pre-inducinR inocula. This was 
prepared by mixing set volumes of the following three components.
i) PNS - 66.7mM potassium dihydrogen phosphate (9.06g/litre), 
16.7mM ammonium sulphate (2.2g/litre) adjusted to pH7.0 with 5N 
sodium hydroxide. This was dispensed in 60ml volumes in 250ml 
conical flasks and autoclaved at 15 p.s.i. 
ii) FeSO^ - 0.8mM ferrous sulphate (0.22g/litre FeSO^,.
adjusted to pH2 with HCl and autoclaved at 15 p.s.i.
iii) Carbon source - 2.5 times final concentration required plus 
1.25mM magnesium sulphate (0.3g/litre MgSO^.JH^O).
Dispensed into 40ml volumes and autoclaved at 15 p.s.i. The 
complete media were prepared by adding 40ml carbon source to 
1.25ml FeSO. and 60ml PNS. --- 4 ---
(f) Defined media for large-scale Rrowth
This was prepared by mixing set volumes of the following 4 
components.
i) 3850ml of 67mM potassium dihydroRen phosphate (9.12g/litre
KH^PO^,) adjusted to pH7 with KOH, autoclaved at 15 p.s.i. in
a 10 litre round bottom flask with a plugged 10ml pipette
inserted through a cotton wool bung.
ii) M rNS contained 40mM magnesium sulphate (9.84g/litre MgSO^,
and 800mM ammonium sulphate (105.6g/litre
(NH.)-SO.), autoclaved in 50ml volumes at 15 p.s.i.4 2 4 r
iii) FeSO^ 0.8mM ferrous sulphate (0.22g/litre FeSO^^H^O) 
adjusted to pH2 with HC1, autoclaved in 50ml volumes at 15 p.s.i.
iv) Carbon source 3.2M sodium acetate or 1.6M glycerol, 
autoclaved in 50ml volumes at 5 p.s.i. The complete media were 
prepared by adding 50ml of each MgNS, FeSO^ and Carbon source 
to potassium dihydroRen phosphate, to give 4000ml.
(g) Specific supplements to defined media
E.coli strain KAT-l/pEM9 required addition of Vitamin B1 (to 
ljig/ml from a 0.5mg/ml stock solution), methionine (to 50pg/ml from a 
25mg/ml stock solution) and ampicillin (to lOOjig/ml from a lOmg/ml, pH7 
stock solution).
2.3.4 Growth of bacteria
(a) Preparation of specifically pre-induced inocula
100ml of complete defined medium (Methods 2.3.3 (e) and
2.3.3.(g)) was inoculated with 0.5ml of a nutrient broth culture and 
grown on an orbital shaker at 37°C. After overnight growth 1ml of 
this culture was inoculated into another 100ml of identical medium (2nd 
passage). A third passage was also grown in this way and could be 
stored for upto 24 hours at 4°C before use. Growth times depended on 
the carbon source but were generally overnight and growth was stopped in 
mid log phase.
(b) LarRe-scale batch culture
Four 4000ml flasks of defined media (Methods 2.3.3 (f) and
2.3.3.(g)), at 37°C were inoculated with third passage cultures to the 
required cell density. Cultures were grown at 37°C on a 4-place 
stirrer (Harvey et al., 1968). Stirring magnets were turned, by 
horse-shoe magnets under the flasks, fast enough to break the vortex in 
the flask causing bubbles to form. Compressed air was passed through a 
cotton-wool plug at a rate of 400ml/min.
(c) Measurement of Rrowth
Bacterial cell density was measured as an apparent absorption at 
420nm. The measurements were carried out in 1cm light-path cuvettes 
using a Unicam SP500 spectrophotometer (Pye Unicam Instruments Ltd.,
U.K.) equipped with a Gilford photoelectric detector and digital read 
out. If necessary the culture samples were diluted 1:10 to give an
A420 *ess 0.5.
(d) HarvestinR of cells
Cells were harvested by centrifugation at 6000g for 15 min at 
4°C (MSE Mistral 6L with a 6x750ml rotor). To harvest 16 litres of 
culture, the same six centrifuge pots were used for 5 runs. The 
accumulated pellets were resuspended in chilled Buffer A (Methods 2.5.1
(a)) and then centrifuged at 30,000g for 10 min at 4°C (MSE18 with an 
8x50ml rotor). The wet weight of the pellets was recorded and the cells 
stored at -20°C.
(e) Growth of E.coli EB106
Eight 2500ml flasks of L-broth at 30°C containing 1% glucose
and lOjig/ml naladixic acid in a final volume of 500ml were inoculated
with 10ml of an overnight L-broth culture of E.coli EB106. Cultures 
were grown at 30°C on an orbital shaker. Growth was monitored and 
cells harvested as before.
(f) Growth of E.coli TGl/pCK505
Eight 2500ml flasks of L-broth at 30°C containing 0.lmg/ml
ampicillin in a final volume of 500ml were inoculated with 5ml of an
overnight L-broth culture of E.coli TGl/pCK505. Cultures were grown at 
30°C on an orbital shaker. Growth was monitored and cells harvested 
as before.
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2.3.5 Disruption of bacteria
The cell pellets (Methods 2.4.4 (d)) were resuspended in two
volumes of Buffer A (Methods 2.5.1 (a)) at 4°C and disrupted by two
passages through the French pressure cell (Cat. No.4-3398A, American
Instruments Company, Maryland, USA) at a pressure of 98 MPa (14,300 
2
l b / m  . The pressure cell, capacity 40ml, was cooled in ice before 
use.
2.4 Enzyme Assays
2.4.1 Instrumentation
All spectrophotometric assays were carried out at 37°C using a 
thermostatted Unicam SP500 spectrophotometer (Pye Unicam Instruments 
Ltd., U.K.) equipped with a Gilford photoelectric detector and chart 
recorder. Quartz cuvettes, 1ml, with a path length of 1cm were used. 
Assay mixes were allowed to equilibrate then the component to initiate 
the reaction was added and mixed in.
One unit of enzyme activity is defined as the amount of enzyme 
required to catalyse the disappearance of one micromole of substrate, or 
the appearance of one micromole of product per minute.
2.4.2 Assays
(a) Isocitrate dehydrogenase
• • *f*
ICDH was assayed by monitoring the reduction of NADP at 340nm 
(Borthwick et al.. 1984a). Each cuvette contained in a final volume of 
lml : 0.15M Tris/HCl pH7.5, 0.5mM MnCl2 , 0.4mM NADP+ , 2.5mM 
D.L-isocitrate and enzyme. The reaction was initiated by the addition 
of enzyme.
(b) Isocitrate dehydrogenase kinase
ICDH kinase activity was assayed by measuring the rate of 
inactivation of ICDH (Nimmo et al., 1984). 15pl of assay 'cocktail* 
(25mM Bicine-NaOH pH9.0, lOmM ATP, 20mM MgCl2 » ImM DTT, 6.0jiM active 
ICDH, 2% v/v glycerol) was incubated at 37°C with 15pl ICDH kinase
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diluted in 50mM MOPS-NaOH pH7.3, lmM EDTA, lmM DTT, Ijil samples of the 
incubation were withdrawn at intervals and assayed for ICDH activity.
The amount of kinase was adjusted so that the inactivation of 
ICDH was linear with time for at least 10 min. ImU kinase is the amount 
of enzyme required to inactivate lnmol ICDH subunits/min.
(c) Isocitrate dehydrogenase phosphatase
32
ICDH phosphatase was assayed by monitoring the release of P
from ICDH (Nimmo et al., 1984) that had been phosphorylated in vitro 
32
using [gamma- P] ATP (see later). The following components were 
incubated in microfuge tubes at 37°C in a final volume of 40pl: 50mM
MOPS-NaOH pH6.7, 12.5mM MgCl2 , 0.5mM ATP, 0.5mM phosphoenolpyruvate, 5%
(v/v) glycerol and ICDH phosphatase. The reactions were started by the
32 .
addition of P-ICDH. After a set time (5-30 min) the reactions were
terminated by the addition of lOpl lOOmg/ml BSA and 0.2ml of 5% (w/v)
TCA. After 10 min at 0°C the tubes were centrifuged at 12,000g for 2
min and 0.2ml portions of the supernatant were counted in 2ml portions of
Ecoscint (National Diagnostics, Somerville, New Jersey, USA) in a Beckman
LS8100 scintillation counter. Dephosphorylation of ICDH was linear with
32
time provided less than 30% of the P was released. ImU ICDH
phosphatase catalyses the release of lnmol of phosphate from
phosphorylated ICDH/min.
ICDH phosphatase was also assayed in some experiments by
measuring reactivation of phosphorylated ICDH. The incubation was as
above and lpl samples were withdrawn and assayed for ICDH activity.
32
P-ICDH was prepared as described by Nimmo et al. (1984).
The following were incubated at 37°C: 32mM Bicine-NaOH pH9.0, 0.64mM
32
DTT, 15.5juM active ICDH, lOmM MgCl2 » 0.5mM [gamma- P] ATP 
(50-100Ci/mol) and 0.25-0.50mU/ml ICDH kinase. The reaction was started 
by the addition of kinase and continued until the ICDH activity had 
fallen to less than 0.5% of the original value. The reaction was 
stopped by the addition of EDTA to a final concentration of lOmM. The
32P-ICDH was separated from ATP by gel filtration at room temperature 
through a column of Sephadex G-50 (3cmxl5cm) equilibrated in MOPS-NaOH 
pH7.3, lmM EDTA, lmM DTT. Protein was dialysed overnight against 50mM 
MOPS-NaOH pH7.3, lmM EDTA, lmM DTT, 40% (v/v) glycerol and stored at 
-20°C.
2.5 Methods of protein purification
2.5.1 Purification buffers
(a) ICDH. ICDH from E.coli EB106
Buffer A : lOmM potassium phosphate, 0.5M potassium chloride 2mM
magnesium chloride pH6.5
Buffer B^: 40mM potassium phosphate, 5mM potassium citrate,
2mM magnesium chloride pH6,5
Buffer B^: lOOmM potassium phosphate 5mM potassium citrate,
2mM magnesium chloride pH6.5
Buffer C : lOmM potassium phosphate, 5mM potassium citrate, 2mM
magnesium chloride pH6.5 containing 10% (v/v) glycerol)
Buffer D : lOmM potassium phosphate, 5mM potassium citrate, 2mM
magnesium chloride pH6.5 containing 40% (v/v) glycerol
(b) ICDH kinase/phosphatase
Buffer E : lOmM potassium phosphate, 0.5M potassium chloride
pH6.5, 2mM magnesium chloride, lmM benzamidine, lmM DTT, 1.2mM 
PMSF
Buffer F : 50mM MOPS-NaOH pH7.3, lmM EDTA, lmM benzamidine, lmM
DTT, 1.2mM PMSF
Benzamidine and DTT were stored as 1M solutions at -20°C and 
added just before use. PMSF was dissolved in ethanol (20mg/ml) and 
added just before use.
2.5.2 Purification of isocitrate dehydrogenase from E.coli ML308 
Active ICDH was purified from glycerol-grown cells by the method
of Borthwick et &1. (1984a). Steps a-c were carried out at 0-4°C, the 
rest at room temperature.
(a) Preparation of crude extract
20-30g E.coli ML308 grown to the end of log phase and harvested 
as described previously (Methods 2.3.4 (b) and 2,3,4 (d)) were passed 
through the French pressure cell twice (Methods 2.3.5) in two volumes 
Buffer A. The resulting material was centrifuged at 40,000g for 20 min 
at 4°C (MSE 18 with an 8x50ml rotor) and the supernatant was decanted 
through glasswool to give the crude extract.
(b) Protamine sulphate treatment
Protamine sulphate (lOOmg/ml in Buffer A) was added dropwise 
with stirring to give a ratio of 0.3mg protamine sulphate per mg 
protein. The suspension was stirred for 15 min and centrifuged at 
40,000g for 10 min. The supernatant was retained.
(c) Ammonium sulphate fractionation
Powdered (NH/,)2S0^ was gradually added to the supernatant
to give 50% saturation (312g/litre) while the pH of the solution was
maintained in the range pH6.3-6.5 by the addition of 5M NH^. The
solution was stirred for 30 min and centrifuged at 40,000g for 10 min,
and the pellet was discarded. (NH,)rtS0, was added to the
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supernatant to give 60% saturation (65g/litre) and the solution was 
stirred and centrifuged as before; the pellet was discarded.
(NH^ , )^S0^ was added to the supernatant to give 75% saturation 
(103g/litre) and the solution was stirred and centrifuged as before.
The pellet was retained and dissolved in a small volume of Buffer
(d) Ion-exchange chromatography
The dissolved pellet was desalted into Buffer B^ on a column
of Sephadex G-25. The material was then loaded onto a column of
DEAE-cellulose (1x10cm) equilibrated in Buffer B^. The column was
washed with this buffer at a flow rate of lOOml/hour until the A„^ ■
280
readings of the effluent were lower than 0.1. The column was then 
washed with Buffer ICDH activity was eluted in a sharp peak and
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fractions with an activity greater than 10 units/ml were pooled and 
dialysed overnight against Buffer C.
(e) Procion-red Sepharose chromatography
The dialysed pool was loaded onto a column of Procion-red 
Sepharose (1x10cm) equilibrated in Buffer C at a flow rate of 
48ml/hour. The column was washed exhaustively with Buffer C until the 
absorbance at 280nm of the effluent was below 0.05. The column was 
then washed with Buffer C containing 0.5mM NADP+ . The ICDH activity 
was eluted as a sharp peak with the NADP+ front; fractions containing 
an activity of more than 5 units/ml were pooled, concentrated by vacuum 
dialysis and dialysed against Buffer D.
The whole procedure was completed in 48 hours. The enzyme was 
stored in Buffer D at -20°C.
2.5.3 Purification of ICDH kinase/phosphatase from E.coli KAT-l/pEM9
The purification scheme was developed by Dr. H.G. Nimmo and I. 
Varela and was based on that devised for purification of ICDH 
kinase/phosphatase from E.coli ML308 (Nimmo et al., 1984, and Varela, I.' 
& Nimmo H.G. 1988).
(a) Preparation of crude extract
20-30g of E.coli KAT-l/pEM9 grown on acetate to the end of log 
phase were passed through the French Pressure cell twice (Methods 2.3.5), 
in two volumes Buffer E. The resulting material was centrifuged at 
40,000g for 20 min at 4°C (MSE 18 with an 8x50ml rotor) and the 
supernatant was decanted through glass wool to give the crude extract.
(b) Protamine sulphate treatment
This was as described in 2.5.2 (b).
(c) Ammonium sulphate fractionation
The fraction precipitating between 30 and 45% was collected as 
described in 2.5.2 (c). The precipitate was redissolved in a small 
volume of Buffer F containing 150mM NaCl. It was desalted into this 
buffer by gel filtration on a column of Sephadex G-25 (2.2x50cm).
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(d) Ion exchange chromatography at pH7.3
The desalted material was loaded onto a column of DEAE-cellulose 
(3.3x6cm) equilibrated in the same buffer. The column was washed with
this buffer until the A of the eluate was zero. The enzyme wasZoO
then eluted with Buffer F containing 250mM NaCl. The flow rate was 
200ml/hr and fractions of 10ml were collected and assayed for ICDH kinase 
activity. The active fractions were pooled and dialysed overnight into 
Buffer F containing lOOmM NaCl.
(e) Chromatography on blue dextran Sepharose
The dialysed material was loaded onto a column of blue dextran 
Sepharose (2.2x12cm) equilibrated in Buffer F containing lOOmM NaCl.
The column was washed with this buffer until the Ao o a of the eluate was
Z o U
zero and was then washed in the same buffer containing ImM NAD . The 
enzyme was then eluted with Buffer F containing 400mM NaCl. The flow 
rate was 60ml/hr and 5ml fractions were collected. A solution of 10% 
(w/v) Lubrol PX was added to the fractions to give a final concentration 
of 0.05% (w/v). The fractions were assayed for ICDH kinase, the active
fractions were pooled and concentrated by vacuum dialysis to
approximately 1ml.
(f) Ion-exchange chromatography at pH7.3 on Mono 0
The concentrated material was diluted with 50mM MOPS-NaOH ImM 
EDTA containing ImM benzamidine, ImM DTT, 1.2mM PMSF and 0.05% (w/v) 
lubrol to reduce the NaCl concentration to lOOmM and loaded onto an FPLC
Mono Q column in Buffer F containing 0.05% (w/v) Lubrol PX. The flow
rate was lml/min and 0.5ml fractions were collected. The column was 
developed with increasing concentrations of NaCl in Buffer F: 0-0.23M
over 4 min, then 0.23-0.39M over the next 20 min. ICDH 
kinase/phosphatase was eluted at a NaCl concentration of approx 0.27M. 
The most active fractions were pooled.
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(g) Ion-exchange chromatography at pH9.0 on Mono 0
The pool fractions were diluted 1 in 4 in 50mM Bicine-NaOH 
pH9.0, 0.05% (w/v) lubrol PX and were loaded on to a Mono Q column 
equilibrated in this buffer containing lOOmM NaCl. The column was 
washed in this buffer and then developed with a linear gradient of 
100-400mM NaCl over 30 min. The flow rate was lml/min and 0.5ml 
fractions were collected. The pH of the most active fractions was 
reduced to pH7.3 by the addition of 200jul of 0.5M MOPS-NaOH pH7.3.
These fractions were pooled and concentrated to 200}il.
(h) Gel filtration on an FPLC Superose 12 column
The concentrated material was loaded onto a Superose 12 column 
equilibrated in Buffer F containing 0.05% (w/v) lubrol PX. The flow 
rate was 0.3ml/min and 1 min fractions were collected. Active fractions 
were pooled and dialysed into 50mM MOPS-NaOH pH7.3, ImM EDTA, ImM DTT,
ImM benzamidine hydrochloride 0.05% (w/v) lubrol PX 40% glycerol and 
stored at -20°C.
2.5.4 Purification of ICDH from E.coli TGl/pCK505
ICDH was purified from E.coli TG1/p CK505 grown on L-broth. The 
method used was adapted from the purification of ICDH from E.coli ML308 
(Method 2.5.2). Steps a-c were carried out at 0-4°C, step d at room 
temperature.
(a) Preparation of crude extract
A crude extract of E.coli TGl/pCK505 was prepared as in 2.5.2(a).
(b) Protamine sulphate treatment 
This was as described in 2.5.2(b).
(c) Ammonium sulphate fractionation 
This was as described in 2.5.2(c).
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(d) Ion exchange chromatography at pH6.5 on Mono 0
The dissolved pellet was desalted into Buffer B^ on a column 
of Sephadex G-25. The material was then dialysed overnight against 20mM 
potassium phosphate, 5mM potassium citrate, 2mM MgCl^ pH6.5. The 
dialysed material was loaded onto an FPLC Mono Q column (8ml) 
equilibrated in 20mM potassium phosphate, 5mM potassium citrate, 2mM 
The flow rate was 4ml/min and 4ml fractions were
collected. The column was washed in this buffer and then developed with
a linear gradient of 0-100% 200mM potassium phosphate, 5mM potassium 
citrate, 2mM MgCl^ pH6.5 over 25 min. ICDH was eluted at a phosphate 
concentration of approximately 120mM. The most active fractions were 
pooled and dialysed into Buffer D and stored at -20°C.
2,6 Polyacrylamide gel electrophoresis techniques
2.6,1 Non-denaturing polyacrylamide gel electrophoresis
This was carried out on 7% (w/v) polyacrylamide gels at pH8.0 
(Davis, 1964).
The following stock solutions were stored at 4°C:
A 36.3g Tris
0.23ml TEMED 
48ml 1M HCl 
H20 to 100ml 
B 28g aery1amide
0.74g N,N*-methylenebisacrylamide (bis)
H20 to 100ml 
C 30g Tris
144g glycine 
H20 to 1000ml
•Gel monomer* was prepared by mixing 1 volume A, 2 volumes B and 
1 volume H20. An equal volume of freshly prepared ammonium
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persulphate (1.4mg/ml) was prepared. Solutions were degassed separately 
and then mixed and poured into gel tubes (dimensions 0.5x10cm). 9cm 
gels were poured, carefully overlayed with H^O and allowed to set.
The tank buffer was solution C which had been diluted 25-fold with H^O 
at 4°C containing 0.1% (v/v) 2-mercaptoethanol. The gels were 
pre-electrophoresed for 30 min at 3mA per tube at 4°C. 5^ il of 
tracking dye (0.01% (w/v) bromophenol blue in 20% (v/v) glycerol) was 
layered onto the top of each gel and electrophoresis was carried out 
until the dye had penetrated the gel. The samples (less than 50jil in 
20% v/v glycerol) were loaded onto the gels and electrophoresis was 
performed at 3mA per tube at 4°C until the tracking dye approached the 
bottom of the gel. The dye front on each gel was marked with a piece of 
wire inserted through the gel.
2.6.2 Staining for ICDH activity in non-denaturinR Reis
Gels to be stained for ICDH activity were soaked in 0.15M 
Tris-HCl pH7.5, 0.5mM MnCl^ for 30 min to remove 2-mercaptoethanol.
The gels were then incubated in a reaction mixture containing 0.15M 
Tris-HCl pH7.5, 2.5mM D,L-isocitrate, 0.4mM NADP*, 0.5mM MnCl^,
0.24mM tetranitro blue tetrazolium and 7SjM phenazine methosulphate.
ICDH activity was visualised by the production of a blue precipitate of 
Formazan. The reaction was stopped by storing the gel in the destaining 
solution described in Methods 2.6.4 (a).
2.6.3 SDS Polyacrylamide gel electrophoresis (discontinuous system) 
Protein samples were analysed by discontinuous slab gel
electrophoresis in the presence of SDS according to Laemmli (1970).
Glass plates were separated by 0.8mm or 1.5mm spacers and sealed with 1% 
(w/v) agarose.
Gels were prepared by mixing the appropriate volumes shown by 
Table 2.1. The acrylamide Tris and H^0 were mixed and degassed.
SDS, ammonium persulphate and TEMED were then added and the mixture was
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poured into the cast immediately. Isopropanol was layered onto the 
separating gel and rinsed off after polymerisation. Then a stacking gel 
was made up and poured around a well-forming template. The wells were 
rinsed after polymerisation. Electrophoresis buffer consisted of 3g 
Tris, 14.4g glycine and 0.1% (w/v) SDS per litre. Samples were 
denatured by addition of at least equal volumes of *sample buffer* which 
comprised 50mM Tris-HCl pH6.8, 1% (w/v) SDS, 10% (v/v) glycerol, 0.01% 
(w/v) bromophenol blue and 1% (v/v) 2-mercaptoethanol, and boiled for 2
minutes. The samples were then loaded into the wells and
electrophoresis was carried out at a constant current of 50mA until the 
tracking dye reached the bottom of the gel.
2.6.4 Staining gels for protein
(a) Coomassie blue
Routinely, gels were stained in 0.1% (w/v) Coomassie Brilliant 
Blue G250, 50% (v/v) methanol, 10% (v/v) acetic acid for 1 hour at 45°C 
and destained in several changes of 10% (v/v) methanol, 10% (v/v) acetic 
acid at 45°C.
(b) Silver staining
A more sensitive method used to locate protein on gels was 
silver staining, based on the method of Wray et al. (1981). Gels were
soaked for at least 24 hours in 3 changes of 50% (v/v) methanol.
Staining solution was prepared by adding Solution A (0.8g AgNO^ in 4 ml 
H^0) dropwise to Solution B (1.4ml 14.8M NH^OH plus 21ml 0.36% (w/v)
NaOH) with vigorous shaking. Distilled water was added to give a final 
volume of 100ml. The gel was gently agitated in staining solution for 8 
minutes and then rinsed for 1 hour with 6 changes of distilled H^0.
The stain was developed by immersing the gel in a solution comprising 
0.12ml 1M citric acid and 0,25ml 38% (v/v) formaldehyde in 500ml 
distilled water. Staining was stopped by washing the gel immediately in 
distilled H^0.
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2.6.5 Drying and autoradiography of polyacrylamide Reis
Slab gels were dried for easy storage or autoradiography. A 
destained slab gel was placed on Whatman 3mm chromatography paper and 
dried using a Biorad Laboratories Slab Gel Dryer model 1125 connected to 
an Aquavac junior (Uniscience Ltd., London, U.K.). Dried down slab gels 
were autoradiographed using Kodak X-OMAT R X-ray film with an 
intensifying screen. The period of exposure was usually from 6 hours to 
14 days.
2.7 Modification of ICDH with phenylglyoxal
2.7.1 Incubations with phenylRlvoxal
ICDH was diluted in 50mM MOPS-NaOH, ImM EDTA pH7.3 at 4°C to 
give a final concentration of 0.2mg/ml. Other additions were as given 
in the text. A sample of the mixture was assayed to establish the 
initial activity of ICDH. Then at zero time a solution of lOOmM 
phenylglyoxal was added to give a final concentration of 10 or 20mM. 
Samples (l-5jil) were assayed for ICDH activity at various times 
thereafter. Results were plotted as log %  activity remaining against 
time.
Some incubations were carried out at increased temperatures as
stated in the Results Chapter 3. Others contained a variety of
phenylglyoxal concentrations in the range l-30mM, the results were
plotted as above and ^or inactivation determined and
replotted as vs Phenylglyoxal concentration.
142.7.2 Incorporation of [7- Cl-phenylRlvoxal
14
Conditions were as Methods 2.7.1 except [7- C]-phenylglyoxal 
(SpCi/umol) was used. To separate protein bound phenylglyoxal from 
unreacted reagent lO i^l samples were spotted onto 2.5cm discs of Whatman 
3mm filter papers. The discs were then placed in 10% TCA for 1 hour 
(approx. 10ml TCA/disc) and then washed a further three times in 10% TCA, 
with each wash lasting 1 hour. The discs were then placed in 4ml
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Ecoscint and the counts measured in a Beckman Liquid Scintillation 
Counter model 8100.
2.7.3 Large scale labelling of ICDH for HPLC
(a) Labelling
14ICDH was incubated with lOmM [7- CJ-phenylglyoxal (5pCi/umol) 
for two and half hours either in the presence or absence of enzyme 
substrates. The activity of the sample was assayed at zero time and 
again at the end of the incubation, as was incorporation of label. A 
Sephadex G-50 column (1.5x25cm) equilibrated in 10% formic acid was then 
used to separate the protein bound phenylglyoxal from the free. The 
fractions obtained were counted for radioactivity and the protein 
containing fractions pooled and freeze-dried (Methods 2.2.9).
(b) Digestion with pepsin
After freeze drying the samples were dissolved in 1ml 10% formic 
acid and 20jil of a lmg/ml pepsin solution added. The digestion mixes 
were left overnight at 37°C on a shaker. Samples were then boiled for 
2 mins, freeze-dried and subjected to HPLC analysis.
(c) HPLC reverse phase chromatography
Peptides were applied to a Waters yubondapak C-18 column 
(30cmx3.9mm) equilibrated in 0.1% trifluoroacetic acid and eluted at 
lml/min with gradients of increasing acetonitrile concentrations as 
described in the text. Peptides were detected at 215nm, 1ml fractions 
were collected.
2.7.4 Reaction with NaBH. '------    4
ICDH was inactivated with lOmM phenylglyoxal (5pCi/umol). 1M 
NaBH^ in 50mM NaOH was added in lOjil aliquots to give a final 
concentration 10-fold in excess of the phenylglyoxal concentration. The 
incubation was then split. lO^il samples were spotted onto filter discs 
and washed in 10% TCA overnight. The remaining incubation was dialysed 
overnight against 50mM MOPS-NaOH, liriM EDTA pH7.3. Disc samples and
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dialysate were counted in the liquid scintillation counter to determine 
the amount of label still associated with the protein.
2.7.5 Inactivation of dephosphorvlated ICDH-P with phenylglyoxal 
ICDH was phosphorylated with unlabelled ATP as in Methods 2.4.2
(c). It was incubated at 37°C in the presence of 0.5mM ADP, lOmM 
MgCl2 , ImM PEP, 0.25mU/ml ICDH kinase in 50mM MOPS-NaOH, ImM EDTA pH7.3 
at set times lpl samples were assayed for ICDH reactivation. After 
complete reactivation 1M EDTA pH7.0 was added to a final concentration of 
lOmM and the sample was dialysed overnight against 50mM MOPS-NaOH, ImM 
EDTA pH7.3. After dialysis lOOmM phenylglyoxal was added to give a 
final concentration of lOmM and lpl samples assayed for loss of ICDH 
activity.
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2.7.6 Digestion of [ Pl-ICDH and [7- C] phenvlglvoxal-ICDH with
thermolvsin
32
[ P3-ICDH was prepared as in Methods 2.4.2 (c). ICDH was 
14
inactivated with [7- C]-phenylglyoxal (5pCi/umol) immediately before 
the addition of the protease. The two labelled samples were digested 
for two hours at 37°C with thermolysin (ICDH-P:thermolysin 4:1,
ICDH-PG:thermolysin 850:1), denatured by boiling in SDS 'sample buffer* 
and loaded onto a 15% SDS gel (Methods 2.6.3). Duplicate tracks of each 
sample were run on opposite sides of the gel, and after completion of the 
run the gel was halved. One portion was soaked in 50% methanol prior to 
silver staining, and the remaining half was immediately dried down, 
without any staining, and autoradiographed (Methods 2.6.5).
2.8 Digestion of ICDH and ICDH-P with chvmotrypsin
ICDH, phosphorylated ICDH and ICDH inactivated with 
phenylglyoxal (Methods 2.7.1) were digested with chymotrypsin 
(chymotrypsin:ICDH 1:72) in 50mM MOPS-NaOH, ImM EDTA pH7.3 at 37°C.
At set time intervals between 0 and 24 hours, samples each containing 
lOpg protein, were removed, denatured and run on a 15% SDS gel.
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Similarly, ICDH was digested in this manner in the presence of either 
200^tM NADP+ or lOO^iM isocitrate. A sample of phosphorylated ICDH
which had been incubated with lOmM phenylglyoxal was digested under the 
same conditions. The unreacted phenylglyoxal was not removed from any 
of the incubations to which it was added. All gels from these 
experiments were soaked in 50% methanol and stained with silver.
2.9 Synthetic peptide studies
2.9.1 Preparation of peptide
The 14-mer synthetic peptide N-Thr-Thr-Pro-Val-Gly-Gly-Gly- 
Ile-Arg-Ser-Leu-Asn-Val-Ala-C was synthesised by solid phase techniques 
essentially as described by Gutte and Merrifield (1971) on a Biosearch 
9500 (San Rafael, California, USA) peptide synthesiser using t-Boc 
(tert-butyloxycarbonal) amino acid substrates. The completed peptide 
was deprotected (side chain groups) and cleaved from the resin with 
hydrogen fluoride treatment (Fig.2.1). The purity of the deprotected 
synthetic peptide was checked on an HPLC reverse phase column (C18 Waters 
y bondpak 30cmx3.9mm) equilibrated in 0.1% TFA and eluted with a gradient 
of increasing acetonitrile concentration.
2.9.2 Analysis of peptide HN2
(a) Amino acid analysis
The peptide sample was hydrolysed for 35 min in 6N HCl at 
165°C under argon. The hydrolysed sample was then dried,
reconstituted in 20pl of EDTA solution (250pg/ml). Analysis was carried 
out by Mr. B. Dunbar at the University of Aberdeen, on an Applied 
Biosystems 420A Derivatizer/130A Separation System.
(b) Liquid phase sequencing
This was carried out in collaboration with Professor J.E. 
Fothergill and Mr. B. Dunbar at the SERC-funded protein sequencing 
facility, Aberdeen University. Automated Edman degradation of the 
peptide sample was performed using an Applied Biosystems Gas Phase
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sequencer operated by Mr. B. Dunbar. The ani]inothiazoline products
were converted to phenylthiohydatoins by treatment with a 1M HC1 solution
containing 1% (v/v) ethanethiol according to the general procedure of
Beckman Instruments. The phenylthiohydantoins were identified and
quantitated by HPLC on a Waters ABI PTH Cno reverse phase column with a
18
pH5 sodium acetate-acetonitrile buffer system.
2.9.3. Phosphorylation of synthetic peptides
5-10mg/ml 14-mer synthetic peptide was incubated with 0.5mM ATP 
(lOjiCi/umol), lOmM MgCl2 » 0.25mu/ml ICDH kinase/phosphatase in 50mM 
MOPS-NaOH, ImM EDTA pH7.3 at 37°C. At set times samples were removed 
and the reaction was stopped in one of 3 ways, according to the method of 
detecting phosphorylation used.
The synthetic peptide Kemptide (Kemp et aJL., 1976) and cAMP 
dependent protein kinase catalytic subunit were used in control 
phosphorylation mixes. lmg/ml Kemptide was incubated with 0.5mM ATP 
(lOjiCi/umol), lOmM MgCl2 , 10 units cAMP dependent protein kinase 
catalytic subunit per lOO^il in 50mM MOPS-NaOH, ImM EDTA pH7.3. The mix 
was incubated at 37°C and samples were removed and analysed as above.
2.9.4 Detection of phosphorylated peptides
(a) Thin layer electrophoresis
After set incubation times kinase incubations were immediately 
put on ice. Samples (5-10pl) were rapidly spotted onto a TLC sheet 
(Machercy and Nagel, W. Germany) lOcmxlOcm along a central line 
(Fig.2.2a) The sheet was carefully saturated with pH6.5 buffer (10% 
pyridine (v/v), 0.5% acetic acid (v/v). Electrophoresis (400 V for 20 
min) was carried out in a Shandon tank and the plates were dried, stained 
with ninhydrin and autoradiographed.
(b) High voltage electrophoresis
A sample of the incubation mixture (15-20jj1) was rapidly spotted 
onto a sheet of Whatman 3MM paper (57x25cm) along a central line
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(Fig.2.2b). The paper was carefully saturated with pH6.5 buffer (10%
pyridine (v/v), 0.5% acetic acid (v/v), electrophoresis (40V/cm for 90
min) was carried out in a lOkV electrophoresis unit (Miles Hivolt Ltd.,
Shoreham, Sussex, U.K.) water cooled system. The paper was dried,
stained with ninhydrin and autoradiographed.
(c) Anion exchange resin analysis
Reactions were terminated in individual samples by the addition
of acetic acid to a final concentration of 30%. The terminated reaction
mixture was applied to a small column containing 2ml AG1-X8 anion
exchange resin equilibrated with 30% acetic acid. The reaction tube was
rinsed with 1ml of 30% acetic acid, which was allowed to completely run
32
into the column. The [ P]-phosphopeptide (as well as the
dephosphopeptide) was then quantitatively eluted with an additional 3ml
of 30% acetic acid. The eluant was collected directly into
scintillation vials in 1ml aliquots. The fractions were counted for
radioactivity by counting Cerenkov radiation (Ross, H.H. (1969)). The 
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unreacted [ P3-ATP remains bound to the resin.
2.10 Phosphorylation of chvmotrypsin digests of ICDH
ICDH was digested overnight at 37°C with chymotrypsin 
(chymotrypsin:ICDH, 1:100) in 50mM MOPS-lmM EDTA pH7.3. After digestion 
a 0.5mg/ml solution of chymostatin (15% v/v acetic acid, 50mM MOPS-NaOH, 
ImM EDTA pH7.3) was added to give a final 10-fold excess with respect to 
the chymotrypsin present. The mix was left at 37°C for 30 min. ICDH 
kinase assays were then carried out on the mix in the presence of 0.5mM 
ATP (lOjiCi/umol), lOmM MgCl^ and 5^ »1 partially purified ICDH kinase.
The experiment was run as a time course. Samples were removed at set 
times, denatured and run on a 15% SDS gel, with suitable controls. The 
gel was stained with Coomassie Blue dried and autoradiographed.
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2.11 ImmunoblottinR techniques
The method is based on that described by Towbin et al. (1970) as 
modified by Batteigner et al. (1982).
2.11.1 Stock solutions
Buffer A (Transfer buffer)
20mM Tris-HCl pH7.2
150mM NaCl
0.5% w/v Tween 20
Buffer B (Blocking buffer)
20mM Tris-HCl pH7.2 
150mM NaCl
Buffer C (Chloronaphthol stain)
50ml lOmM Tris-HCl pH7.4
30mg chloronapWkol in 10ml methanol
150jil 4% v/v 1*2^ 2
H2^2 was m *xec* immediately before use.
2.11.2 Conditions
SDS-PAGE was carried out (Method 2.6.3). When electrophoresis 
was complete, the proteins were transferred to 0.45p nitrocellulose paper 
(Adderman and Co., Kingston-upon-Thames, Surrey KT2 6NH) using a Bio-Rad 
trans-blot cell containing Buffer A containing 16.6% methanol. The 
transfer was run at 350mA for 4 hours, after which the nitrocellulose 
paper was placed in Buffer B containing 5% normal goat serum at 4°C for 
at least 16 hours. The nitrocellulose paper was then rinsed twice in 
Buffer B. The paper was then soaked in Buffer A containing 5% (v/v) 
normal goat serum and 0.5% (v/v) antisera at 25°C for 90 min, after
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which the nitrocellulose paper was washed 4x12 min in Buffer A and then
1x12 min in buffer B. The nitrocellulose paper was then soaked in
Buffer B containing 5% (v/v) normal goat serum and 0.05% peroxidase
conjugate goat anti rabbit IgG at 23°C for 90 min, washed 5x12 min in
Buffer B and developed by soaking in Buffer C for 5 min at 23°C. The
final product was then washed in distilled H^O, dried and stored.
2.12 Circular dichroism
Circular dichroism analysis of ICDH and ICDH-P in the presence
and absence of cofactors NADP* and NADPH was carried out in 50mM MOPS,
ImM EDTA pH7.3. The analysis was carried out at the Department of
Biochemistry, University of Newcastle by Roman Hlodon on a Jobin-Yvon
dichrograph III equipped with a temperature controlled cell holder.
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Ellipticity values (mean residue molar ellipicity in deg.cm 
decimole ^) were calculated using the following equation:-
= m.r.w. x sensitivity x displacement x 3300 
concentration x pathlength 
where m.r.w. -= mean residue weight
displacement = difference between sample and reference at any 
given time 
concentration = lmg/ml 
pathlength = 1cm
Figure 2.1 Basic scheme of solid phase peptide synthesis (Stewart 
& Young, 1984)
L Labile group protecting amino group
S Stable blocking group protecting functional amino
acid group
X Polymer reactive group
1 2
R ,R A m m o  acid side chain
DCM Dichloromethane
DIPC N,N-diisopropylcarbodiimide
HI R1 0
Polymer(l)-- NH— CH— C -- OH + JxJ-—
Attach
v
Hi- ?1 8 ,______
[[]— NH— CH— C-— 0— [Polymer
Deprotect (25% TFA in DCM)
t
m — r1 o
H2N— CH— C — 0— [Polymer
[l ]— NH-CH(R2 )-C0-X DTPC. ; in DCM 
(couple)
0 -
R2 0 0 - - R1 0
I I I I ------
I— CH— C— NH-- CH— C— 0-- Polymer
Repeat deprotect 
and couple
[l ]— |Peptlde|--- C— 0 — |Polymer
Cleave (hydrogen 
fluoride)
■
Peptide + [polymer
Figure 2.2 Electrophoretic analysis of peptides
Diagram of sample loading
(a) Thin layer chromatography, pH6.5
(b) High voltage paper electrophoresis, pH6.5
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Table 2.1 Preparation of SDS polyacrylamide gels
- quantities and stock solutions used.
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Table 2.1
Stock solution
Stacking 
gel (ml)
Separating gel 
10% 15%
(ml)
20%
30% acrylamide 0.8% 
bisacrylamide 1.5 10 15 20
1.5M Tris HCl 
pH8.8 - 7.5 7.5 7.5
0.5M Tris HCl 
pH6.8 3.75 - -
h 2° 9.45 12.05 7.05 2.05
10% (w/v) SDS 0.15 0.3 0.3 0.3
10% (w/v) ammonium 
persulphate 
(freshly prepared) 0.15 0.15 0.15 0.15
TEMED 0.01 0.01 0.01 0.01
CHAPTER THREE
Chemical Modification of Isocitrate Dehydrogenase 
with PhenylRlvoxal
3.1 Introduction
Chemical modification of amino acid side chains is an important 
method for identification of residues involved in protein function either 
at the active site of an enzyme or at points distinct from the active 
site such as allosteric sites (e.g. Vandenbunder et al.,1981) or areas of 
subunit interaction (e.g. Perutz, 1978). In order to achieve a complete 
understanding of how proteins carry out their biological function, we 
require a detailed knowledge of how their binding sites are 
constituted. This has become a key problem in the area of protein 
structure - function analysis.
Escherichia coli isocitrate dehydrogenase, hereafter ICDH, 
provides a well studied protein which has been shown to be controlled by 
a reversible phosphorylation of a specific serine residue. It has been 
suggested that this phosphorylation occurs close to or at the NADP+ 
binding site in such a way as to prevent binding of co-factor, and that 
this renders the enzyme inactive. The binding of NADP* at the active 
site is believed to produce a charge-charge interaction, between the
4-
phosphate group(s) of NADP and a positively charged residue at the 
active site, which produces a conformational change. The introduction 
of the phosphate group on a serine residue close to the NADP+ binding 
site could trigger a similar conformational change, and this would be 
expected to block binding of co-enzyme.
We first addressed the question of the existence and nature of 
the positively charged group(s) at the co-enzyme binding site of ICDH 
using chemical modification reagents. Since arginine residues are often 
found at co-factor binding sites, and there is an arginine residue 
adjacent to the phosphorylated serine, we decided to choose the 
arginine-specific dicarbonyl reagent phenylglyoxal.
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Results
3.2 Purification of ICDH
Table 3.1 shows a purification table for isolation of ICDH from 
E. coli ML308. The purification procedure was carried out routinely and 
reproducibly. The average yield was greater than 50% with a 
170-190-fold purification. A 10% SDS gel was run after each 
purification to check the purity of the final product (Fig. 3.1).
3.3 Inactivation of ICDH with phenylglyoxal
Phenylglyoxal was found to inactivate pure ICDH rapidly in a 
pseudo-first order process (Method 2.7.1) (Fig. 3.2). The half-life of 
the enzyme activity was in the range 2.4 - 3.4 minutes (10 
determinations) at pH7.3 and 0°C with 20mM phenylglyoxal. The 
inactivation reaction was very reproducible with only slight variations 
between distinct batches of pure ICDH. The rate of inactivation could 
be increased, as expected, by carrying out the inactivations at higher 
temperatures.
3.3.1 Effect of phenylglyoxal concentration
When similar inactivations were carried out using two other 
dicarbonyl reagents. 2 ,3-butanedione and 1,2— cyclohexanedione it was 
found that little or no inactivation of ICDH occurred (Fig. 3.3). This 
gave rise to the question of whether inactivation of ICDH with 
phenylglyoxal was rapid because this reagent was an affinity label for 
the enzyme. If this were the case then one would expect the 
inactivation to show saturation kinetics with respect to phenylglyoxal 
concentration. Inactivations of ICDH were therefore carried out using a 
range of phenylglyoxal concentrations (l-30mM) and the half-life of 
enzyme activity was calculated. Figure 3.4 shows a plot of 
phenylglyoxal concentration against the reciprocal of In the
case of saturation kinetics, ^  would tend to a maximum as the
phenylglyoxal concentration increases. The data obtained gave a
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biphasic graph. This suggests that phenylglyoxal has some affinity for 
ICDH but that it can react with the enzyme without binding to it in 
advance.
3.3.2 Protection against inactivation
Both NADP* (50-200jiM) and isocitrate (25-100jiM) can protect
the enzyme against inactivation by phenylglyoxal (Figs. 3.5 and 3.6
respectively). The effect of isocitrate is at first sight surprising in
view of the fact that the enzyme obeys an ordered mechanism with NADP*
binding first (Nimmo, 1986). The most likely explanation of this
anomaly is that, since the last step of purification involves elution
with NADP*, the enzyme preparation actually contains small amounts of
the co-enzyme. This possibility is tested in the next section. This
may also be responsible for the slight variations seen between batches of
ICDH during inactivation with phenylglyoxal. The protection data
allowed us to calculate K values for these substrates. Figure 3.7
s
shows the method of graphical determination of Kg for NADP*. The 
values obtained (16pM and 60pM for isocitrate and NADP respectively) are 
similar to the values of 8jiM and 22.7jiM determined under somewhat 
different conditions (Table 3.2). The data are consistent with the idea 
that phenylglyoxal affects the active site of the enzyme. The fact that 
both NADP* and isocitrate protect against inactivation raises the 
question of the number of arginine residues that react with 
phenylglyoxal. While direct measurement of the number of reactive 
groups would be achieved using radioactively labelled phenylglyoxal (see 
chapter 4), some useful information could also be gained from protection 
experiments. For example, if there was an arginine residue at the 
sub-site for each substrate, one might expect that each substrate alone 
would only give partial protection. The data drawn in Fig. 3.7 for 
NADP* and the corresponding data for isocitrate (Fig. 3.8) show that 
this is not the case. Experiments in which both isocitrate and NADP
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were present initially would be difficult to interpret because of the
possibility that some of the substrates would be converted to products by
the high enzyme concentration, even in the absence of added divalent
metal ions. We therefore carried out abortive substrate protection
experiments which involved protection of the enzyme activity with one
substrate and one product e.g. NADPH and isocitrate.
The results obtained showed no increase in protection was
achieved, which is consistent with the modification of only one arginine
residue by phenylglyoxal (Fig. 3.9). However, these experiments are
14
only indirect and we therefore used [7- C] phenylglyoxal to look more 
closely at the stoichiometry of the enzyme inactivation reaction.
3.3.3 Inactivation of ICDH from E.coli TGl/pCK505 with phenylRlvoxal 
E.coli TGl/pCK505 (Method 2.3.1) carries the plasmid pCK505 
which bears the icd structural gene encoding ICDH, and it overexpresses 
it 10-fold. The purification procedure of ICDH from this strain (Method 
2.5.5) does not involve the procion-red sepharose step of the ML308 ICDH 
purification (Method 2.5.2), and hence eliminates the elution step 
employing NADP . Thus the ICDH has been purified without allowing 
NADP* to bind at its co-factor binding site. Since the mechanism of 
ICDH involves a compulsory order process with NADP*binding first, we 
asked whether isocitrate would be able to protect the ICDH purified from 
TGl/pCK505 from inactivation with phenylglyoxal.
TGl/pCK505 ICDH was inactivated with phenylglyoxal as in method 
2.7.1. Protection experiments were carried out with either 200pM 
NADP* or lOOpM isocitrate. Figure 3.10 shows the results obtained.
NADP protected the enzyme against inactivation with phenylglyoxal, 
however isocitrate was unable to protect ICDH against loss of activity. 
This suggested isocitrate was unable to bind at the active site in the 
absence of NADP*.
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3.3.4 Labelling of ICDH with [7-^Cl-phenylglyoxal
Inactivation of ICDH using radioactively labelled phenylglyoxal 
was carried out essentially as with non-radioactive compound (Method
2.7.1). In order to measure the incorporation of label into the protein 
successfully it was necessary to separate the unreacted label from the 
protein sample. This was done by precipitating the protein sample onto 
filter paper discs by immersion into 10% trichloroacetic acid. Any 
unreacted label was removed by successive washings with TCA (Method
2.7.2). To determine the most suitable washing method several identical
14
samples of either [7- C]-phenylglyoxal or ICDH reacted with 
14
[7- C]-phenlyglyoxal were spotted onto filter discs and subjected to a 
variety of washing procedures. It was found that the majority of the 
unbound label was removed by the first washing and that equilibration 
between the disc and the solution was achieved within 15 min. Therefore 
4x15 min washes gave satisfactory reduction of non-precipitated label to
I S’
background level, further^washes removed no more label. Under these
conditions the modification of ICDH by phenylglyoxal was found to be
stable. However instability of the adduct in the long term will be
discussed in Chapter 4. We could therefore use this method to monitor
the time-course of incorporation of label into ICDH. Incorporation of 
14
[7- C]-phenylglyoxal into ICDH and inactivation of the enzyme were
assessed in the following way. At set time intervals samples were
removed and assayed for enzyme activity. At the same times samples were
14
taken and used to determine incorporation of C-radioactivity into the 
protein. The results showed that the loss of ICDH activity was linearly 
related to incorporation of label into the enzyme. Extrapolation of 
this relationship to 100% inactivation corresponded to incorporation of 
0.98nmol phenylglyoxal/nmol ICDH subunit (Mean of 4 experiments ranges 
0.87 - 1.06), (Fig. 3.11). Thus complete inactivation of enzyme
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activity appeared to be dependent on modification of one arginine residue
by one molecule of phenylglyoxal.
Incorporation of radioactive phenylglyoxal into the protein was
reduced if the inactivation experiments were carried out in the presence
of either 200jiM NADP or IOOjiM isocitrate (Figs.3.12 and 3.13
respectively). The reduction of incorporation correlated with a
reduction in loss of enzyme activity. When incorporation of 
14
[7- C]-phenylglyoxal/ICDH subunit was plotted against inactivation,
the data from all three conditions (ICDH, ICDH + 200jjM NADP+ and ICDH +■
lOO^iM isocitrate) fell on the same line. This indicated the same
arginine was modified in all three cases. (Fig. 3.14).
143.3.5 LabellmR of phosphorylated ICDH with [7- C]-phenvlKlyoxal
In order to test accessibility of arginine in ICDH-P we measured
14
the incorporation of radioactivity from [7- C]-phenylglyoxal.
Samples could not be assayed for activity since phosphorylated ICDH is
already inactive. Results were very striking; little or no 
14
[7- C]-phenylglyoxal was incorporated into the protein over the time
course of the experiment (Fig. 3.13., Table 3.3). The experiment was
carried out four times and always gave the same result. This indicated
that the arginine modified in active ICDH was in some way protected by
phosphorylation and hence inaccessible to the phenylglyoxal.
This result was so striking that it became necessary to rule out
the possibility that it was caused by some non-specific effect of the
phosphorylation process. We therefore investigated whether ICDH that
had been first phosphorylated and then dephosphorylated could still be
inactivated by phenylglyoxal. We prepared phosphorylated ICDH as in
32
method 2.4.2.c), using either unlabelled ATP or [%- P]-ATP. The
dephosphorylation, and hence reactivation of the ICDH, was monitored
32
either using release of P from the protein by precipitation of the 
protein in a similar manner to ICDH phosphatase assays (Method 2.4.2.c))
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or by recovery of enzyme activity. After complete reactivation and 
dephosphorylation of ICDH was obtained phenylglyoxal was added to a final 
concentration of lOmM and again the activity loss monitored. The 
initial results showed that, surprisingly, the ICDH could not be 
inactivated by phenylglyoxal. However on examination of the effects of 
the individual components of the ICDH-P reactivation mix on the 
inactivation of ICDH by phenylglyoxal it was found that several 
components, MgCl^ and ADP in particular, could protect the ICDH 
activity from inactivation with phenylglyoxal. (Fig. 3.15). In an 
experiment in which the dephosphorylated reactivated sample was dialysed 
against 50mM Mops-NaOH/, ImM EDTA pH7.3, and then treated with 
phenylglyoxal, rapid inactivation of the ICDH was observed (Fig. 3.16). 
This confirms that phosphorylation has a specific effect on the 
accessibility of ICDH to phenylglyoxal.
3.4. Effect of phenylRlyoxal on chymotryptic digestion
of ICDH and ICDH-P
The effect of phosphorylation on the accessibility of ICDH to 
phenylglyoxal was also examined in experiments using limited 
proteolysis. Partial chymotryptic digestion of ICDH produced a very 
distinctive pattern when fragments were run on an SDS gel. (Fig.
3.17a)) Digestion in the presence of either substrate, NADP or 
isocitrate, had no effect on the digestion pattern obtained. ICDH-P
' ■ ■ i
proved to be much more resistant'to digestion but the same digestion 
pattern was obtained (Fig. 3.18a). However when ICDH was first 
inactivated with phenylglyoxal then digested with chymotrypsin the 
pattern obtained was very different (Fig. 3.17b)). In this experiment 
there was a time dependent further degradation of the initial digestion 
peptides to much smaller peptide material. However when phosphorylated 
ICDH, which had been pre-incubated with phenylglyoxal, was digested with 
chymotrypsin the normal ICDH chymotrypsin digestion pattern was obtained
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(Fig. 3.18b)). Comparison of Figs. 3.17 and 3.18 shows that 
phenylglyoxal affects active ICDH but not phosphorylated ICDH.
3.5 Discussion
Selective chemical modification of arginine residues in proteins 
under mild conditions is desirable for a number of purposes, especially 
in connection with the definition of the active sites of enzymes. The 
group of reagents used to selectively modify arginine residues in 
proteins are the c<-dicarbonyl compounds, particularly phenylglyoxal, 
2,3-butanedione and 1 ,2,-cyclohexanedione. Using such reagents arginines 
have been identified as essential residues in the function of many 
enzymes (Riordan, 1979). In each of these enzymes, the essential 
arginine is though to interact with a negatively charged group of a 
substrate or co-factor molecule, especially the phosphate groups of NAlf 
and NADP* co-enzymes. This idea has been confirmed by X-ray 
crystallographic studies, for example of lactate dehydrogenase (Adams et 
&l., 1973).
In virtually all of the examples of enzyme modification with 
dicarbonyl reagents, the chemical modification is not only limited to 
arginyl residues but to a selected few of the total arginines present per 
molecule (Table 3.4), Since as a rule hydrophilic residues are located 
at the surface of proteins, and therefore accessible to the solution, 
this would suggest that factors other than simply accessibility affect 
how the arginines react. A good example of this selective modification 
is found with creatine kinase (Borders and Riordan, 1975). Only one of 
the 18 arginyl residues per subunit reacts with phenylglyoxal. It 
reacts with phenylglyoxal 10-15 times faster than does the free amino 
acid. Several factors could be involved in determining the reaction 
selectivity. Since most polar groups would be exposed on the surface, a 
few may be involved in polar interactions with other amino side chains, 
others may be solvated and hence their reaction is slow. Some, however,
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may be in a chemical environment that enhances their activity and that 
may be essential to their biological function. Thus the very properties 
of an arginine residue at an active site, produced by its local 
environment, also seem to increase its susceptibility to dicarbonyl 
reagents.
Phenylglyoxal proved to be a good choice of chemical 
modification reagent to investigate the active site of ICDH. It 
inactivated ICDH in a rapid and reproducible manner. Table 3.5 shows 
inactivation data for phenylglyoxal with a variety of enzymes. ICDH 
appears to be fairly rapidly inactivated as compared to the other 
examples quoted. Inactivation of ICDH with either 2 ,3-butanedione or 
1,2-cyclohexanedione was very poor. Little inactivation was observed 
with cyclohexanedione and butanedione appeared to inactivate ICDH but at 
a very slow rate. A comparison of the inactivation of three different 
enzymes with the three dicarbonyl reagents is shown in Table 3.6. The 
data indicate that the three reagents are of broadly comparable 
reactivity.
This suggested that phenylglyoxal might be acting as an affinity 
label for ICDH. However the results obtained were ambiguous.
Saturation kinetics were not observed. However the apparent 
pseudo-first order rate constant clearly did not increase linearly with 
the concentration of phenylglyoxal. One possible explanation is that 
two effects are being observed. Phenylglyoxal may be able to bind to 
the NADP site of ICDH before reacting but can also react directly without 
binding. It might be easier to observe saturation kinetics if the 
arginine residue in ICDH was less reactive.
Protection against inactivation by phenylglyoxal could be 
achieved with either NADP*or isocitrate. The fact that both substrates 
protect suggests that phenylglyoxal modification occurs at the active 
site of the enzyme. The results from inactivation experiments using
68.
ICDH purified from TGl/pCK505 indicate that protection by isocitrate is 
related to the small amounts of NADP+ associated with the ICDH as a result 
of the purification step involving NADP+elution from procion-red 
sepharose (Method 2.5.2). The increased protection observed with 
isocitrate may be as a result of a tighter binding to the active site of 
the two substrates together. The possibility of a conformational change 
on binding of both substrates, hence increasing the protection, cannot be 
ruled out. The results shown in Figure 3.9. of "dual substrate" 
protection experiments confirm the result that both substrates did not 
significantly increase the protection achieved with isocitrate alone.
However our data do not prove conclusively that phenylglyoxal 
reacts at the active site. We cannot rule out the possibility that on 
substrate binding a conformational change occurs which adventitiously 
protects an arginine residue distinct from the active site from 
modification.
Addition of both substrates in an inactivation experiment did 
not increase the protection achieved. This is consistent with the view 
that modification of only one arginine residue is involved in 
inactivation. However, it may be the case that there are two arginines 
which can be modified at this site, but reaction of either one results in 
complete inactivation of the enzyme. If so, the stoichiometry 
experiments would indicate that the labelling of these residues must be 
mutually exclusive.
14
Use of [7- C]-phenylglyoxal provided a convenient tool to 
investigate the inactivation reaction in greater depth. A correlation 
between incorporation with complete inactivation corresponding to 
incorporation of Inmol phenylglyoxal/nmol ICDH subunit. The 
stoichiometry and the reaction mechanism have not been conclusively 
determined for the arginine-phenylglyoxal reaction, and this will be 
discussed more fully in Chapter 4. However reports have indicated two
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different possible stoichiometries for the reaction of 2:1 and 1:1 for 
phenylglyoxal and arginine respectively.
Takahashi (1968) reported a 2:1 adduct for Ribonuclease A 
whereas Borders & Riordan (1975) reported a 1:1 adduct for creatine 
kinase. ICDH appears to fall into the second class. This suggested 
modification of only 1 arginine residue per enzyme subunit. A reduction 
in incorporation of radioactive label was achieved by inclusion of one or 
other of the substrates in the incubation, and this was accompanied by a 
reduction in the loss of activity. Graphical comparison of the results 
from the three labelling experiments showed a linear relationship between 
label incorporated and inactivation which is also good evidence for the 
existence of only one modified residue. The ability to reduce the label 
by presence of substrate gave a potentially useful method for isolating a 
specifically labelled peptide.
The hypothesis that osphorylation occurs close to or at the
4-
NADP binding site was supported by the result that phosphorylation of 
ICDH prevented incorporation of phenylglyoxal into the protein. This 
suggested the active site of ICDH contained one particularly reactive 
arginine which can be protected against modification either by binding of 
NADP* or by phosphorylation. The amino acid sequence round the site 
of phosphorylation is already known (Borthwick et al., 1984b). There is 
an arginine residue immediately adjacent to the phosphorylatable 
serine. It is tempting to speculate that this is the residue modified 
by phenylglyoxal.
During the course of work with phenylglyoxal we also considered 
the effect phenylglyoxal modification had on the overall conformation of 
the protein. Protease digestion was used as the analysis method. 
Phosphorylation of ICDH is known to increase its resistance to protease 
digestion (Garland & Nimmo, 1984). Phenylglyoxal was also found to 
affect protease digestion but in the opposite manner. Phenylglyoxal
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caused the digestion to proceed further. Degradation to smaller peptide 
material suggested the availability of more sites for protease action. 
This may occur if some sites were made accessible due to a conformation 
change, such as perhaps a general opening out of protein structure. 
Another possibility is the phenylglyoxal-arginine adduct itself provided 
another recognition site for the action of chymotrypsin.
Phosphorylation of ICDH prevented the increased susceptibility to 
protease digestion after inactivation with phenylglyoxal. The results 
suggested phosphorylation and phenylglyoxal action occur at a common site 
in ICDH, the active site.
Attempts to use phenylglyoxal as a tool to isolate a 
specifically labelled active site peptide are described in the next 
chapter.
Figure 3.1 Purification of isocitrate dehydrogenase from E.coli
ML308
10% polyacrylamide gel run in the presence of SDS monitors the 
purification of ICDH (Methods 2.5.2)
Track A Crude extract
B Protamine sulphate supernatant 
C Ammonium sulphate supernatant 60-75% pellet 
D Gel filtration pool 
E DEAE - cellulose pool 
F Procion red pool 
G Molecular weight markers

Fifture 3.2 Inactivation of isocitrate dehydrogenase with 20mM
phenylglyoxal
ICDH was inactivated with a solution of 20mM phenylglyoxal as 
in Methods 2.7.1.
The activity at each time point is expressed as a percentage of 
the initial activity before the addition of phenylglyoxal. The 
percentage activity remaining was then plotted on a logarithmic 
scale vs time (mins).
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Figure 3,3 Inactivation of isocitrate dehydrogenase with the 
dicarbonyl reagents 2,3-butanedione and 1,6- 
cyclohexanedione
ICDH was inactivated with either 150mM 2,3-butanedione or 50mM 
1,6-cyclohexanedione as in Methods 2.7.1.
Results were plotted as for Figure 3.2.
•  150mM 2,3-butanedione
A 50mM 1,2-cyclohexanedione
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Figure 3.5 Inactivation of isocitrate dehydrogenase with 20mM 
phenylglyoxal - protection with NADP+
ICDH was inactivated with 20mM phenylglyoxal as in Methods
2.7.1 in the presence of increasing concentrations of NADP*.
X no additions 
A  50jiM NADP+
O lOOpM NADP*
▲  150pM NADP+
• 200)iM NADP*
Results were plotted as for Figure 3.2.
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Figure 3.6 Inactivation of isocitrate dehydrogenase with 20mM 
phenylglyoxal - protection with isocitrate
ICDH was inactivated with 20mM phenylglyoxal as in Methods
2.7.1 in the presence of increasing concentrations of isocitrate.
X  no additions 
A  25pM isocitrate
O  50pM isocitrate
A  75pM isocitrate
•  IOOjiM isocitrate
Results were plotted as in Figure 3.2.
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FiRure 3.7 Determination of K for NADP* in the presence of
20mM phenylglyoxal
The half-lives for ICDH inactivation were determined from each
4-
of the NADP incubations m  Figure 3.5. The half-life values 
determined were then replotted against the corresponding NADP* 
concentration.
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Figure 3.8 Determination of the K value for isocitrate in the
presence of 20mM phenylglyoxal
The half-lives for ICDH inactivation were determined from each 
of the isocitrate incubations in Figure 3.6. The results were then 
replotted against the corresponding isocitrate concentration.
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FiRure 3,9 Abortive substrate protection experiments
ICDH was inactivated with 20mM phenylglyoxal as in Method
2.7.1 in the presence of the following substrates and products
■  no additions 
•  200pM alpha-ketoglutarate 
▲  lOOpM NADPH 
A  200jiM NADP*
□  200)iM NADP* +• 200jiM alpha-ketoglutarate 
O  lOOpM isocitrate 
V  100}iM isocitrate +- lOOpM NADPH
Results were plotted as for Figure 3.2.
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Figure 3.10 Inactivation of isocitrate from E.coli TGl/pCK505 with 
phenylglyoxal
ICDH purified from E.coli TGl/pCK505 was inactivated with a 
solution of lOmM phenylglyoxal as in Methods 2.7.1. Results were 
plotted as for Figure 3.2,
O no additions 
■  + 200pM NADP*
A + IOOjjM isocitrate
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Figure 3.11 Incorporation of [7- C]-phenylglyoxal into
isocitrate dehydrogenase- %  Inactivation vs
Incorporation
14
ICDH was inactivated with [7- C]-phenylglyoxal and the label 
incorporated determined as in Methods 2.1.2. The amount of label 
incorporated was determined as nmol phenylglyoxal/nmol ICDH subunit 
for each time point and the results plotted against percentage 
inactivation of the ICDH at the corresponding time point.
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14Figure 3.12 Incorporation of [7- C]-phenylglyoxal into
isocitrate dehydrogenase - Effect of 200jiM NADP*
14 . .ICDH was inactivated with [7- C]-phenylglyoxal. Activity
loss and incorporation of label were monitored as in Methods 2.7.1 
and 2.7.2, respectively. The experiment was also carried out in 
the presence of 200jjM NADP*.
Activity loss
▲  no additions 
A  + 200pM NADP+
Incorporation of label
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Figure 3,13 Incorporation of [7- C]-phenylglyoxal into
isocitrate dehydrogenase - Effect of isocitrate and 
phosphorylation
. 14
ICDH was inactivated with [7- C]-phenylglyoxal m  the
presence of IOOjiM isocitrate. Activity loss and incorporation of
label were monitored as in Methods 2.7.1 and 2.7.2, respectively.
The data were plotted against time.
Phosphorylated ICDH was also incubated with
14
[7- C]-phenylglyoxal and incorporation of label determined as in 
Methods 2.7.2. Again the results were plotted against time.
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Figure 3.14 Correlation between incorporation of label into
isocitrate dehydrogenase and loss of enzyme activity
The data from Figures 3.11 and 3.12 were replotted as nmol 
phenylglyoxal incorporated/nmol ICDH subunit vs % inactivation.
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Figure 3.15 Effect of phosphorylated isocitrate dehydrogenase
reaction mix components on phenylglyoxal inactivation 
of isocitrate dehydrogenase
ICDH was inactivated with lOmM phenylglyoxal as in Methods 
2.7.1, in the presence of the following metabolites
•  no additions 
V  0.5mM ADP 
A  ImM PEP
▲  ICDH kinase/phosphatase 
O lOmM MgCl2
Results were calculated and plotted as for Figure 3.2.
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FiRure 3.17 Digestion of isocitrate dehydrogenase with
chymotrypsin - Effect of phenylglyoxal
A. Shows a time course of digestion of ICDH with chymotrypsin. 
Digestion was carried out as in Methods 2.8. The digested 
samples were run on a 15% SDS gel and stained with silver.
B. Shows a time course of digestion of ICDH, first inactivated 
with lOmM phenylglyoxal (Methods 2.7.1), then digested with 
chymotrypsin. Digestion was carried out as in Methods 2.8.
The digested samples were run on a 15% SDS gel and stained with 
silver.
« ICDH
A
TIME (hr)  _g4 6 3____1_ 0.5 0
« ICDH
TIME (hr) 24  6 3 1 0.5 0
Figure 3,18 Digestion of phosphorylated isocitrate dehydrogenase
with chymotrypsin - Effect of phenylglyoxal
A. Shows a time course of digestion of phosphorylated ICDH with 
chymotrypsin. Digestion was carried out as in Methods 2.8.
The digested samples were run on a 15% SDS gel and stained with 
silver.
B. Shows a-time course of digestion of phosphorylated ICDH, first 
incubated with lOmM phenylglyoxal for 30 min (Methods 2.7.1), 
then digested with chymotrypsin. Digestion was carried out as 
in Methods 2.8. The digested samples were run on a 15% SDS 
gel and stained with silver.
8?.
T I M E l  hr) 0 1 3 6 24
ICDH
A
TIM E (hr)
« ICDH
B
Ta
bl
e 
3.
1 
Pu
ri
fi
ca
ti
on
 
of
 
is
oc
it
ra
te
 
de
hy
dr
og
en
as
e 
fr
om
 
E.
co
li
 
ML
30
8 
gr
ow
n 
on
 
20
mM
 
g
l
y
c
e
r
o
l
. 0)
o
4J
0)
CSJ
m
csj
co
T3
O
xz
-P
0)
X
c
♦H
TJ
o
c
•r*
r-f
-P
P
O
©
p
CO
c
o
•r*
-p
CO
o
•r*
CM
•rH
P
P
A
a)
-p
o
a)
b0
co
+i
co
.c
o
ca
0)
O
co
*ri
CO
-P
©
Q
To
ta
l 
S
p
e
c
i
f
i
c
 
St
ep
 
Pr
ot
ei
n 
Ac
ti
vi
ty
 
Ac
ti
vi
ty
 
Yi
el
d 
P
u
r
i
f
i
c
a
t
i
o
n
 
 
 
. 
 
(m
s)
 
u
n
i
t
s
 
u
n
i
t
s
/
m
R
 
%
 
 
-
f
o
l
d
89.
o
o
eg 00
* %
00 00 eg
eg 00
rH
pv O' rv* « *
p-s <r
O nO m
sO
O' 00 O' in
* * * «
o ps ps nO
eg ps
rH
00 00 Ps
o O' eg
m 'O 'IT
eg rH rH
in
es
in
eg
rH
eg
eg
00
in
eg
oo
<D
in
o
<0
ST JZo 0u
w o o
eg in in
o
ST rH •o
X 3 o
X rH u
rH
-tJ <D c
O O o
cd o 1 •rl
u P'S Ed o
■p 1 <5 o
X o w IH
w vO Q a-
Table 3.2 Comparison of K and K values of isocitrate 
s m
dehydrogenase for NADP* and isocitrate
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Table 3.2
Ligand Ks Km
NADP+
Isocitrate 
Citrate
60pM 22.7pM
16pM 8pM
3. 6mM
14
Table 3.3 Incorporation of [7- C]-phenylglyoxal into
isocitrate dehydrogenase and phosphorylated isocitrate 
dehydrogenase.
- Effect of NADP* and isocitrate.
14
ICDH and ICDH-P were incubated with [7- C]-phenylglyoxal m  
the presence or absence of NADP+ or isocitrate as in Methods 
2.7.2. This table shows the incorporation obtained after 150 
min, expressed as nmoles phenylglyoxal incorporated/nmol ICDH 
subunit.
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Table 3.3
Incubation nmol PG incorp./nmole
ICDH subunit
ICDH 0.977
ICDH+200jiM NADP+ 0.589
ICDH+lOOpM isocitrate 0.239
ICDH-P 0.01
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Table 3.5 Comparison of the inactivation of three enzyme 
activities with different dicarbonyl reagents
(a) Bovine carboxypeptidase A
(b) Beef liver glutamate dehydrogenase
(c) Pig heart aspartate aminotransferase
a Riordan (1979)
b David et al. (1976)
c Blumenthal & Smith (1974)
d Riordan & Scandurra (1975)
e Gilbert & O'Leary (1975)
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Table 3.5 
(a)
Reagent
Reaction
time
(min)
Molar
excess
reagent
% activity
remaining
peptidase
%  activity
remaining
esterase
Phenylglyoxala 60 150 37 64
2,3-butanedionea 15 150 14 290
1»2-cyclohexanedionea 30 150 99 108
(b)
Reagent
Reaction
time
(min)
Molar
excess
reagent
%
activity
remaining
Phenylglyoxalk 90 150 0
2 ,3-butanedioneb 150 150 15-20
l,i-cyclohexanedionec 5 750 45
(c)
Reagent
Reaction
time
(min)
Molar
excess
reagent
%
activity
remaining
Phenylglyoxal^ 30 175 15
2 ,3-butanedione^ 20 550 5
1 ,2.-cyclohexanedionee 100 15600 0
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CHAPTER FOUR
Attempts to Isolate a Peptide Labelled with [7- C]-Phenylglyoxal 
from the Active Site of Isocitrate Dehydrogenase
4.1. Introduction
The complete amino acid sequence of E. coli ICDH was recently 
deduced from the nucleotide sequence of the icd gene (Thorsness and 
Koshland, 1987). The sequence round the phosphorylation site was 
determined by conventional means (Borthwick et al.., 1984; Malloy et al., 
1984). These known sequences are of great value in that they provide a 
basis for studies of other structural features of ICDH, such as the 
active site of the enzyme.
Inactivation of ICDH with phenylglyoxal is believed to result in
modification of an active site arginine residue, as judged by protection
experiments (see Chapter 3). The initial objective of the work
described in this chapter was to isolate peptides from ICDH that were 
14
labelled with [7- C]-phenylglyoxal. Sequencing would then allow 
comparison with the whole primary sequence and the phosphorylation 
site. If the modified arginine proved to be adjacent to the 
phosphorylatable serine residue, this would provide evidence to support 
the proposed theory that phosphorylation occurs close to or at the 
NADP+ binding site. Of course, the tertiary structure of an enzyme’s 
active site is normally constructed from residues separated in the 
primary sequence, brought together to form the active site by protein 
folding. It is quite possible that the arginine residue at the 
co-enzyme binding site, i.e. the residue labelled by phenylglyoxal, is 
not the arginine which is adjacent to the phosphorylatable serine in the 
primary sequence but a residue spatially close to the serine residue as a 
result of tertiary structure. If this were the case, identification of 
the arginine residue modified by phenylglyoxal would neither confirm nor 
deny the hypothesis about phosphorylation given the absence of a high 
resolution 3-dimensional structure of the enzyme. However any attempt 
to identify this arginine residue would prove useful in that an active 
site residue would be defined.
96.
It has been claimed that arginine modification by phenylglyoxal 
is more stable under acid conditions (Patthy and Thesz, 1980), and that 
labelled peptides can be isolated. For example, arginine residues have 
been identified in rabbit muscle aldolase (Patthy et a^., 1979), glucose 
1-phosphatase (Vandenbunder et al., 1981) and lysozyme (Patthy and Smith, 
1975). Therefore we intended to do digestion and peptide purification 
in acid conditions, of ICDH which had been labelled with phenylglyoxal in 
the presence or absence of NADP* or isocitrate. We hoped that these 
compounds might protect specific peptides, thus allowing identification 
of an active site peptide.
4.2 Results
14
4.2.1 Large scale labelling of ICDH with [7- Cl phenylglyoxal
4.2.2 Labelling
Large scale labelling of ICDH involved some alterations to the
conditions used in previous labelling experiments (Method 2.7.2), as well 
as development of a suitable method to remove unreacted label. 
Incorporation experiments had been carried out with an enzyme 
concentration of 0.2 mg/ml and a phenylglyoxal concentration of 
10-20mM. To save on radioactive reagent, and also to reduce the 
reaction volume, the concentration of the ICDH was increased to 1 
mg/ml. However, trial experiments with this enzyme concentration and 
non-radioactive phenylglyoxal resulted in very little enzyme inactivation 
over a two hour time course. Due to the increase in ICDH concentration, 
the concentration of the ICDH storage buffer (lOmM potassium phosphate, 
5mM potassium citrate, 2mM Magnesium chloride 40% glycerol pH6.5) 
components also increased greatly. Citrate in particular was found to 
protect the enzyme against inactivation with phenylglyoxal. This 
allowed a Kg of 3.6mM for binding of citrate to ICDH to be determined 
(Fig. 4.1). MgCl^ at this higher concentration was also known to 
affect the rate of inactivation with phenylglyoxal (see Fig. 3.15).
97.
s.
Dialysis of the ICDH against 20mM potassium phosphate* 2mM MgCl^t 10% 
glycerol, pH6.5 to remove the citrate overcame the problem and allowed 
inactivation of 1 mg/ml ICDH using lOmM phenylglyoxal.
Large scale labelling of ICDH was carried out with enzyme alone
. + .or in' the presence of 200|iH NADP of IOOjiM isocitrate. Activity was
monitored at the start and at the end of a 2-1/2 hour incubation. Each
reaction was stopped by loading the sample on to a Sephadex G-50 column
equilibrated in 10% formic acid. The labelled fractions were pooled,
freeze dried and resuspended in a smaller volume of 10% formic acid for
digestion with pepsin. At each stage a small sample was monitored for 
14
presence of C-radioactivity. After overnight digestion the samples
were freeze dried and then dissolved in a small volume of 0.1% TFA
14
(100-200pl). A small sample was counted for presence of C-
radioactivity still associated with the peptides.
4.2.3 HPLC Analysis of peptide samples 
14
C-labelled peptides were separated by reverse-phase
chromatography on a C 0 column, equilibrated in 0.1% TFA and eluted
lo
with a gradient of acetonitrile in 0.1% TFA. Figure 4.2 shows a trace
of peptide separation of labelled ICDH which had been digested with
14
pepsin. A sample from each fraction was counted for C- 
radioactivity and these data are also shown. There was one major peak 
of radioactivity eluted early on in the run (Peak 1) Table 4.1 shows the
radioactivity associated with this peak for the three samples ICDH, ICDH
+- . . 14
+ 200pM NADP and ICDH + lOOpM isocitrate. The C- radioactivity
incorporated for the protected samples was reduced as compared to the
ICDH alone, as we would expect from the protection experiments (Chapter
3).
14
The C- radioactivity associated with the ICDH sample after 
HPLC separation (Pool 1, Fig. 4.2) was 71% of the initial radioactivity 
associated with the peptide sample before the protease digestion step.
98.
The radioactive fractions from this HPLC separation were pooled and
freeze dried and rerun on a reverse - phase column with a shallower
. . .  14
acetonitrile gradient (Fig. 4.3). Only 39% of the initial C was
found to be still associated with the peptide fractions after this run
(Fig. 4.3). The two radioactive peaks were pooled independently, freeze
dried and run on an HPLC gel filtration column (TSK, G2000 SW column (7.5
x 600mm), LKB) equilibrated in 0.1% TFA. Analysis of the fractions
14
obtained showed that only 15% of the initial C- radioactivity was
recovered. Only one radioactive peak was observed but it did not
correspond to any of the peptide peaks as judged by the ^race
(Fig. 4.4). Any further analysis of the peptide sample failed because 
14 .of the loss of C- radioactivity at each step (Table 4.2).
The data thus suggested an instability of the 
arginine-phenylglyoxal adduct in acid conditions which were previously 
thought to promote stability. We therefore decided to assess the 
stability of the adduct more carefully.
4.3 Stability of the phenylglyoxal-arginine adduct
The stability of the adduct was studied in the following ways:
4.3.1 Dialysis
ICDH was inactivated with phenylglyoxal (Method 2.7.1). The 
mixture was then dialysed against 50mM Mops-NaOH, ImM EDTA pH7.3 for long 
time intervals and the mix assayed for regain of the ICDH activity.
Data showed that regeneration of ICDH activity could be achieved with 
long periods of dialysis, over 24 hours, and indicated an instability of 
the ICDH-phenylglyoxal adduct (Table 4.3).
4.3.2 Washing with trichloroacetic acid
14
ICDH was inactivated with [7- C)-phenylglyoxal, lOpl samples
were spotted onto filter paper discs and washed for 4x1 hour periods in
10% TCA (Method 2.7.2). At this point one disc was removed and counted 
14
for C- radioactivity. This washing period was known to remove any
99.
unreacted label from the discs, but not protein-associated label.
(Chapter 3). The remaining discs were left in 10% TCA and washed for
increasing lengths of time, up to 48 hours. Discs were removed at set
times over this period and counted for protein-associated label. Figure
4.5 shows that label is lost from ICDH over the time course. It appears
to be a biphasic decay with the initial phase corresponding to rapid loss
o$ unreacted label followed by a slow decay of protein-associated label.
4.3.3 Stabilisation with NaBH.
  --------------  —  4
It has been suggested that the reaction of arginine with
phenylglyoxal may proceed by formation of a Schiff-base (Takahashi,
1968). It is possible to trap a Schiff-base, and hence stabilize the
structure, by addition of NaBH^, (e.g. Chaudhuri et al., 1986). It was
found that NaBH, could inactivate ICDH in the absence of 
4
phenylglyoxal. As a consequence we could not test whether NaBH^ 
stabilised the ICDH-phenylglyoxal adduct by monitoring any regain of 
activity after dialysis. However, incorporation of label, and loss of
label, could be monitored by precipitating the protein with TCA. Table
14 . +
4.4 shows the C- radioactivity associated with ICDH — NaBH^
treatment for several washing conditions (Method 2.7.4) ICDH that had
14
been treated with phenylglyoxal and then NaBH^ contained no more C-
radioactivity than control enzyme treated with phenylglyoxal alone.
Thus treatment with NaBH, did not affect the stability of the
4 J
phenylglyoxal-arginine adduct indicating that Schiff-base formation in
the reaction between phenylglyoxal and ICDH was unlikely.
32
4.4 Comparison of thermolytic digests of P- ICDH and
[7-^ C]-phenylglyoxal ICDH
These results indicated that the arginine-phenylglyoxal adduct 
was unstable over long periods of washing or dialysis. I therefore
decided to reduce the time between labelling of ICDH and analysis of the 
peptide digests. To do this I digested labelled ICDH and used SDS-PAGE
100.
separation of the peptides directly after labelling and without removing
unbound label by dialysis or precipitation (Method 2.7.6).
The first requirement was to find a suitable protease for
32
digestion. The objective was to compare peptides from P- phospKo 
14
ICDH and C- phenylglyoxal inactivated ICDH in order to establish 
whether the same peptide was labelled in each case. Therefore the 
prerequisite was that the protease produced the same digestion pattern 
with P-ICDH and phenylglyoxal-inactivated ICDH. Chymotrypsin, for 
example, would not be suitable (Section 3.4). Several proteases, and 
various digestion conditions were tested before thermolysin was found to 
be the most suitable (Figure 4.6).
14
ICDH was inactivated with [7- C]-phenylglyoxal and
immediately digested with thermolysin, without removing unbound label.
32
P- ICDH was similarly digested with thermolysin. Duplicate samples 
were run on either side of a 15% SDS gel. This enabled one half to be 
stained for protein while the other half was dried down immediately after 
electrophoresis for autoradiography. The results are shown in Figure 
4.7. At least one radioactive band appears common to both digests, and 
corresponds to a protein staining band for both samples. The 
radioactive band runs above the gel dye front. SDS PAGE of the 
radioactive fragments and comparison with myoglobin fragments indicated 
that the labelled peptide was less than 2.5kDa in size.
This is good, albeit indirect, evidence that the arginine
residue at the active site of ICDH is in the same thermolytic fragment as 
the phosphorylatable serine residue.
4.5 Discussion
The stability of the arginine-phenylglyoxal adduct has been a
well documented problem, with reports of both stable and unstable adducts
being formed. Takahashi (1968) reported that the inactivation of 
arginine residues with phenylglyoxal had a stoichiometry of two 
phenylglyoxal to one arginine. He reported that the product was stable 
under acidic conditions but decomposed slowly at neutral or alkaline
101 .
pH. The stability was such that a labelled peptide could be isolated.
Borders & Riordan (1975) reported a 1:1 stoichiometry for the
phenylglyoxal arginine reaction for creatine kinase. Peters et al.
(1981) suggested that the question of irreversibility and stoichiometry
were not unrelated. They stated that formation of a stable 2:1 adduct
proceeds via a 1:1 adduct that is formed reversibly (Fig. 4.8). It has
been suggested that the formation of the 2:1 adduct is in some cases
prohibited by the steric constraints of protein structure, accounting for
the frequent observation of 1:1 adducts.
The reaction products of the arginine-dicarbonyl reaction have
caused much discussion. No reaction mechanism has yet been established,
although many possible schemes have been put forward. Patthy and Thesz
(1980) proposed that the reaction of the guanidino group with dicarbonyl
reagents proceeds via a set pathway, the rate limiting step being
essentially identical with an amine-carbonyl addition reaction. They
described the obligatory step of the reaction as the formation of a
double carbinolamine a compound containing vicinal cis-hydroxyl groups.
In the case of the 1,2 cyclohexanedione-arginine reaction they established
the formation of such a compound (Patthy et al., 1979). Stabilization
of the butanedione-arginine reaction can be achieved by inclusion of
borate in the inactivation mixture. However, addition of borate to an
ICDH-phenylglyoxal inactivation experiment had no such effect on the
14
stability. Incorporation of [7- C]- phenylglyoxal into ICDH (Section
3.3.3) indicated that incorporation of 1 phenylglyoxal molecule per 
enzyme subunit resulted in complete inactivation of enzyme activity.
This obviously suggests that an active site arginine reacts with one 
phenylglyoxal. However it does not rule out the possibility that two 
phenylglyoxal residues have reacted with one arginine residue but at only 
half of the sites still resulting in inactivation of the dimeric ICDH.
102.
The lack of stability is not, perhaps, surprising in view of the 
results of Peters et aJL^data. However our initial experiments had 
shown that the modification was stable for up to four hours in TCA. Our 
decision to isolate a labelled peptide using acidic conditions, was based 
on this observation and the fact that others had shown these to be the 
most suitable for stabilization of the inactivation product. In 
retrospect the nature of the observed 1:1 adduct with ICDH indicated that 
the inactivation product would prove to be of an unstable nature. HPLC 
analysis of labelled peptides proved unsuccessful. The modification 
proved to be unstable in the longterm when unreacted label was removed in 
acid or neutral conditions. My more detailed analysis of the stability
confirmed this. As a consequence of the instability, we failed to
. . .  . 14
achieve our initial objective of isolating a C- labelled peptide.
Attempts to stabilize the inactivation product with NaBH^ proved 
unsuccessful.
We therefore looked for an alternative method which would enable 
us too compare the site(s) labelled by phenylglyoxal with the 
phosphorylation site. The thermolytic digestion experiment shows the
existence of at least one common radioactively labelled peptide between
32 14
P- ICDH and [7- C]-phenylglyoxal ICDH. In the primary sequence
of ICDH, excluding the adjacent arginine residue, the nearest arginine to
the phosphorylatable serine residue is 14 residues away. Although we
have no conclusive evidence it seems most likely that the arginine
modified by phenylglyoxal is the residue adjacent to the phosphorylatable
serine. This supports the idea that phosphorylation of ICDH occurs at
its co-enzyme binding site.
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Figure 4.3 HPLC separation of isocitrate dehydrogenase peptic
digests - (B)
The pooled fractions from Figure 4.2 (Pool 1) were further 
purified by a second run on a bondapak C18 reverse-phase HPLC 
Column. The peptides were eluted with a shallower acetonitrile 
gradient. The total running time for the gradient was 60 min.
Only the 5-34 min section of the chromatogram is shown. The flow 
rate was lml/minute. 1ml fractions were collected. A sample of 
each fraction (50yil) was counted for radioactivity and this data is 
also shown.
The following fractions were pooled:
Pool 1 - Fractions 10-12 
Pool 2 - Fractions 16-17
105. .
O -  9
%  a c e t o n i t r i l e
un
30J.O
POOL \ p o o c  2.
f r a c t i o n  n u m b e r
Figure 4.4 HPLC separation of isocitrate dehydrogenase peptic
digests - (C)
Pool 2 from Figure 4.3 was further purified by separation on an 
HPLC gel filtration column (TSK G2000 SW column, 7.5 x.600mm). The 
flow rate was 0.5ml/minute. One minute fractions were collected.
A sample of each fraction (50pl) was counted for radioactivity and 
this data is also shown.
Only the 40-68 minute section of the chromatogram is shown.
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32Figure 4.6 Digestion of I P)-phospho-isocitrate dehydrogenase
14
and [7 C]-phenylglyoxal-isocitrate dehydrogenase 
with thermolysin
Phosphorylated ICDH and ICDH labelled with phenylglyoxal were 
digested with thermolysin as in Methods 2.7.6. The digested 
samples were run on a 15% SDS gel and stained with silver (Methods 
2.6.4b).
14 .
Tracks A,B - [7- C]-phenylglyoxal-ICDH thermolytic digests
32
Tracks C,D - [ P]-phospho ICDH thermolytic digests
ICDH
32Figure 4.7 Digestion of I P]-phospho-isocitrate dehydrogenase
14and [7- C}-phenylglyoxal-isocitrate dehydrogenase 
with thermolysin
Samples were prepared as in Figure 4.6. The digested samples 
were run on a 15% SDS gel, the gel was immediately dried down and 
autoradiographed (Methods 2.7.6).
32
Tracks A,B - Autoradiograph of [ P]-phospho ICDH thermolytic 
digests
14
Tracks C,D - Autoradiograph of [7- C]-phenylglyoxal ICDH 
thermolytic digests
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14Table 4,1 C radioactivity associated with Peak 1 from Figure
4,2 for three isocitrate dehydrogenase-phenylglyoxal 
incubations
14
ICDH was labelled with [7- C] phenylglyoxal m  the presence 
or absence of 200jjM NADP+ or lOOpM D,L-isocitrate (Methods 2.7.3), 
digested with pepsin and separated on an HPLC reverse phase column 
(Methods 2.7.3b-c).
The radiocativity was determined for each of the three 
incubations for the Peak corresponding to PEAK 1 in Figure 4.2.
111.
Table 4.1 
Sample
ICDH
ICDH + 200pM NADP+
ICDH + lOOyM isocitrate
CPM Associated with Radioactive 
Peak 1
5300
2000
1100
Table 4.2
14 . 14C-radioactivity associated with the [7- C]-
phenylglyoxal-isocitrate dehydrogenase peptic digests
during the purification procedures employed
100% corresponds to radioactivity associated with the labelled 
ICDH sample before peptic digestion.
112.
Table 4.2 
Stage
Before peptic digestion 
After peptic digestion 
1st HPLC C18 column 
2nd HPLC C18 column 
HPLC gel filtration
[14C]-CPM
Incorporated
55400
51700
39530
21675
8425
% Initial Incorp.
100
93
71
39
15
Table 4.3 Effect of dialysis on the reactivation of isocitrate 
dehydrogenase inactivated with phenylglyoxal
ICDH was inactivated with lOmM phenylglyoxal (Methods 2.7.1). 
The activity was measured at zero time before the addition of the 
phenylglyoxal and this was taken as 100% activity. The activity 
was measured after 50 min and the sample then dialysed against 50mM 
MOPS ImM EDTA pH7.3 for 17 and 24 hours and reassayed for ICDH 
activity.
113.
Table 4.3
units/ml % Act.
28.9
50 min 0.48
17 hr dialysis of final
inactivated product 4.82
Phenylglyoxal inactivation 
0 time
remaining
100
1.6
16.7
24 hr dialysis of final 
inactivated product 9.12 31.6
Table 4.4 Effect of NaBH. on the stability of the isocitrate ---------- 4
dehydrogenase - phenylglyoxal adduct
14 .
ICDH was inactivated with [7- C]-phenylglyoxal (5pCi/pmol)
as in Methods 2.7.1. The inactivated sample was then treated with
NaBH. as in Methods 2.7.4. The incubation mix was then split and 
4
the stability of the inactivation product analysed using TCA washing 
(Methods 2.7.2) and dialysis.
As a comparison, control ICDH was inactivated with
14
[7- C3-phenylglyoxal and the label associated with the protein 
determined by TCA washing (Methods 2.7.2).
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Table 4.4 
ICDH Sample
Phenylglyoxal inactivated + 4 x 15 min TCA washes
Phenylglyoxal inactivated +- NaBH^ treatment 
+ 4 x 15 min TCA washes.
Phenylglyoxal inactivated + NaBH^ treatment
-i- 4 x 15 min TCA washes + overnight TCA washes
Phenylglyoxal inactivated + NaBH^ treatment
+ overnight dialysis + 4 x 15 min TCA washes
CPH
827
245
168
41
CHAPTER FIVE
Substrate Recognition of ICDH Kinase
115.
5.1 Introduction
In the mid - 1970*s it became clear that many eukaryotic protein 
kinases recognise elements of primary structure. Two lines of evidence 
suggest this. First, the phosphorylation site sequences were determined 
for various protein substrates and a number of protein kinases. It was 
found that the various sites phosphorylated by any one kinase showed some 
similarity to each other. Secondly it was found that synthetic peptides 
can be used as substrates and this has resulted in the elucidation of a 
number of the structural features of the substrates of the various 
protein kinases. It has become clear that although the primary 
structure of the phosphorylation site is not the only factor involved, it 
is usually possible to distinguish different groups of protein kinases as 
a result of their ability to phosphorylate specific peptide sequences. 
Protein kinases can be classed according to their regulatory agent. For 
example cAMP-dependent protein kinase is activated by cyclic AMP and it 
will phosphorylate an exposed serine residue located in a sequence 
preceded by two basic amino acid residues. If the serine is preceeded 
by only one basic residue then it will be a poor substrate (review Cohen, 
1988). One substrate for this enzyme is glycogen synthase (1A) its 
phosphorylation sequence is Arg-Arg-Ala-Ser (e.g. Cohen, 1988), this is 
just one of the many sites phosphorylated in glycogen synthase. Other 
kinases can be activated by calcium and calmodulin for example 
phosphorylase kinase (e.g. Krebs and Fischer, 1956), or there are protein 
kinases which are independent of any regulatory agent. For example 
Ca5€in kinase II phosphorylates exposed serine (or threonine) residues 
followed by one or more glutamic acid residues the first of which occurs 
one position removed from the serine. It has a broad substrate 
specificity in vitro, but it is known to phosphorylate glycogen synthase 
in vivo (e.g. Singh et al., 1982). However, its role in vivo is 
uncertain.
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More recently there has been the recognition of tyrosine 
phosphorylation as an important modification in the action of some 
hormones and growth factors. They are phosphorylated by protein kinases 
which are regulated by first messengers. Examples of these are the 
receptors for insulin (Ullrick et al., 1985) and epidermal growth factor 
(Cohen et al.. 1982; Staros et al., 1985). The binding of the ligand 
appears to activate the intrinsic protein kinase activity of the 
receptor, which is manifested experimentally as autophosphorylation of the 
receptor. It is at present uncertain whether the chain of intracellular 
events elicited by the hormone is a consequence of a conformational 
change in the receptor resulting from this phosphorylation, or whether it 
results from the phosphorylation of an extrinisic substrate, the identity 
of which is still unknown.
Eukaryotic proteins whose activities are affected by
phosphorylation are normally allosteric proteins and phosphorylation
frequently results in changes in affinity of the target enzyme for a
substrate or an allosteric cofactor. For example phosphorylation of
glycogen phosphorylase at serine - 14 reduces the K for AMP verya
considerably and the inhibition by metabolites that bind at the activator 
site, namely ATP, ADP and glucose - 6- phosphate (e.g. Graves and Wang, 
1972; Sprang et al♦, 1988).
In contrast to eukaryotic phosphorylation is the phosphorylation
of ICDH from E. coli ML308. Phosphorylation of this enzyme on a single
serine residue per subunit, almost totally inactivates it, (Borthwick et 
al., 1984a). The phosphorylation sequence of ICDH has been determined 
and it is unlike any known phosphorylation sequences (Borthwick et al. 
1984c). The proposed hypothesis of how this phosphorylation reaction 
affects enzymatic activity states that phosphorylation occurs close to or 
at the NADP binding site and hence prevents cofactor binding (Nimmo,
1984). The proposed location of the phosphorylation site differs from
117.
the eukaryotic proteins whose phosphorylation residues normally occur at 
highly accessible points on the protein surface (e.g. phosphorylase, see 
Fig. 5.12) and raises the question of how ICDH is recognised by its 
kinase. We therefore synthesized a 14- residue peptide corresponding to 
the region round the phosphorylation site of ICDH to study the substrate 
specificity of ICDH kinase.
5.2 Preparation of synthetic peptides
A 14- residue synthetic peptide, hereafter HN2, was
synthesized. It corresponded to the first fourteen residues of the
32
chymotryptic peptide isolated from P- labelled ICDH digests and, 
contains the phosphorylatable serine as residue 10, (Fig. 5.1). HPLC 
analysis using a reverse-phase column of the peptide sample revealed 1 
major and 4 minor peaks (Fig. 5.2) amino acid analysis of the individual 
peaks showed they all contained the 14 desired residues (not shown). 
Possible explanations of the multiple peaks would include incomplete 
deprotection of side chain groups or deamination of the asparagine side 
group. Amino acid analysis (Table 5.1) and sequencing (Table 5.2) of 
the HN2 peptide showed that it contained the desired residues on the 
correct order. The major peak shown in Figure 5.2 constituted 72% of 
the peptide sample as judged by absorbance at 215nm. Since this peak 
contained material of the correct amino acid composition and was the 
major component no further purification of the peptide was carried out.
5.3 Phosphorylation of synthetic peptides
Phosphorylation experiments were carried out in a similar way to 
ICDH phosphorylation experiments (Method 2.9.3). The ICDH kinase used 
in these experiments completely inactivated ICDH in less than 8 minutes 
(Fig. 5.3).
Two methods were used to detect phosphorylation. In both cases 
the method was tested by carrying out controls in which the synthetic 
peptide kemptide was phosphorylated by cAMP-dependent protein kinase 
catalytic subunit.
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5.3.1. Electrophoretic analysis of peptides
Phosphorylation of the synthetic peptides could only be detected
if the phospho peptide could be fully separated from unreacted ATP. HN2
contained only one charged amino acid residue, arginine, and so at
neutral pH it would have an overall positive charge, while the ATP would
have a net negative charge of nearly three. Electrophoresis at pH6.5
should therefore result in migration of the ATP and peptide HN2 in
opposite directions thus achieving separation. If phosphorylation of
the peptide occurred the positive charge would be cancelled out and the
peptide would have an overall charge close to zero. This would still
32
allow separation of peptide and [tf- P]-ATP.
32
Initially, trial electrophoretic separations of [ ^ - P]ATP
and synthetic peptide were carried out using thin layer electrophoresis
at pH6.5. The thin layer plates were stained with ninhydrin to locate
32
peptide samples, and autoradiographed to detect [ ^ - P]ATP.
Comparison of the peptide spot and autoradiograph indicated that
sufficient separation of the ATP and peptide samples had not occurred.
32
In a kinase assay it would be difficult to distinguish [ P]ATP from
phosphorylated peptide using this method.
I therefore tried an alternative method of electrophoresis, high
voltage paper electrophoresis. This has been successfully used to 
32
separate [ P]ATP from peptides and phosphorylated peptide samples
(e.g. Daile and Carnegie, 1974). Using this technique I achieved
32
efficient separation of [ PJATP from peptide HN2, Time course ICDH 
kinase assays were then carried out using HN2 as a substrate (Method 
2.9.4b). At set time points samples were removed and spotted onto the 
electrophoresis paper. Similar time course experiments were carried out 
with cAMP-dependent protein kinase catalytic subunit and kemptide.
Figures 5.4 and 5.5 show phosphorylation of kemptide occurred with the 
appearance of a second ninhydrin staining spot of lower mobility
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(Fig.5.4). This corresponded to a radioactive spot on the
autoradiograph (Fig.5.5). No phosphorylation was observed with ICDH
kinase and peptide HN2 (Figs'.5.6 and 5.7). The data suggest that
recognition of elements of primary structure does not play a major role
in the recognition of ICDH by ICDH kinase.
5.3.2 Anion exchange resin analysis
The second method used to monitor the possible phosphorylation
reaction employed the anion exchange resin AG- 1X8 .  The resin binds 
32
unreacted [ P]ATP under the conditions used (Method 2.9.4.c) 
whereas the peptide and phosphorylated peptide will not bind to the 
column. Incubations of peptide HN2, at a range of concentrations 1-10 
mg/ml with ICDH kinase were set up as for the electrophoretic analysis, 
and the samples taken at different times were analysed using AG-1 X8 
resin as in (Method 2.9.4.C). The eluate fractions were collected and 
counted for radioactivity. The data obtained were plotted as cpm vs 
time of incubation. Figure 5.8 shows the graph obtained P was 
incorporated into kemptide in the presence of cAMP dependent protein 
kinase catalytic subunit in a time dependent manner. However no 
phosphorylation of peptide HN2 by ICDH kinase was observed.
Anion exchange resin analysis of kinase incubations containing 
ICDH kinase and kemptide or cAMP-dependent protein kinase catalytic 
subunit and HN2 showed neither kinase activity could phosphorylate the 
other synthetic peptide (Fig.5.9).
Quantitative analysis of the results obtained from anion 
exchange was carried out to determine how poor a substrate peptide HN2 
was for ICDH kinase. The ICDH kinase used in the assay had the ability 
to phosphorylate ICDH at a rate of 0.056 nmol/min. Assuming that HN2 
was as good a substrate as ICDH I calculated how many cpm would be 
incorporated into the peptide sample after a 60 min kinase incubation. 
Calculations showed thst less than 0.74% of the expected cpm value
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was associated with the peptide sample. Similar analysis of a 120 min
32
kinase incubation indicated less than 0.4% of the expected P had been 
incorporated into the peptide.
5.4 Phosphorylation of chvmotryptic digests of ICDH
The apparent inability of ICDH kinase to phosphorylate the 
peptide HN2 raises the question of what ICDH kinase does recognise. Can 
it only phosphorylate intact ICDH? I decided to test this by assessing 
whether ICDH kinase could phosphorylate ICDH that had been digested with 
chymotrypsin. It seemed possible that the digest (Fig.5.10) might 
contain fragments of ICDH that retained enough secondary or tertiary 
structure to be recognised by the kinase. ICDH was first digested 
overnight with chymotrypsin. Before proceeding with the kinase assays 
chymostatin, an inhibitor of chymotrypsin, was added to prevent 
chymotryptic digestion of the added kinase.
Partially purified ICDH kinase was used in this experiment. 
Therefore, we could not assign any of the protein-staining bands to ICDH 
fragments. However, a sample of the digested material was run 
separately and stained with silver to check that digestion had occurred 
(Fig.5.10). No autophosphorylation of the kinase sample was observed, 
hence any radioactive bands observed with the ICDH digests could be 
attributed to phosphorylation of ICDH or its fragments. However the 
results showed that no phosphorylation, other than undigested ICDH, was 
detected for the chymotryptic digests (Fig.5.11). This suggested ICDH 
kinase recognised only intact ICDH as a phosphorylatable substrate.
5.5. Discussion
The work in this chapter addressed the question of how ICDH 
kinase recognises its protein substrate. No evidence was obtained that 
ICDH kinase could phosphorylate a 14- residue peptide corresponding to 
the sequence round the phosphorylation site. Of the two methods used to
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detect phosphorylation, only the anion-exchange analysis allowed a
quantitative determination of how good a substrate HN2 was for the
kinase. The quantitative results from the ion-exchange analysis showed
that HN2 was a very poor substrate for the ICDH kinase being
phosphorylated at less than 0.4% of the rate of ICDH. It is however
important to note that a range of peptide concentrations were tested in
the kinase assay, but this was limited by the peptide solubility in the
buffer used (maximum concentration 12mg/ml). It may be the situation
then that HN2 is a substrate for ICDH kinase but, if so the K value
m
must be very high well above the concentrations we have used.
This apparent inability of ICDH kinase to phosphorylate a short
peptide sequence distinguishes it from most eukaryotic kinases which 
recognise and phosphorylate synthetic peptides corresponding to regions 
of primary sequence.
Since ICDH kinase appears not to recognise the primary sequence 
of its phosphorylation site, it must recognise some other feature(s) of 
the enzyme structure such as the overall enzyme conformation or two 
distinct separated areas of the protein structure. Analysis of 
phosphorylation of chymotryptic digests of ICDH also proved negative.
The fragments generated by partial protease digestion were of greater 
size than the peptide HN2 and it was thought that some of these fragments 
might have retained regions of secondary structure which could be 
recognised by the kinase. However, it appeared from the experiment that 
ICDH kinase only recognised intact ICDH as a phosphorylatable 
substrate. However, the conclusion from this experiment cannot be 
definitive. I cannot rule out the possibility that a potential 
substrate was generated by the digestion, but only at a very low 
concentration so that its phosphorylation was not detectable.
The lack of ability of ICDH kinase to phosphorylate either HN2 
or proteolytic fragments may not be quite so surprising as the properties
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of eukaryotic protein kinases might imply. Phosphorylation of 
eukaryotic proteins by their protein kinases usually alters the 
allosteric properties of the enzyme, whereas phosphorylation of ICDH 
totally inactivates the enzyme. Differences between the eukaryotic 
kinase substrates and ICDH can also be observed in the effects of 
proteolysis. For many eukaryotic phosphoproteins, proteolytic digestion 
removes the phoshphorylation site and generates a form whose biological 
properties resemble those of the dephosphoprotein. For example 
phosphorylase b i s  phosphorylated by phosphorylase kinase to the active a 
form. Trypsin digestion of phosphorylase a produces a 
pseudophosphorylase b which has the same properties as phosphorylase b 
but has lost its first 16 amino acid residues including the 
phosphorylated serine. Thus reversal of the phosphorylation, and its 
effects, have been mimicked by proteolytic cleavage (Cori and Cori,
1945; Keller, 1955).
In contrast the kinetic effects of phosphorylation on ICDH
cannot be reversed by proteolytic removal of the phosphoserine residue
(Garland and Nimmo, 1984). This is understandable in view of the
• +
hypothesis that phosphorylation of ICDH occurs close to or at its NADP 
binding site. If this idea is correct then proteolytic removal of the 
phosphoserine residue would destroy the NADP binding site and 
irreversibly inactivate the enzyme.
Phosphorylation sequences of eukaryotic kinase substrates are 
often located at one end or the other of the primary sequence, and can 
form ’’arm like” structures which are very accessible to the cellular 
components. The structure of phosphorylase shows this very well 
(Fig.5.12) (Sprang and Fletterick, 1979; Sprang et al., 1988). 
Proteolytic cleavage of such a structure may in no way affect the enzyme 
structure and activity, only removing the possibility of controlling its 
activity by phosphorylation, and would reverse the effects of 
phosphorylation on the biological properties of the protein.
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It seems from my results that ICDH kinase recognises the 
conformation of intact ICDH rather than an element of primary structure 
at the phosphorylation site. The kinase presumably recognises either 
the molecule as a whole or several distinct parts of it, the 
phosphorylation site being an integral part of the enzyme strucure.
This together with the proposed site of phosphorylation indicates that 
ICDH control by phosphorylation occurs by a mechanism quite different 
from those involved in most other phosphorylation systems studied to date.
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Figure 5.2 HPLC analysis of peptide HN2
The purity of the deprotected synthetic peptide was checked on 
an HPLC reverse phase column (Methods 2.9.1).
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FiRure 5.3 Inactivation of isocitrate dehydrogenase with ICDH 
kinase
ICDH was inactivated with a purified sample of ICDH kinase as 
in Methods 2.A.2b. The results were plotted as activity remaining 
(%) vs time (min).
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Figure 5.4 Phosphorylation of kemptide by the catalytic subunit 
of cAMP-dependent protein kinase. Electrophoretic 
analysis-ninhydrin stain.
Kinase assays were carried out using kemptide and 
cAMP-dependent protein kinase catalytic subunit as described in 
Methods 2.9.3. Samples were removed at set times and 15-20pl was 
rapidly spotted onto the electrophoretogram as in Methods 2.9.4b. 
Control kinase incubations were set up which omitted either the 
peptide or the kinase.
The electrophoretogram was dried and stained with ninhydrin.
Control one - 30 min kinase assay/no kinase added
Control two - 30 min kinase assay/no peptide added
Control
Control
30min
two
one
Figure 5.5 Phosphorylation of kemptide by the catalytic subunit 
of cAMP-dependent protein kinase. Electrophoretic 
analysis - autoradiogram.
Autoradiograph of ninhydrin stained electrophoretogram from 
Figure 5.4.
Control one - 30 min kinase assay/no kinase added 
Control two - 30 min kinase assay/no peptide added
1 2 8.
32© P— P ep tid e Peptide
4— C o ntro l  two
Control one
I5min
Omin
FiRure 5.6 Phosphorylation of HN2 with ICDH kinase.
Electrophoretic analysis - Ninhydrin stain
Kinase assays were carried out using the synthetic peptide HN2 
and ICDH kinase/phosphatase as described in Methods 2.9.3. Samples 
were removed at set times and 15-20pl rapidly spotted onto the 
electrophoretogram as in Methods 2.9.4b. Control kinase 
incubations were set up which omitted either the peptide or the 
kinase. The electrophoresis was run for 90 min, the paper dried 
and stained with ninhydrin.
Control one - 50 min kinase assay/no kinase
1 2 9.
o
dnp- lysine
4 O min
*30min
4 60min
4 Control One
Figure 5.7 Phosphorylation of HN2 with ICDH kinase.
Electrophoretic analysis - autoradiogram
Autoradiograph of ninhydrin stained electrophoretogram from 
Fig.5.6.
Control one - 60 min kinase assay/no kinase added
C ontro l
One
32
Figure 5.8 Incorporation of P into synthetic peptides - anion 
exchange resin analysis
Kinase assays were carried out as in Methods 2.9.3. HN2 and 
ICDH kinase/phosphatase incubations and kemptide and cAMP dependent 
protein kinase catalytic subunit were set up and samples taken over 
a time course experiment. Reactions were stopped by the addition 
of acetic acid to a final concentration of 30%. Samples were 
analysed by anion exchange chromatography as in Methods 2.9.4c.
The peptide samples collected were counted for radioactivity and the 
results plotted against the corresponding time point.
▲  Kemptide/cAMP dep protein kinase catalytic subunit 
•  HN2/ICDH kinase/phosphatase
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32Figure 5,9 Incorporation of P into synthetic peptides - anion 
exchange resin analysis
The experiment was carried out as in Figure 5.8 except the 
kinase incubations contained HN2 and cAMP dependent protein kinase 
catalytic subunit or kemptide and ICDH kinase/phosphatase.
•  HN2/cAMP dep protein kinase catalytic subunit 
A  Kemptide/ICDH kinase/phosphatase
■  Kemptide/cAMP dep protein kinase catalytic subunit
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Figure 5.10 SDS analysis of peptide HN2 and chymotryptic digests 
of ICDH
lOjig of ICDH was digested overnight with chymotrypsin 
(ICDH:chymotrypsinf 72:1) and the digest run on a 20% SDS gel. 
Track A - ICDH chymotryptic digest 
Track B - 5pg peptide HN2 
Track C - lOpg peptide HN2 
Track D - 25pg peptide HN2
1 3 3.
A B C D
H N 2
Figure 5.11 Autoradiograph of isocitrate dehydrogenase
chymotryptic digest kinase assays
ICDH was digested with chymotrypsin, treated with chymostatin 
and used in a time course ICDH kinase experiment as in Methods 
2.10. Control kinase incubations were carried out with undigested 
ICDH, no added ICDH digests and without treatment with 
chymostatin. Samples were run on a 15% SDS gel and 
autoradiographed.
Track A - undigested ICDH 
Track B - No ICDH chymotryptic digest 
Track C - no chymostatin treatment 
Track D - 0 min )
Track E - 15 min )
Track F - 30 min ) Kinase incubation time points
Track G - 60 min )
Track H - 90 min )
1 3 4 .
A B C  D E F G H
4—  I C D H - P
Figure 5.12 Structure of phosphorylase a
A ’barrel and arrow' schematic diagram of phosphorylase a 
illustrating the course and folding of the polypeptide backbone. 
Skeletal inserts are shown at the pyridoxal phosphate covalently 
bound through lysine 679, the Ser-14-P moiety and the bound ligands 
AMP, glucose, caffeine and maltopeptose.
(Taken from a review by Fletterick, 1980)

Table 5,1 Amino acid analysis of peptide HN2.
Amino acid analysis was carried out as in Methods 2.9.2
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Table 5.1
Amino
acid
ASX
GLX
SER
GLY
HIS
ARG
THR
ALA
PRO
TYR
VAL
MET
ILE
LEU
PHE
LYS
pmol
recovered
5759
49
5279
19612
689
5018
8527
7007
6043
29
12432
516
5234
5935
99
0
No. of 
residues 
1.0 
0 
0.9
3.3 
0.1 
0.9
1.4 
1.2 
1.0
0
2.1
0.1
0.9
1.0
0
0
composition
7.0 
0.1
6.4 
23.9
0.8
6.1 
10.4
8.5
7.3 
0
15.1
0.6
6.4
7.2 
0.1
0
Table 5,2 Gas phase sequencing of peptide HN2
Sequence analysis was carried out as in Methods 2,9,2 (b),
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Table 5,2
Sequence No, PTH amino acid pmol recovered
1 THR 25.0
2 THR 22.5
3 PRO 31,0
4 VAL 25.0
5 GLY 20.7
6 GLY 27.0
7 GLY 24.5
8 ILE 16.0
9 ARG 8.8
10 SER 4.6
11 LEU 7.8
12 ASN 7.8
13 VAL 4.5
14 ALA 3.0
CHAPTER SIX
Conformational Analysis of Isocitrate Dehydrogenase 
with Circular Dichroism
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6.1 Introduction
The knowledge of the three-dimensional structures of a 
number of enzymes and other proteins, derived from X“raY 
crystallographic studies has greatly enhanced our understanding in 
structural terms of the properties of these molecules. However, it 
is also important to establish structural features of these 
molecules in solution and, in particular, to monitor changes in 
structure which may occur as a result of changes in environment or 
of interactions with various ligands such as substrates, inhibitors 
or activators. Solution studies do not have the degree of 
resolution afforded by crystallographic techniques; they can, 
however, lead to the description of the general structural features 
of a biological macromolecule and pinpoint some particular details 
about the location and interaction of various specific groups on 
proteins.
For the purpose of this study Circular Dichroism (CD) was
chosen as the technique best suited to look at our system. While
CD spectra in the far ultraviolet reflect principally peptide bOnd
transitions, and thus the secondary structure of a protein,
important information on enzyme structure may be derived also from
transitions of the side chains. These may reflect features of both
the secondary and tertiary structures. CD bands characteristic of
occur urv
amino acid side chains^the spectral region below 330nm. Above 
240-250nm there is no overlap with peptide bond transitions so that 
this region may be used to follow changes in side chain conformation 
and environment. The principal contributions are made by 
tryptophan and tyrosine residues, as well as by cystine disulphide 
bridges (see Timasheff, 1970).
We hoped, therefore, to use CD analysis in the near U.V. 
region to detect conformational changes in the structure of ICDH on
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either NADP* binding to the enzyme or on phosphorylation of the 
ICDH. Any results obtained using this technique might help to 
substantiate the proposed model of how phosphorylation affects ICDH 
activity (see Fig. 1.5).
6.2 Analysis of ICDH and ICDH-P conformations
Analysis of protein conformation by circular dichroism 
requires quite large quantities of protein material. Usually a
solution with an A_on of approximately 1 is required. In the
280
case of ICDH this corresponded to a solution of approximately 
lmg/ml. The construction of the ICDH overproducing strain E.coli 
TGl/pCK 505 which overproduces ICDH by a factor of 10-fold allowed 
large quantities of ICDH to be purified with relative ease (Methods 
2.5.4).
All protein CD analysis were carried but in 50mM MOPS ImM 
EDTA pH7.3. A blank CD spectrum was run for the MOPS buffer and 
this was subtracted from the protein analysis runs. We wished to 
establish if a conformational change occurred on NADP+ binding to 
ICDH and phosphorylation of the ICDH and to ascertain if the same 
conformational change occurred for both cases.
The following CD analysis were carried out in the near U.V. 
region. The results obtained are plotted as ellipticity per mean 
residue weight against wavelength (rim) (Methods 2.12). 
i) ICDH (Fig.6.1)
ii) ICDH + 150pM NADP* (Fig.6.2)
iii) ICDH + 50pM NADPH (Fig.6.4)
iv) phospho-ICDH (Fig.6.6)
v) phospho-ICDH +• 150pM NADP* (Fig.6.7)
vi) phospho-ICDH +■ 50jiM NADPH (Fig.6.9)
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These initial spectra were then used to determine difference spectra
for ICDH on cofactor binding and phosphorylation and for
phospho- ICDH in the presence of cofactors. The spectra obtained
were as follows:-
vii) ICDH - (ICDH + 150pM NADP*) (Fig.6.3)
viii) ICDH - (ICDH + 50pM NADPH) (Fig.6.5)
ix) ICDH-P - (ICDH-P + 150pM NADP*) (Fig.6.8)
x) ICDH-P - (ICDH-P + 50pM NADPH) (Fig.6.10)
xi) ICDH - (ICDH-P) (Fig.6.11)
xii) (ICDH + lSOpM NADP*) - (ICDH-P 150pM NADP*) (Fig.6.12)
xiii) (ICDH -I- 50pM NADPH) - (ICDH-P 50pM NADPH) (Fig.6.13)
From these results the following points can be taken.
Firstly this method has indicated that phosphorylation of ICDH 
induces no detectable conformational change (Fig.6.11). This 
result, at first, appears to contradict the proposed effect of ICDH 
phosphorylation. However, the results obtained suggest a second 
line of thinking which is still consistent with our model.
The complex difference spectrum in the region of 250-280nm
-f-
m  Figure 6.3 can be attributed to the spectrum of NADP in this 
region. However, this figure also shows a clear trough at 292nm 
which represents a change in the spectrum contributed by the 
protein. While this might reflect a conformational change in the 
protein, it is quite possible that this results from displacement of 
a solvent molecule from a partially exposed tryptophan residue by 
NADP*. The corresponding difference spectrum for phospho-ICDH 
(Fig.6.8) shows no such feature at 292nm, consistent with the view 
that NADP* cannot interact with this form of the enzyme. As a 
result, when the spectra of the active and phosphorylated forms of 
ICDH in the presence of NADP* are compared the difference spectrum 
shows a peak at 292nm (Fig.6.12). Similar results were obtained
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with NADPH. As shown in Figure 6.5, NADPH induces a spectral 
change at 292nm in active ICDH, but only a very minor change is seen 
with phosphorylated ICDH (Fig.6.10). Again, when the active and 
phospho forms of the enzyme are compared in the presence of NADPH, 
the difference spectrum shows a positive feature around 290nm 
(Fig.6.13).
One conclusion can be taken from this set of data. If, as 
seems likely, phosphorylated ICDH cannot bind NADP*, the lack of 
binding is due to the presence of the phosphate group as a block 
rather than to a change in the conformation of ICDH. Taking this 
point into consideration, our model (Fig.1.5) is still relevant. 
Consider if phosphorylation occurs near to the NADP*binding site of 
ICDH. If the phosphorylation occurs at the phosphate binding site, 
but is sufficiently removed from the aromatic binding subsite of the 
NADP molecule so as not to affect the ellipticity of the 
tryptophan residue that appears to be part of that subsite, then our 
model still holds.
6.3 Discussion
Analysis of protein structure in solution can be monitored 
by a variety of spectroscopic techniques, for example fluorescence,
ORD, CD and nuclear magnetic resonance (see Freifelder, 1982 for an 
overview). Each technique has its advantages for a particular type 
of study. For this particular study we chose the method of 
circular dichroism to look for conformational changes in E.coli ICDH 
under particular situations.
The model proposed by Nimmo (1984) (Fig.1.5), suggests a 
conformational change may be involved in the mechanism of 
inactivation of ICDH by phosphorylation. In eukaryotic 
phosphorylation systems it has been generally assumed that 
phosphorylation stabilises different conformational states of the 
protein. Little direct evidence however has been established
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relating to the magnitude or characteristics of these conformational 
changes. However, recently evidence relating to conformational 
changes on phosphorylation was achieved for glycogen phosphorylase 
(Sprang et aJL., 1988). These workers compared the refined crystal 
structures of dimeric glycogen phosphorylase b and a and revealed 
structural changes that represented the first step in the activation 
of the enzyme. On phosphorylation of serine-14, the N-terminus of 
each subunit assumes an ordered helical conformation and binds to 
the surface of the dimer. The consequent structural changes in the 
N- and C-terminal regions led to strengthened interactions between 
subunits and altered the binding sites for allosteric effectors and 
substrates (Sprang et al. 1988).
How can this type of situation be related to E.coli ICDH? 
Although phosphorylation of ICDH occurs it does not serve to alter 
allosteric properties of the enzyme but instead completely 
inactivates the enzyme activity. In the original model, the 
proposed conformational change was suggested to alter the enzyme 
structure in such a way as to 'close* the nucleotide binding site 
and hence prevent cofactor access and binding. The CD data 
obtained from the conformational analyses of ICDH indicated that no 
detectable change occurred on either cofactor binding or 
phosphorylation. This result seems in contrast to our original 
model. However, the results do not show that a conformational 
change has not occurred; they indicate only that no change 
detectable by circular dichroism occurred.
One interesting result was obtained from the CD analysis, 
an apparent inability of phosphorylated ICDH to bind the enzyme 
cofactor NADP*. In the original model the phosphorylation of 
ICDH is proposed to produce a similar conformational change as 
NADP binding and prevent binding by a charge-charge repulsion
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mechanism. This can be modified in terms of these results to 
phosphorylation prevents binding by blocking the NADP* binding 
site, possibly involving a charge-charge repulsion mechanism. Work
carried out by Garland and Nimmo (1984) using fluorescence 
spectroscopy indicated that phosphorylated ICDH was unable to bind 
its cofactor NADPH. Addition of NADPH to active ICDH resulted in 
an enhancement of the fluorescence of the coenzyme with no change in 
its emission or excitation spectra. The addition of NADPH to 
inactive ICDH had no effect on either the fluorescence yield or the 
excitation and emission spectra of the coenzyme (Garland & Nimmo,
1984).
It would appear then that the model proposed by Nimmo 
(1984) has correctly predicted the inability of phosphorylated ICDH 
to bind its cofactor, thus inactivating it. The lack of detection 
of a conformational change using CD does not rule out the 
possibility. Conclusive evidence however, on why phosphorylated 
ICDH is inactive will only be determined when the crystal structure 
of the enzyme is determined.
Figure 6.1 Circular dichroism spectrum of isocitrate dehydrogenase
Results are plotted as ellipticity (units per mean molar 
ellipticity) against wavelength (nm). Data obtained as described 
in Methods 2.12.
[X] = ellipticity
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)
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Figure 6.2 Circular dichroism spectrum of isocitrate 
dehydrogenase in the presence of 150jjM NADP+
Results are plotted as for Figure 6.1.
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Figure 6.3 Circular dichroism difference spectrum of the 
isocitrate dehydrogenase +- 150jiM NADP* spectrum 
subtracted from the spectrum for isocitrate 
dehydrogenase.
Results are plotted as for Figure 6.1.
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Figure 6.4 Circular dichroism spectrum of isocitrate 
dehydrogenase in the presence of 50pM NADPH
Results are plotted as for Figure 6.1.
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Figure 6,5 Circular dichroism difference spectrum of the 
isocitrate dehydrogenase + 50jiM NADPH spectrum 
subtracted from the spectrum for isocitrate 
dehydrogenase.
Results are plotted as for Figure 6.1.
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Figure 6.6 Circular dichroism spectrum of phosphorylated 
isocitrate dehydrogenase
Results are plotted as for Figure 6.1.
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Figure 6.7 Circular dichroism spectrum of phosphorylated 
isocitrate dehydrogenase in the presence of 150jiM 
NADP*
Results are plotted as for Figure 6.1.
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Figure 6,8 Circular dichroism difference spectrum of the 
phosphorylated isocitrate dehydrogenase + 150pM 
NADP* spectrum subtracted from the spectrum for 
phosphorylated isocitrate dehydrogenase.
Results are plotted as for Figure 6.1.
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FiRure 6,9 Circular dichroism spectrum of phosphorylated 
isocitrate dehydrogenase in the presence of 50pM NADPH.
Results are plotted as for Figure 6.1.
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Figure 6.10 Circular dichroism difference spectrum of the
phosphorylated isocitrate dehydrogenase +- 50pM, NADPH 
spectrum subtracted from the spectrum for 
phosphorylated isocitrate dehydrogenase.
Results are plotted as for Figure 6.1.
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Figure 6.11 Circular dichroism difference spectrum of the
phosphorylated isocitrate dehydrogenase spectrum 
subtracted from the spectrum for isocitrate 
dehydrogenase.
Results are plotted as for Figure 6.1.
5 0
40
30
20
10
0
10
20
30
40
50
260 270 200 290 300 310
WAVELENGTH (nra)
Figure 6,12 Circular dichroism difference spectrum of the
phosphorylated isocitrate dehydrogenase + 150pM
NADP* spectrum subtracted from the spectrum for 
* •
isocitrate dehydrogenase + 150jiM NADP .
Results are plotted as in Figure 6.1.
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FiRure 6.13 Circular dichroism difference spectrum of the
phosphorylated isocitrate dehydrogenase +- 50jaM NADPH 
spectrum subtracted from the spectrum for isocitrate 
dehydrogenase + 50pM NADP*.
Results are plotted as in Figure 6.1.
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Figure 6.14 Circular dichroism spectrum of 150pM NADP+
Results are plotted as voltage against wavelength (nm).
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FiRure 6.15 Circular dichroism spectrum of 50juM NADPH.
Results are plotted as voltage against wavelength (nm).
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CHAPTER SEVEN
General Discussion
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7.1 Role of phosphorylation of ICDH
The phosphorylation of ICDH in E.coli was the first example 
of the control of a bacterial enzyme by a phosphorylation/ 
dephosphorylation mechanism. The present interest in the study of 
the phosphorylation of ICDH arose from the initial observations made 
by Holms and Bennett (1971) and Bennett and Holms (1975). These 
workers were primarily concerned with providing an explanation for 
the decrease in the level of ICDH activity when a culture of E.coli 
ML308, previously grown on limiting glucose adapted to acetate which 
had accumulated in the medium. Bennett and Holms concluded that 
covalent modification of ICDH was one possible explanation for the 
reversible inactivation of the enzyme. Since these early reports a 
great deal of information has been gained about the system. The 
work has been carried out by three groups, Koshland's (Berkeley),
Reeves (Tempe) and here at Glasgow and has proved conclusively that 
the mechanism involved in the inactivation of ICDH is 
phosphorylation in both S.typhimurium and E.coli.
Bennett and Holms (1971) proposed that ICDH was inactivated 
in order to allow flux through the glyoxylate bypass. Work carried 
out by Koshland’s group measuring fluxes through the system and by 
the Glasgow group studying the individual components of the system, 
both confirmed this initial hypothesis put forward by Bennett and 
Holms, Thus the role of phosphorylation of ICDH was to control 
usage of isocitrate under one particular condition, growth on 
acetate. This inactivation of ICDH allows a build-up in the levels 
of intracellular isocitrate enabling isocitrate lyase to operate and 
results in efficient use of acetate carbon via the glyoxylate bypass.
Although a lot of work has been carried out on the function 
of phosphorylation within the cell, and on the individual components 
of the system, little work has been done on why phosphorylated ICDH
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is inactive. This provided a starting point for the work reported 
in this thesis.
7.2 The active site of isocitrate dehydroRenase
One of the main findings of this work was the 
identification of an arginine residue at the active site of ICDH.
This residue could be protected either by NADP binding or 
phosphorylation. The data conformed to the hypothesis proposed by 
Nimmo (1984) that phosphorylation of ICDH occurred close to or at 
the NADP+ binding site (Fig.1.5). However, we were unable to 
determine any sequence data to compare with the known protein and 
phosphorylation sequences.
The proposed location of the ICDH phosphorylation site 
raises the question concerning the evolution of such a control 
mechanism. Consider E.coli and its ability to grow on a variety of 
carbon sources. Here we make the assumption that the TCA cycle was 
the pathway first evolved by the cell. At a later stage the 
glyoxylate bypass was evolved to allow growth on acetate. This 
provided the cell with an alternative route for the available 
isocitrate during growth on acetate, and resulted in competition 
between ICDH and the glyoxylate bypass enzyme isocitrate lyase for 
their common substrate. To enable efficient use of acetate carbon 
via the glyoxylate bypass the cell would have to alter the activity 
of one of the two enzymes, either by decreasing the activity of ICDH 
or increasing the activity of ICL. In the case of E.coli it 
appears the former choice was adopted, it was easier for the cell to 
reduce the levels of ICDH activity rather than to create a more 
efficient lyase.
Consider then how the E.coli cell could regulate its level 
of ICDH activity. ICDH is not an allosteric protein and it can be 
said that it plays no role in the control of the TCA cycle except
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during growth on acetate. One method of activity control would be 
for the ICDH to be controlled by an allosteric mechanism. To 
create an allosterically controlled ICDH would involve evolution of 
an allosteric binding site within the protein molecule which would 
necessitate considerable change to the protein structure. In the 
case of eukaryotes, proteins whose activities are controlled by 
phosphorylation are normally allosteric. The phosphorylation of 
such proteins usually has the effect of ’locking* the enzyme 
structure into one particular conformation and over-riding the 
allosteric control mechanism. In ICDH this is not possible since 
there is no allosteric control. However, one simple way of 
inactivating an enzyme via phosphorylation would be to modify its 
active site. In the case of ICDH the modification appears to 
prevent the binding of NADP*.
The sequence of the ICDH protein is known. However, 
analysis of the primary structure reveals no protein region which 
bears any resemblance to known nucleotide binding domains (Thorsness 
& Koshland, 1987). This may indicate that ICDH, as a result of its 
control by phosphorylation, has evolved a slightly different 
nucleotide binding site to accommodate this function.
7.3 ICDH kinase/phosphatase
The mechanism of phosphorylation of ICDH differs 
significantly from that of eukaryotic enzymes. This is also 
reflected in the kinases which carry out the reactions. Eukaryotic 
kinases recognise and phosphorylate short linear sequences of amino 
acids. Such kinase recognition sequences are thought to occur on 
’arm-like* structures located on the outside of the protein 
molecule. The phosphorylation of this structure is sufficient to 
lock the conformation into one particular shape. The ICDH kinase 
of E.coli« however, does not recognise as a potential substrate a
'162.
short linear sequence corresponding to the phosphorylation 
sequence. It seems only to recognise the whole protein as a 
substrate. This can be related to the location of the 
phosphorylation site within the protein itself. The active site of 
the enzyme will form an integral part of the protein. As a result 
the kinase must in turn ’surround* the protein to gain access to the 
active site. Thus substrate recognition involves the overall 
protein shape, and cannot be achieved by the phosphorylation site 
sequence alone located in the active site of the enzyme.
The gene for the ICDH kinase/phosphatase has been sequenced 
and it is unlike any determined for eukaryotic kinases. This 
suggests a different evolutionary origin for this enzyme.
Similarly the kinase and phosphatase activities are located on the 
same bifunctional protein which is also contrary to eukaryotic 
protein kinases and their corresponding phosphatase activities 
(except maize pyruvate phosphate di-kinase interconverting enzyme) 
(Sugiyma, 1973). E.coli appears to have evolved a completely 
different phosphorylation system to that found in eukaryotes. The 
reasons for this difference may be in the availability of possible 
’starter* proteins from which to evolve a kinase and phosphatase 
activity. Results from LaPorte’s group suggest that the kinase and 
phosphatase activities share the same active site (Stueland et al., 
1987). This would be consistent with the evolution of a reversible 
kinase activity further evolving to produce a kinase and phosphatase 
function. This would result in an ability to control both 
activities closely, a situation which occurs with the bifunctional 
kinase/phosphatase.
The origin of the ICDH kinase/phosphatase however still 
remains unknown. It is only with sequence comparison of the gene 
sequence to other known gene sequences that we might envisage an
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answer, and at the same time discern why E.coli adopted a different 
evolutionary pathway to create a kinase quite distinct from that of 
eukaryotes.
7.4 Future Work
The work carried out in this thesis has provided a variety 
of directions for future work. The first relates to the arginine 
residue modified by phenylglyoxal. Recently a new 
arginine-modifying reagent, 4-(oxoacetyl) phenoxyacetic acid (OPA) 
has been developed (Duerksen-Hughes et al., 1987). This was 
reported to produce a stable modification of arginine residues. It 
would be interesting to repeat the phenylglyoxal labelling 
experiments with this reagent, which might yield a stable 
modification of ICDH. This would enable isolation of a labelled 
peptide for sequence analysis. However it is not clear in chemical 
terms that arginines modified by OPA would always be more stable 
than arginine residues modified by phenylglyoxal. Instability of 
the adduct might well be a problem with this reagent too.
Secondly we believe the arginine residue modified with 
phenylglyoxal is the arginine residue adjacent to the 
phosphorylatable serine residue in ICDH. We have the icd gene from 
E.coli ML308 and K12. The K12 gene has already been sequenced 
(Thorsness & Koshland, 1987) and the ML308 gene is currently being 
sequenced in Glasgow. Site-directed mutagenesis will be used as a 
tool to alter this arginine. This should help to clarify the 
functional role, if any, of this arginine residue. For example, an 
arginine to lysine change would retain the charge of the arginine 
residue, but should render the enzyme insensitive to phenylglyoxal 
inactivation.
A third direction relates to the conformation of ICDH. We 
used circular dichroism in the near U.V. region and were unable to 
detect any conformational changes, but seemed to detect an inability
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of phospho-ICDH to bind NADP+ . This lack of detection of a 
conformational change on NADP+ binding and phosphorylation does 
not necessarily mean that no change has occurred. Thus using 
circular dichroism in the far U.V. region which detects changes in 
amounts of secondary structure features such as alpha-helix and 
beta-sheet, might reveal a conformational change under these 
conditions.
Another interesting line of investigation concerns E.coli 
strain EB106. This is an icd mutant which is believed to contain a 
single point mutation in the icd gene. It synthesises a completely 
inactive ICDH protein (Apostolakos et al., 1982). We are 
interested in why this mutant ICDH is inactive. The protein is 
produced in the cell which suggests that it folds properly.
However, it would be interesting to purify this protein and compare 
its conformation with those of active and inactive ICDH. Further, 
attempts to phosphorylate the protein, modify it with phenylglyoxal
4- %
and study its ability to bind NADP might be useful. Ultimately, 
sequencing of the mutant icd might throw further light on the 
structure/function relationships within ICDH.
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